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Acetaminophen (APAP) is the leading cause of acute liver failure in the United States, 
and alcoholic liver disease (ALD) is a worldwide health problem that claims two million lives per 
year.  Currently, the only cure for either disease is liver transplantation in severe disease states. 
Therefore, new therapeutic options for treatment of these liver diseases are greatly needed.  To 
develop new therapeutic options, the mechanisms involved in APAP and alcohol-induced liver 
toxicities must be better understood. We previously demonstrated that autophagy was 
protective against both APAP and alcohol-induced liver injuries by removing damaged 
mitochondria by mitophagy, which is a selective form of autophagy specific for mitochondria. 
However, the mechanisms for induction of mitophagy in the liver are unknown. Parkin is an E3 
ubiquitin ligase that is well known to be required for mitophagy induction in mammalian cell 
models after mitochondrial depolarization. Therefore, we evaluated the role of Parkin in inducing 
mitophagy as a protective mechanism against APAP and alcohol-induced liver injuries. For 
alcohol treatment, acute-binge and chronic-plus-binge (Gao-binge) models were used.  
First, we found that APAP and alcohol produced opposite responses in Parkin KO mice. 
Parkin KO mice were protected after APAP treatment, but they had more liver injury and 
steatosis after alcohol treatment compared to WT mice.  It is well known that c-Jun N-terminal 
kinase (JNK) activation exacerbates APAP-induced liver injury, and it has recently been shown 
that myeloid leukemia cell differentiation protein (Mcl-1) mediates protection against APAP-
induced liver injury. In addition, liver regeneration has been shown to be the most important 
repair mechanism for APAP-induced liver injury. We found that Parkin KO mice had decreased 
JNK activation, increased Mcl-1 expression, and increased hepatocyte proliferation after APAP 
treatment in their livers compared to WT mice.  In contrast to protection after APAP treatment, 
Parkin KO mice were more susceptible to alcohol-induced liver injury than WT mice because of 
Parkin’s role in maintaining a healthy population of mitochondria, likely through activation of 
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mitophagy. Alcohol caused greater mitochondrial damage in Parkin KO livers compared to WT 
livers. Parkin KO mice had severely swollen and damaged mitochondria that lacked cristae after 
alcohol treatment, which were not seen in WT mice. In addition, Parkin KO mice had decreased 
mitophagy, β-oxidation, mitochondrial respiration, and cytochrome c oxidase activity after acute-
binge alcohol treatment compared to WT mice. Furthermore, Parkin KO mouse liver 
mitochondria had less capacity to adapt to Gao-binge treatment compared to WT mouse liver 
mitochondria. The fact that Parkin KO mice were protected against APAP-induced liver injury 
but had increased liver injury and steatosis after alcohol treatment compared to WT mice 
suggests that Parkin has multiple roles in maintaining cellular homeostasis in addition to its role 
in initiation of mitophagy, and these various roles my differ in importance depending on the 
amount and type of liver injury produced. Therefore, Parkin’s roles in regulating proliferation, 
JNK activation, and Mcl-1 expression were likely more important than mitophagy during APAP-
induced liver injury while its role in mitophagy induction to maintain mitochondrial homeostasis 
was likely more important during alcohol-induced liver injury.  
Second, we surprisingly found that even though Parkin has been shown to be required 
for mitophagy induction in in vitro models, Parkin was not essential for mitophagy induction in 
the liver. We found that mitophagy still occurred in Parkin KO mice based on electron 
microscopy analysis after APAP and alcohol treatments. However, mitophagy levels were 
reduced in Parkin KO mice compared to WT mice, and Parkin translocated to mitochondria in 
WT mouse livers after both APAP and alcohol treatments. These results suggest that Parkin-
induced mitophagy is still likely an important protective mechanism in the liver even though 
compensatory adaptive mechanisms exist for mitophagy induction in the absence of Parkin. In 
addition, these compensatory mechanisms may not be as efficient as Parkin in inducing 
mitophagy in the liver because mitophagy levels were reduced in Parkin KO mice compared to 
WT mice after APAP and alcohol treatments. Parkin-independent mechanisms for mitophagy 
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induction in the liver are currently unknown, but they may involve activation of other proteins 
known to mediate mitophagy, such as Mul1, which has been shown to act in parallel to the 
Parkin pathway in Drosophila.  
Third, we found that whole-body knockout of Parkin and acute knockdown of Parkin had 
opposite responses to APAP overdose. While Parkin KO mice were protected against APAP-
induced liver injury compared to WT mice, acute knockdown of Parkin in mouse livers resulted 
in increased liver injury compared to WT mice after APAP treatment. Whole-body Parkin KO 
mice were protected because they had increased Mcl-1 and proliferation levels and decreased 
JNK activation, and mice with acute knockdown had exacerbated APAP-induced liver injury 
because they had reduced Mcl-1 and proliferation levels and increased JNK activation. In 
addition, mitophagy was reduced in both Parkin KO mice and mice with acute knockdown of 
Parkin compared to WT mice. However, mitophagy levels were only slightly reduced in whole-
body knockout mice while they were significantly reduced in mice with acute Parkin knockdown.  
These opposite responses between Parkin whole-body KO and acute knockdown mice were 
likely due to a lack of time to develop compensatory and adaptive mechanisms in the acute 
knockdown mice that were present in the whole-body knockout mice.  
Overall, our findings indicate that Parkin-induced mitophagy is likely a mechanism of 
protection in the liver, but compensatory mechanisms exist for induction of mitophagy in the 
absence of Parkin. However, these compensatory mechanisms may only play a minor role in 
the liver. In addition, Parkin has multiple roles in maintaining cellular homeostasis in addition to 
mitophagy, which causes Parkin KO mice to respond differently to various types of liver injury. 
However, our findings from Parkin KO mice likely better reflect physiological conditions in 
people that have chronic loss of Parkin function, such as Autosomal-Recessive Parkinson’s 
disease patients, who have mutations in the Park2 (Parkin) gene. Finally, our results indicate 
that evaluation of drug-induced liver injury mechanisms using whole-body knockout mice should 
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be interpreted with caution due to adaptive and compensatory mechanisms that may be 
activated in knockout mice. In addition, modulating Parkin-mediated mitophagy may be a 
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1.1 Autophagy-Lysosome and Ubiquitin-Proteasome Systems for Protein Degradation 
            Intracellular protein degradation is a necessary process for maintaining cellular function 
and health, and it occurs via two unique systems: the ubiquitin-proteasome system (UPS) and 
the autophagy-lysosome system. The UPS is important for degradation of approximately 80% of 
proteins including short-lived or abnormally folded and damaged proteins.  Many of these 
proteins are involved in processes including DNA repair, transcription, translation, cell cycle, 
and cell stress response (Lilienbaum 2013). The proteasome contains both a core 20S subunit 
and a 19S regulatory subunit. The 20S subunit contains proteases and peptidases capable of 
breaking down proteins into single amino acids. The 19S subunit helps the 20S subunit 
recognize ubiquitinated proteins while also unfolding and translocating them to the 20S subunit. 
In addition to regulation by the 19S subunit, the 26S proteasome can also be regulated post-
translationally (Schmidt and Finley 2014). The autophagy-lysosome system is an evolutionary 
conserved pathway that is necessary for degradation of long-lived proteins and organelles in 
addition to aggregated proteins (Korolchuk, Menzies et al. 2010, Lilienbaum 2013). Autophagy 
is extensively discussed in section 1.2. Both of these systems help during starvation conditions 
by providing recycled amino acids, and they also both protect against cellular dysfunction and 
death by preventing the accumulation of damaged proteins.  
 In order for proteins to be degraded by the UPS, they must first be covalently tagged 
with ubiquitin, which occurs through a series of steps involving E1, E2, E3, and E4 ubiquitin 
ligases and other enzymes. Ubiquitin attaches to the E1 activating enzyme by binding its 
carboxy-terminal glycine to one of the E1 enzyme’s cysteine residues, which requires ATP. The 
activated ubiquitin is then transferred to a cysteine residue of an E2 conjugating enzyme. In the 
third step, the ubiquitin is attached to a protein that is already bound by an E3 ligase (Kornitzer 
and Ciechanover 2000). This can occur by two methods depending on if the E3 ligase contains 
a RING (really interesting new gene) domain or HECT (homologous to the E6AP carboxy 
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terminus) domain. In the case of the E3 ligase containing a RING domain, the E3 ligase 
transfers ubiquitin directly to the targeted protein (Metzger, Pruneda et al. 2014). When an E3 
ligase contains a HECT domain, ubiquitin is first transferred to a catalytic cysteine residue within 
the HECT domain, then the E3 ligase transfers the ubiquitin to the targeted protein (Scheffner 
and Kumar 2014). Once the first ubiquitin is attached, the targeted protein can become 
polyubiquitinated by attachment of additional ubiquitin proteins. The process of 
polyubiquitination can utilize an E4 ubiquitin ligase / polyubiquitinating enzyme, which attaches 
multiple ubiquitins to a lysine residue on an already protein-bound ubiquitin and signals for the 
protein to be degraded by the proteasome (Koegl, Hoppe et al. 1999, Lilienbaum 2013) (Figure 
1.1). Ubiquitinated proteins can also be degraded by autophagy.   
 The autophagy and ubiquitin-proteasome systems must both be tightly regulated in order 
to maintain cellular homeostasis and survival, and they are each activated by different 
conditions in the cell. Generally, autophagy degrades long-lived proteins (Yorimitsu and 
Klionsky 2005) while the UPS degrades short-lived proteins (Goldberg 2003). In addition, 
autophagy can degrade protein aggregates, while the UPS is restricted to degradation of 
soluble proteins (Korolchuk, Menzies et al. 2010, Lamark and Johansen 2012). The UPS and 
autophagy are also activated by ubiquitin-tagging of different lysine residues. The UPS is 
generally activated by polyubiquitination (at least 4 ubiquitins) of ubiquitin lysine 48 residues 
(Baboshina and Haas 1996, Thrower, Hoffman et al. 2000), while autophagy is generally 
activated by polyubiquitination of ubiquitin lysine 63 residues (Tan, Wong et al. 2008). Even 
though each system is activated by different signals, autophagy can compensate for a defective 
UPS to degrade damaged proteins (Ding, Ni et al. 2007, Pandey, Batlevi et al. 2007, Korolchuk, 
Menzies et al. 2010).  However, the UPS cannot compensate for defective autophagy 
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1.2.1 Three Types of Autophagy 
Autophagy occurs via three distinct pathways in mammalian cells: microautophagy, 
chaperone-mediated autophagy (CMA), and macroautophagy. All three pathways result in 
delivery of cargo to the lysosome for degradation.  
Microautophagy is a non-selective process induced in starvation conditions where 
portions of cytoplasm and intact organelles are engulfed directly by lysosomes via lysosome 
membrane protrusion without prior sequestration into autophagosomes. The invaginated 
lysosome containing its cargo then extends into an autophagic tube and contents are degraded 
in the lysosome (Mijaljica, Prescott et al. 2011). Currently, little is known about the regulation of 
microautophagy or its functional role in human health.  
Chaperone-Mediated Autophagy (CMA) only occurs in mammalian cells, and it is 
activated during prolonged starvation in order to provide nutrients and energy by degrading 
unnecessary proteins to replenish amino acids (Cuervo, Knecht et al. 1995). CMA is also 
activated during cellular injury, such as during oxidative stress for degradation of oxidized 
proteins (Kiffin, Christian et al. 2004). CMA is characterized by selection of specific cytosolic 
proteins by the chaperone heat shock-cognate protein of 70 kDa (hsc70), which shuttles 
unfolded proteins directly across the lysosome membrane (Chiang, Terlecky et al. 1989). 
Similar to microautophagy, CMA allows for degradation of proteins in lysosomes without prior 
sequestration into autophagic vesicles. However, CMA differs from microautophagy because 
CMA is a selective process that uses chaperones to target cargo for degradation. During CMA, 
individual proteins containing the KFERQ motif are selected for degradation (Dice 1990). 
Approximately 30% of proteins in the cytosol contain this motif (Chiang and Dice 1988). Proteins 
degraded by CMA include glycolytic enzymes, proteasome subunits, and transcription factors 
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among others (Arias and Cuervo 2011). Once delivered to the lysosome surface by hsc70, the 
selected protein interacts with the lysosome membrane protein lysosome-associated membrane 
protein type 2A (LAMP-2A) (Cuervo and Dice 1996). The protein then interacts with the 
lysosome form of hsc70 (lys-hsc70), which helps unfold the protein and later facilitates its 
translocation across the lysosome membrane for degradation (Chiang, Terlecky et al. 1989, 
Salvador, Aguado et al. 2000, Agarraberes and Dice 2001, Orenstein and Cuervo 2010). 
Maintenance of appropriate CMA levels is important because disruptions in CMA balance 
contribute to pathologies in neurodegenerative diseases, such as Parkinson’s disease and 
Alzheimer’s disease when CMA is reduced, and upregulation of cancer cell proliferation and 
survival when CMA is overactive (Cuervo and Wong 2014). However, the exact mechanisms for 
CMA regulation are not fully understood.  
Macroautophagy (hereafter referred to as autophagy) is an evolutionarily conserved 
process that results in a cell’s “self-eating” to degrade cellular proteins and organelles and is the 
most studied autophagic process. Autophagy is different from both microautophagy and CMA 
because sequestration of cargo in the cytosol occurs away from the lysosome membrane 
through the formation of autophagosomes. Autophagy is a protective process that provides the 
cell with nutrients in response to starvation to produce energy.  During starvation conditions, 
degradation of cytoplasmic proteins and organelles by autophagy provides amino acids that can 
be used in gluconeogenesis or to produce ATP by entering the Krebs cycle (Rabinowitz and 
White 2010). In addition, degradation of lipids by autophagy produces free fatty acids that can 
be used to produce energy by β-oxidation in the mitochondria (Singh, Kaushik et al. 2009). In 
addition to providing energy during starvation, autophagy also breaks down damaged proteins 
and organelles in order to prevent cellular injury.  Double-membrane autophagosomes engulf 
these proteins and organelles in the cytoplasm and then fuse with lysosomes to degrade their 
components via lysosome proteases (Parzych and Klionsky 2014). Autophagy can be both a 
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selective and non-selective process. Non-selective autophagy breaks down proteins and 
organelles during starvation in order to provide the cell with necessary nutrients. Selective 
autophagy removes damaged organelles and protein aggregates using specific receptors, and it 
can occur in both nutrient-rich and poor conditions. (Reggiori, Komatsu et al. 2012). Mitophagy, 
the focus of this dissertation, is selective degradation of mitochondria by autophagy. Mitophagy 
along with other forms of selective autophagy are further discussed in section 1.3. 
Autophagy is well studied in both yeast and mammalian cells. There are 5 steps in the 
autophagy process known as 1: initiation and nucleation of the phagophore/isolation membrane, 
2: elongation of the isolation membrane, 3: closure and maturation to form a double-membrane 
autophagosome, 4: fusion with lysosomes (or endosomes followed by lysosomes) to form the 
autolysosome, and 5: degradation of cargo in lysosomes by lysosomal hydrolases (Figure 
1.2.1A). Autophagy initiation occurs at a single phagophore assembly site (PAS) in yeast and is 
regulated by the Atg1-Atg13-Atg17-Atg31-Atg29 kinase complex (Feng, He et al. 2014). In 
mammalian cells, autophagy initiation is different than in yeast because it occurs at multiple 
cytosolic sites instead of a single PAS, and it is regulated by the UNC-51-like kinase 1 (ULK1) 
complex containing ULK1 (Atg1 yeast homolog), ATG13,  RB1-inducible coiled-coil 1 (FIP200), 
and Atg101 (Itakura and Mizushima 2010, Chen and Klionsky 2011, Parzych and Klionsky 
2014). Upon activation, ULK1 can auto-phosphorylate itself and then phosphorylate ATG13 and 
FIP200 to initiate autophagosome biogenesis (Jung, Jun et al. 2009). 
 After induction, nucleation occurs in both yeast and mammalian cells to generate 
phosphatidylinositol 3-phosphate (PtdIns(3)P), which is a phospholipid required for trafficking of 
phospholipid-binding proteins to the autophagosome membrane. Nucleation is regulated by a 
class III phosphatidylinositol 3-kinase (PtdIns3K) complex containing the PtdIns3K VPS34 
(Vps34 in yeast), p150 (Vps15 in yeast), Beclin1 (Atg6 in yeast), and either ATG14 or UVRAG 
(Feng, He et al. 2014, Parzych and Klionsky 2014). ATG14 and UVRAG both bind to Beclin1 
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mutually exclusively.  ATG14 in this complex is important for autophagy induction, and UVRAG 
in this complex can participate in both autophagy and endocytosis (Feng, He et al. 2014).  
After induction and nucleation, autophagosome membrane elongation in both yeast and 
mammalian cells requires two ubiquitin-like conjugation systems to form a phagophore. In 
ubiquitin systems, an E1 ligase is a ubiquitin activating enzyme, an E2 ligase is a ubiquitin 
conjugating enzyme, and an E3 ligase assists in transferring ubiquitin from an E2 ligase to a 
substrate, as previously discussed in section 1.1. The first ubiquitin-like system in autophagy 
includes formation of a complex from the autophagy-related genes (Atg genes) Atg12, Atg5, and 
Atg16 in yeast. This complex forms by irreversible attachment of Atg5 to Atg12 by the E1-
activating enzyme Atg7 and the E2-conjugating enzyme Atg10 (Ohsumi 2001, Yorimitsu and 
Klionsky 2005). Atg16 then reversibly binds the Atg5-Atg12 complex (Ohsumi 2001, Kuma, 
Mizushima et al. 2002, Yorimitsu and Klionsky 2005). Orthologs for mammalian cells are ATG5, 
ATG7, ATG12, and ATG16L1 (Ohsumi 2001). The second ubiquitin-like system is the Atg8 
system. In yeast, Atg8 is cleaved by Atg4 and a glycine residue is exposed at the C terminus of 
Atg8, making it available for binding to the E1-like activating enzyme Atg7. Atg8 is then 
activated by Atg7, which then transfers it to the E2-like conjugating enzyme Atg3. Atg3 in 
conjunction with the E3-like Atg5-Atg12-Atg16 complex then mediates lipidation of Atg8 through 
conjugation of its exposed glycine residue to phosphatidylethanolamine (PE) (Ichimura, Kirisako 
et al. 2000). Atg8 conjugation with PE is reversible because Atg8 can be cleaved after the 
glycine residue to separate it from PE by Atg4 (Kirisako, Ichimura et al. 2000). The Atg5-Atg12-
Atg16 complex mediates elongation and curvature of the autophagosome, but it dissociates 
from the autophagosome membrane after formation. Unlike the Atg5-Atg12-Atg16 complex, the 
Atg8-PE complex remains on the autophagosome membrane after formation (Yorimitsu and 
Klionsky 2005). The elongation process in mammalian cells is similar to yeast with LC3 acting 
as a homolog of Atg8. The cleaved form of LC3 with the exposed glycine residue is known as 
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LC3-1, and the PE-conjugated form is known as LC3-II (Geng and Klionsky 2008). Atg9 in yeast 
(ATG9 in mammals) is important for phagophore membrane expansion. It is unique because it 
is the only membrane-spanning Atg protein, and it helps induce membrane expansion by 
shuttling between the autophagosome formation site and peripheral sites to recruit membrane 
(Young, Chan et al. 2006). Sources for autophagosome membrane recruitment required for 
membrane elongation are still highly debated, but they are hypothesized to include endoplasmic 
reticulum, Golgi, the plasma membrane, and mitochondria (Parzych and Klionsky 2014).  
Once elongated, the phagophore matures and closes into a double-membrane 
autophagosome, but this process is still not completely understood.  The autophagosome later 
transports the cargo to the endosome or lysosome in mammalian cells or to vacuoles in yeast. 
In mammalian cells, movement of the autophagosome to the lysosome requires microtubules 
(Monastyrska, Rieter et al. 2009). In mammals, autophagosome-lysosome fusion requires both 
the GTPase RAB7 and the lysosome membrane protein LAMP-2. (Tanaka, Guhde et al. 2000, 
Jager, Bucci et al. 2004).  UVRAG activates RAB7 to promote the fusion of autophagosomes 
with lysosomes to form autolysosomes (Jager, Bucci et al. 2004). In yeast, fusion of the 
autophagosome with a vacuole releases an autophagic body into the lumen of the vacuole 
where it is degraded by vacuolar hydrolases. In both yeast and mammalian cells, the cargo 
within the autophagosome along with the autophagosome inner membrane are degraded in the 
vacuole or lysosome, respectively. The components resulting from the degradation are then 
exported into the cytoplasm for further use in protein synthesis and energy production (He and 
Klionsky 2009). In mammalian cells, autophagosomes can also first fuse with endosomes 
before later fusing with lysosomes (Berg, Fengsrud et al. 1998).  Autophagy machinery is 
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1.2.2 History of Autophagy  
           The term “autophagy” is a combination of the Greek words “phagy” and “auto” meaning 
eat and self, respectively (Yang and Klionsky 2010). Christian de Duve discovered lysosomes in 
1955, and he later described and coined the term “autophagy” after he observed single-
membrane vesicles containing organelles or cytoplasm in rat hepatic cell lysosomes by electron 
microscopy (EM) in 1963 (De Duve 1963). He also discovered alongside others that autophagy 
could be induced by glucagon (Ashford and Porter 1962, De Duve and Wattiaux 1966, Deter, 
Baudhuin et al. 1967). The first inhibitors of autophagy were discovered in 1977.  Pfeifer 
showed that insulin inhibits autophagy using EM analysis of rat liver cells (Pfeifer 1977), and 
Mortimore and Schworer showed that amino acids, specifically Leucine, Tyrosine, 
Phenylalanine, Glutamine, Proline, Histidine, Tryptophan, and Methionine,  also inhibit 
autophagy in rat liver cells (Mortimore and Schworer 1977). Seglen and Gordon showed that 
Leucine was the strongest amino acid inhibitor of autophagy in 1980 (Seglen, Gordon et al. 
1980). Seglen and Gordon also discovered the first pharmacological inhibitor of autophagy in 
1982, which was 3-methyladenine (3-MA) (Seglen and Gordon 1982). However, its mechanism 
of action was not proven until 1997 when Meijer’s group showed that 3-MA inhibits autophagy 
by targeting Class III phosphatidylinositol 3-kinase (PI-3K), which is required for 
autophagosome formation (discussed in section 1.2.1). Meijer and colleagues also showed that 
Rapamycin (discussed in section 1.2.1) was an autophagy inducer in 1995 (Blommaart, Luiken 
et al. 1995).   
 Even though early studies leading to the discovery of autophagy were performed in the 
mammalian system, most of the studies that have contributed to our current knowledge of the 
autophagic process were performed in yeast. Dr. Ohsumi, who is known as the “Father of 
Autophagy”, discovered many important genes and their functions in the autophagy pathway 
using studies in yeast.  Ohsumi’s group was the first to discover autophagy-related (Atg) genes 
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in yeast in 1993 using a genomic library screen (Tsukada and Ohsumi 1993), and they were 
also the first to describe functions of some of these genes in the autophagy pathway.  In 
addition, Ohsumi’s group was the first to show that the autophagy pathway in yeast is similar to 
that in mammalian cells (Tsukada and Ohsumi 1993, Mizushima, Sugita et al. 1998, Kabeya, 
Mizushima et al. 2000, Mizushima, Kuma et al. 2003). Dr. Beth Levine’s group also contributed 
to this knowledge by identifying Beclin 1 as the mammalian homolog of yeast Atg6 in 1999 
(Liang, Jackson et al. 1999). In 2000, LC3-II was shown to be on mammalian autophagosome 
membranes and was suggested to be used as a marker for detection of autophagy (Kabeya, 
Mizushima et al. 2000). 
 Even though Ohsumi discovered several autophagy genes in 1993, their function in the 
autophagy pathway was unknown for some time.  In 1997, Ohsumi’s group found that Atg1 is a 
kinase needed to initiate the autophagy pathway (Matsuura, Tsukada et al. 1997). Soon after, 
they along with Klionsky’s group proved that a ubiquitin-like Atg12 conjugation system is also 
required for autophagosome formation (Mizushima, Noda et al. 1998, Mizushima, Sugita et al. 
1998, Kim, Dalton et al. 1999). Ohsumi’s group also later proved the importance of Atg8 
lipidation for autophagosome formation (Ichimura, Kirisako et al. 2000) and showed that Atg8 is 
present on the autophagosome membrane (Kirisako, Baba et al. 1999). Finally in 2001, his 
group showed the importance of the Vps34 complex in the autophagy pathway (Kihara, Noda et 
al. 2001). Currently, there are over 30 known Atg genes. 
 
1.2.3 Regulation of Mammalian Autophagy  
 Autophagy is activated by starvation, ER stress, hypoxia, proteasome inhibition, 
oxidative stress, protein aggregates, and pathogen infection (He and Klionsky 2009, Ding 2010, 
Ding, Manley et al. 2011). Mammalian target of rapamycin (mTOR) is an inhibitor of autophagy 
activation and is considered to be the master regulator of autophagy. mTOR is a 
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serine/threonine kinase important for maintaining cell growth, protein synthesis, and cellular 
homeostasis, and it is divided into two complexes including mTOR complex 1 (mTORC1) and 
mTOR complex 2 (mTORC2). mTORC1 activity is regulated by the  phosphatidylionsital-3 
kinase (PI3K) / protein-kinase B (AKT) signaling pathway, the AMP-activated protein kinase 
(AMPK) signaling pathway, and by the presence of amino acids in the lysosome. The PI3K / 
AKT pathway and lysosomal amino acids both result in activation of mTORC1 and inhibition of 
autophagy. The AMPK signaling pathway results in mTORC1 inhibition and autophagy 
activation. There is currently not a lot known about the mTORC2 complex, but it has been 
shown to be an activator of AKT, which is a positive regulator of mTORC1, as mentioned 
previously (Sarbassov, Guertin et al. 2005). 
mTORC1 activation by the PI3K / AKT pathway requires insulin or growth factors, which 
bind the insulin receptor and lead to phosphorylation of AKT by PI3K. Activated AKT then 
phosphorylates and inactivates the tuberous sclerosis (TSC) tumor suppressor complex 
(TSC1/2), which is an mTORC1 inhibitor. TSC1/2 is a GTPase-activating protein (GAP) that 
inactivates the Ras homolog enriched in brain (Rheb) GTPase by converting it from the active 
GTP-bound form to the inactive GDP-bound form, and activated Rheb is needed for mTORC1 
activation.TSC1/2 phosphorylation by AKT results in its inactivation and dissociation from the 
lysosome, and dissociation of TSC1/2 from the lysosome by AKT-mediated phosphorylation 
results in Rheb activation, leading to activation of mTORC1 (Inoki, Li et al. 2002, Potter, 
Pedraza et al. 2002, Inoki, Zhu et al. 2003, He and Klionsky 2009, Menon, Dibble et al. 2014).  
mTORC1 activation by lysosomal amino acids is dependent on Rag GTPases (Rag A-
D), which are part of the ragulator complex on the lysosome. When amino acids are present in 
the lysosome, Rag proteins are activated and form heterodimers comprised of an A/B (GTP-
bound) subunit with a C/D (GDP-bound) subunit, which then bind to mTORC1 and recruit it to 
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the lysosome. Once on the lysosome, mTORC1 interacts with Rheb resulting in mTORC1 
activation (Sancak, Bar-Peled et al. 2010).  
AMPK, which is activated during low energy conditions by a high AMP/ATP ratio, inhibits 
mTORC1 signaling via phosphorylation of TSC2 in the TSC1/2 complex (Inoki, Zhu et al. 2003). 
In addition, AMPK can phosphorylate Raptor in the mTORC1 signaling pathway, which results 
in mTORC1 inactivation and autophagy activation (Gwinn, Shackelford et al. 2008). AMPK can 
also phosphorylate ULK1 on Ser317 and Ser 777, resulting in its activation and induction of 
autophagy (Kim, Kundu et al. 2011).  
mTORC1 inhibits autophagy by attaching to the ULK1/2 complex (ULK1/2, ATG13, 
FIP200) in mammalian cells. Once attached, the mTORC1 kinase phosphorylates ULK1/2 on 
Ser757, which prevents ULK1-mediated phosphorylation of ATG13 and FIP200. ULK1/2 
phosphorylation also disrupts the interaction between ULK1 and the positive autophagy 
regulator AMPK, resulting in autophagy inhibition. During starvation, mTORC1 dissociates from 
the ULK1/2 complex, allowing for autophagy activation (Jung, Jun et al. 2009, Kim, Kundu et al. 
2011). mTORC1 also regulates autophagy by phosphorylating and inhibiting nuclear 
translocation of transcription factor EB (TFEB), which is a transcription factor important for 
inducing lysosome and autophagy-specific genes. During starvation, the dephosphorylated form 
of TFEB is able to translocate to the nucleus and induce transcription of these genes 
(Settembre, Zoncu et al. 2012). A summary of mTOR-dependent autophagy regulation is shown 
in Figure 1.2.3. Autophagy can also be regulated by mTOR-independent mechanisms. For 
example, autophagy is regulated by the transcription factor FoxO3 (Forkhead box transcription 




























































1.2.4 Pharmacological Modulation of Autophagy 
Pharmacological modulators of autophagy are of great interest due to the role of 
autophagy in many pathological conditions such as cancer, drug-induced liver injury, 
neurodegenerative diseases, pathogenic infections, cardiovascular disease, liver disease, and 
aging (Ding 2010, Kroemer 2015). In addition, one of the key methods for studying autophagy 
involves its pharmacological modulation. Common drugs used for autophagy manipulation 
include drugs that target mTORC1 and drugs that are mTORC1-independent and target AMPK, 
phosphatidylinositol, and lysosome function. Several drug screens for determining new 
autophagy modulators have been completed or are currently ongoing, but the effects on 
autophagy by drugs found in these screens still need to be confirmed (Rubinsztein, Codogno et 
al. 2012). 
The role of mTOR in autophagy regulation was discussed in section 1.2.3. mTOR-
dependent modulators for autophagy activation include rapamycin (binds FK-506 and inhibits 
mTORC1), torin 1 (inhibits MTORC1 and mTORC2 kinase activity), and metformin (inhibits 
mTORC1 and activates ULK1 via AMPK activation), among others (Kim and Guan 2015, 
Vakifahmetoglu-Norberg, Xia et al. 2015). mTOR-independent inhibitors of autophagy include 
the PI3K inhibitors 3-Methyladenine (3-MA) and wortmannin, the calcium channel antagonist 
thapsigargin, and inhibitors of lysosomal degradation such as chloroquine and Bafilomycin A, 
which cause a rise in lysosomal pH. E64d, pepstatin A, and leupeptin also inhibit 
autophagosome degradation through inhibition of lysosome hydrolases, proteases, and 







1.2.5 Mechanisms for Detection of Autophagy Induction 
 Common methods for determining autophagy activation include analysis of 
autophagosome formation by electron microscopy (EM) and quantification of LC3-II and 
Sequestosome 1 /p62 protein levels by Western blot. Fluorescence microscopy for LC3 puncta, 
which are representative of autophagosome formation, is another commonly used method. In 
this dissertation, autophagosomes and lysosomes along with their contents were identified and 
quantified by EM. Initial autophagosomes (AVi) can be identified by their double membrane, and 
they contain intact organelles or cytosol. Late-stage autolysosomes (AVd) can be identified by a 
single membrane, and they contain organelles that are partially degraded (Klionsky, Abdalla et 
al. 2012) (Figure 4.4.5 G and J). Quantification of LC3-II protein levels by Western blot was 
also used in this dissertation for determining autophagy activation.  Both the lipidated (LC3-II, 16 
kDa) and delipidated (LC3-I, 18 kDa) forms of LC3 can be detected by western blot, but the 
lipidated LC3-II form is the only form that is present on mature autophagosomes, which is why it 
is commonly used as a marker of autophagy activation (Klionsky, Abdalla et al. 2012). In 
addition, determination of p62 protein levels by western blot was used for determining 
autophagy activation because p62 is degraded in the lysosome during autophagy (Manley, 
Williams et al. 2013). The role of p62 in autophagy is further discussed in section 1.3.2. 
The best approach for monitoring autophagy activation involves using these methods in 
combination with an autophagy flux assay. It is now widely accepted that proper analysis of 
autophagy activation requires an autophagy flux assay, which takes all parts of the autophagy 
pathway from autophagosome formation to degradation of cargo in the lysosome into account. 
The autophagy pathway is dynamic and involves many steps, which were previously discussed 
in section 1.2.1. Many of these steps can be activated or inhibited, causing results interpreted 
without an autophagy flux assay to be questionable. For example, an increase in LC3-II protein 
levels can be due to either increased autophagosome formation or decreased autophagosome 
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degradation in the lysosome. Therefore, assays used for determining autophagy activation, 
such as EM and quantification of LC3-II levels, should always be performed along with an 
autophagy flux assay to accurately determine autophagy activation or inhibition. In this 
dissertation, chloroquine (CQ) was used for all autophagy flux assays. CQ inhibits degradation 
of cargo in the lysosome by raising lysosome pH. When treatment with an autophagy inducer is 
combined with CQ, LC3-II levels, or the number of autophagosomes, will be increased 
compared to treatment with the inducer or CQ alone (Klionsky, Abdalla et al. 2012). 
 
1.2.6 Protective Roles of Autophagy in the Liver 
 Autophagy plays several important roles in the liver in order to maintain homeostasis 
and cell survival. One important role of autophagy in the liver is degradation of damaged 
organelles and aggregated proteins. Hepatocellular injury and death would occur if cellular 
components such as lipids, aggregated proteins, and damaged or excess organelles were 
allowed to accumulate over time in the absence of autophagy (Czaja, Ding et al. 2013) .   
Autophagy in the liver also allows for energy production during starvation. During 
starvation, autophagy in the liver provides amino acids and substrates needed for energy 
production and hepatocellular survival. At basal levels, autophagy degrades approximately 1.5% 
of hepatic protein in one hour. However, in starvation conditions, this level of hepatic protein 
degradation increases to 4.5% (Schworer, Shiffer et al. 1981).  
 Autophagy also helps regulate fat accumulation in the liver by degrading lipid droplets, 
which provides free fatty acids that can then be used in the β-oxidation pathway for energy 
production. The process of degradation of fat in the liver via autophagy is a selective from of 
autophagy termed lipophagy (Singh, Kaushik et al. 2009, Liu and Czaja 2013).  
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Autophagy also has several important roles in protection from liver diseases. The role of 
autophagy in protection against alcoholic liver disease (ALD) and drug-induced liver injury by 




1.3 Selective Autophagy with a Focus on Mitophagy for Degradation of Damaged 
Mitochondria 
 Selective autophagy occurs in nutrient rich or poor conditions and functions to isolate 
and degrade damaged proteins and organelles (Reggiori, Komatsu et al. 2012). Different types 
of selective autophagy are named according to the cargo they degrade. Reticulophagy or 
ERphagy is for degradation of endoplasmic reticulum (Hamasaki, Noda et al. 2005), ribophagy 
is for degradation of ribosomes (Kraft, Deplazes et al. 2008), xenophagy is for degradation of 
pathogens (Levine 2005), pexophagy is for degradation of peroxisomes (Dunn, Cregg et al. 
2005), lipophagy is for degradation of lipid droplets (Singh, Kaushik et al. 2009), aggrephagy is 
for degradation of protein aggregates (Yamamoto and Simonsen 2011), and mitophagy, the 
subject of this dissertation, is the selective degradation of damaged mitochondria by autophagy 
(Lemasters 2005, Narendra, Tanaka et al. 2008). John Lemasters gave “mitophagy” its name in 
2005 (Lemasters 2005), but mitochondria were observed in lysosomes by Ashford and Porter in 
1962 (Ashford and Porter 1962). Mechanisms of mitophagy induction have been well studied in 
yeast and in mammalian cells. However, most have not been studied in the liver. There are 
several mechanisms for mitophagy induction in mammalian systems including both Parkin-
dependent (discussed in section 1.3.2) and Parkin-independent pathways (discussed in section 
5.1.1).  In addition, mitochondrial dynamics (fission and fusion) are important for proper 
mitophagy induction.    
 
1.3.1 Mitochondrial Fission and Fusion are Important for Mitophagy 
Mitochondria are dynamic organelles that continuously undergo fission and fusion, and 
the length of mitochondria is determined by their fission and fusion rates. Mitochondria can be 
either a large network of fused organelles or they can be divided into many smaller fragments 
depending on the needs of the cell. These fission and fusion events are necessary for cell 
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survival because they allow the cell to adapt to changing conditions needed for cell growth, 
division, and distribution of mitochondria during differentiation (van der Bliek, Shen et al. 2013). 
Mitochondrial fission and fusion also allow the cell to adapt to injury because damaged 
mitochondria can segregate from healthy mitochondria, leading to degradation of damaged 
mitochondria by mitophagy and fusion of healthy mitochondria (Twig, Elorza et al. 2008).  
Mitochondrial fusion in mammals is mediated by the pro-fusion genes mitofusin 1 and 
mitofusin 2 (MFN1/2) and optic atrophy 1 (OPA1). MFN1/2 are GTPases that are responsible for 
fusion of outer mitochondrial membranes, and OPA1 is a dynamin-related GTPase responsible 
for fusion of inner mitochondrial membranes. Outer and inner mitochondrial membrane fusions 
mostly occur simultaneously (Westermann 2010, van der Bliek, Shen et al. 2013). Mitochondrial 
fission in mammals is mediated by dynamin-related protein 1 (Drp1), which is a cytosolic protein 
that can be recruited to the surface of mitochondria where it interacts with mitochondrial fission 
1 (Fis1) to initiate mitochondrial fission (Westermann 2010). It has been suggested that 
mitochondria fission factor (Mff), which is an outer mitochondrial membrane protein that 
interacts with Drp1, is an essential factor for Drp1-mediated mitochondrial fission (Gandre-
Babbe and van der Bliek 2008, Otera, Wang et al. 2010).  In addition, mitochondria and 
endoplasmic reticulum are often tightly associated and in physical contact. It was reported that 
mitochondrial fission proteins, such as Drp1, are localized at the endoplasmic reticulum-
mitochondria contact site and that the endoplasmic reticulum may play a role in the process of 
mitochondrial fission (Friedman, Lackner et al. 2011).  
It has been suggested that fragmented mitochondria are more easily engulfed by 
autophagosomes during mitophagy. In addition, elongated mitochondria are spared from 
autophagosome sequestration (Ding and Yin 2012). After photo-labeling, mitochondria 
underwent continuous cycles of fission and fusion, and fission events resulted in two sets of 
daughter mitochondria with either increased or decreased membrane potential (Twig, Elorza et 
23 
 
al. 2008). Daughter mitochondria with higher membrane potential proceeded to fusion while 
depolarized daughter mitochondria were degraded by mitophagy (Twig, Elorza et al. 2008). 
Therefore, mitochondrial fission is a necessary step for mitophagy induction. However, 
mitochondrial fission alone is not enough to induce mitophagy. Mitochondria must be both 
damaged/depolarized and fragmented and may also possibly need to recruit other autophagy 
receptor proteins for mitophagy induction to occur (Ding and Yin 2012). In addition, excessive 
fusion of mitochondria has been shown to inhibit the mitophagy process (Twig and Shirihai 
2011), further suggesting an importance of mitochondrial fragmentation as a prerequisite to 
mitophagy induction. 
 
1.3.2 Parkin-dependent Mitophagy 
Parkin is encoded by the Park2 gene and is a 465 amino acid protein (Kitada, Asakawa 
et al. 1998). Parkin is well known for its protective role in the brain because loss of Parkin plays 
a role in development of Autosomal Recessive Parkinson’s disease, and the Park2 gene was 
discovered in 1997 by Mizuno’s group as an unidentified gene responsible for this disease 
(Matsumine, Saito et al. 1997). The gene was cloned in 1998 by Shimizu’s group (Kitada, 
Asakawa et al. 1998). Approximately 10% of early onset Parkinson’s disease cases are caused 
by mutations in the Park2 gene (Houlden and Singleton 2012), and gene mutations can occur 
throughout the Park2 gene and cause loss of Parkin function (Wauer and Komander 2013, 
Seirafi, Kozlov et al. 2015). In addition to genetic mutations, Parkin can also be inactivated post-
translationally via oxidation, nitrosylation, or phosphorylation (Walden and Martinez-Torres 
2012). Even though the majority of research regarding Parkin has been related to 
neurodegenerative diseases such as Parkinson’s disease, we found that Parkin is also highly 
expressed in the liver in mice (Ding and Yin 2012).   
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Parkin is an E3 ubiquitin ligase (Shimura, Hattori et al. 2000). The mechanism for 
ubiquitination by E3 ligases was discussed in section 1.1. Parkin contains several domains 
including a UBL (ubiquitin-like) domain, which is recognized by the proteasome, and  three 
RING (really interesting new gene) domains (RING0, RING1, and RING2) in addition to an IBR 
(in between RING) domain (Figure 1.3.2A). The RING1 domain contains an E2 ligase binding 
site, the RING2 domain contains a catalytic cysteine residue (Cys431) necessary for transfer of 
ubiquitin from Parkin to substrate, and the RING0 domain is a zinc-finger domain (Hristova, 
Beasley et al. 2009, Riley, Lougheed et al. 2013). Parkin is a RING-HECT (RING and HECT 
domains discussed in section 1.1) hybrid E3 ligase. Parkin does not have a HECT domain, but it 
transfers ubiquitin to substrate using a combination of mechanisms from RING and HECT E3 
ligases. To ubiquitinate a substrate protein, Parkin first transfers ubiquitin from an E2 ligase to 
its RING1 domain and then moves it to its RING2 domain. The ubiquitin is transferred within the 
RING2 domain to a catalytic Cys431 residue before being further transferred to a lysine amino 
group on the substrate protein (Wenzel, Lissounov et al. 2011, Riley, Lougheed et al. 2013, 
Trempe, Sauve et al. 2013, Zheng and Hunter 2013).  
Parkin is well known to induce mitophagy in in vitro systems after treatment with the 
mitochondrial uncoupler Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) via ubiquitination 
of outer mitochondrial membrane proteins.  Parkin was originally found to be involved in the 
mammalian mitophagy pathway in 2008 by Richard Youle’s group (Narendra, Tanaka et al. 
2008). Parkin translocated from the cytosol to depolarized mitochondria in Parkin-expressing 
HEK293 cells and in HeLa cells with YFP-Parkin overexpression after CCCP treatment. In 
addition, Parkin preferred depolarized mitochondria to healthy mitochondria because Parkin 
only translocated to depolarized mitochondria after CCCP treatment, which was shown using 
MitoTracker Red staining, a dye used to analyze mitochondrial polarization. HeLa cells with 
lower MitoTracker Red intensity, indicative of depolarization, had a greater accumulation of 
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YFP-Parkin expression after CCCP treatment. Furthermore, mitochondrial mass was decreased 
in Parkin-overexpressing HeLa cells after CCCP treatment but unchanged in non-Parkin 
expressing HeLa cells, suggesting that Parkin recruitment to depolarized mitochondria induced 
their degradation. Finally, Parkin co-localized with the autophagosome marker LC3 after CCCP 
treatment, indicating that Parkin-induced degradation of mitochondria was via mitophagy. Parkin 
also selectively translocated to damaged mitochondria while avoiding healthy mitochondria, 
which was analyzed by fluorescence loss in photobleaching (FLIP) in YFP-Parkin expressing 
HeLa cells (Narendra, Tanaka et al. 2008).  
 Parkin-dependent mitophagy requires both Parkin and PINK1 (phosphatase and tensin 
homolog (PTEN)-induced kinase 1). PINK1 is upstream of Parkin in this pathway because 
overexpression of Parkin in PINK1-deficient Drosophila partially rescued the PINK1 mutant 
phenotype while overexpression of PINK1 failed to do so in Parkin-deficient Drosophila (Clark, 
Dodson et al. 2006, Park, Lee et al. 2006, Yang, Gehrke et al. 2006). In addition, Parkin directly 
interacts with PINK1 (Um, Stichel-Gunkel et al. 2009), and overexpression of PINK1 alone can 
initiate translocation of Parkin to mitochondria without mitochondrial damage (Kawajiri, Saiki et 
al. 2010). The specificity for PINK1’s role in recruiting Parkin was further shown by ectopic 
expression of PINK1 on peroxisomes, which resulted in recruitment of Parkin and degradation 
of the PINK1-expressing peroxisomes by autophagy (Lazarou, Jin et al. 2012).  
PINK1 promotes Parkin-mediated mitophagy by recruiting Parkin to damaged 
mitochondria. PINK1 also activates Parkin’s E3 ligase activity to induce ubiquitination of 
mitochondrial outer membrane proteins and subsequent degradation of mitochondria in 
autophagosomes. PINK1 is normally cleaved and degraded in healthy mitochondria. However, 
PINK1 becomes stabilized on the outer mitochondrial membrane when mitochondria are 
depolarized, which signals Parkin recruitment to damaged mitochondria. To induce PINK1 
cleavage in healthy mitochondria, the transporter outer membrane (TOM) complex on the outer 
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mitochondrial membrane imports PINK1 into the inner mitochondrial membrane through the 
transporter inner membrane (TIM)  complex where it is degraded by PARL (presenilin-
associated rhomboid-like protein) (Jin, Lazarou et al. 2010). Cleavage by PARL removes the N-
terminus of PINK1, and the truncated PINK1 protein is released into the cytosol where it is 
degraded by the UPS (Yamano and Youle 2013). However, when mitochondria are depolarized, 
import of PINK1 into the inner mitochondrial membrane is blocked and PINK1 is no longer 
cleaved and degraded and instead becomes stabilized on the outer mitochondrial membrane 
(Jin, Lazarou et al. 2010). Accumulation of misfolded proteins in the mitochondria can also 
stabilize PINK1 on the outer mitochondrial membrane without mitochondrial depolarization. 
However, the mechanism for PINK1 stabilization in this model is unknown (Jin and Youle 2013). 
In addition to its stabilization on the outer mitochondrial membrane, PINK1 must also 
phosphorylate itself on Serine228 and Serine204 to recruit Parkin to mitochondria (Okatsu, Oka 
et al. 2012).  
In addition to PINK1, several other genes were found to be important for regulation of 
Parkin mitochondrial translocation using a genome-wide small interfering RNA (siRNA) 
screening. Translocase of outer mitochondrial membrane 7 (TOMM7) stabilizes PINK1 on the 
outer mitochondrial membrane whereas seven in absentia homolog 3 (SIAH3), a mitochondrial 
resident protein, de-stabilizes PINK1 on mitochondria. Furthermore, two other proteins, HSPA1L 
(an HSP70 family protein) and Bcl2-associated athanogene 4 (BAG4, a nucleotide exchange 
factor for HSP70), positively and negatively regulate Parkin mitochondrial translocation, 
respectively (Hasson, Kane et al. 2013).  
Parkin, unless activated, remains in an auto-inhibited state by several mechanisms, 
preventing its transfer of ubiquitin to substrate. The RING0 domain blocks the RING2 domain, 
preventing ubiquitin transfer. The UBL domain of Parkin also blocks the E2 binding site on the 
RING1 domain, preventing acceptance of ubiquitin from an E2 ligase. In addition, there is 
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distance between the E2 binding site and the E2 catalytic Cys431 residue within the RING2 
domain that requires a conformational change to allow for ubiquitin transfer from E2 to E2-
Cys431 (Riley, Lougheed et al. 2013, Trempe, Sauve et al. 2013, Wauer and Komander 2013). 
PINK1-mediated phosphorylation of Parkin activates Parkin’s E3 ligase activity. PINK1 
phosphorylates Ser65 in Parkin’s UBL domain (Kondapalli, Kazlauskaite et al. 2012, Shiba-
Fukushima, Imai et al. 2012, Iguchi, Kujuro et al. 2013), which promotes a conformational 
change in Parkin and activation of its E3 ligase activity allowing it to transfer ubiquitin from its E2 
binding site to its E2-Cys431 residue and finally to its targeted outer mitochondrial membrane 
protein (Iguchi, Kujuro et al. 2013). It was also recently shown that PINK1 phosphorylates 
ubiquitin at Ser65. Ser65-phosphorylated ubiquitin binds to Ser65-phosphorylated Parkin with 
21-fold greater affinity compared to non-phosphorylated Parkin, resulting in greater levels of 
Parkin activity and mitochondrial protein ubiquitination (Kane, Lazarou et al. 2014, Koyano, 
Okatsu et al. 2014). PINK1-induced phosphorylation of both Parkin and Ubiquitin at Ser65 acts 
as a feed-forward loop for ubiquitination of substrate proteins on the outer mitochondrial 
membrane. Once Parkin is recruited to the mitochondria and activated by Ser65 
phosphorylation, PINK1 phosphorylates ubiquitin (Ser65) attached to mitochondrial proteins by 
Parkin, which tethers Parkin to the mitochondria allowing for further ubiquitination of outer 
mitochondrial membrane proteins by Parkin to initiate mitophagy (Ordureau, Sarraf et al. 2014, 
Shiba-Fukushima, Arano et al. 2014). 
Parkin ubiquitinates several mitochondrial outer membrane proteins through lysine48 
and lysine63 ubiquitin linkages (Chan, Salazar et al. 2011) with the help of four known E2 
ligases: UBE2L3, UBE2D2, UBE2D3, and UBE2N (Geisler, Vollmer et al. 2014). Harper’s group 
found 36 outer mitochondrial membrane proteins that are Parkin substrates (Sarraf, Raman et 
al. 2013). The most studied of these substrates for mitophagy initiation include the mitochondrial 
fusion proteins MFN1/2, the mitochondrial trafficking protein Miro1, Translocase of outer 
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mitochondrial membrane 20 (TOM20), and Voltage-dependent anion channel (VDAC). 
Ubiquitination of MFN1/2 initiates their subsequent degradation by the proteasome resulting in 
mitochondrial fission and fragmentation (Gegg, Cooper et al. 2010, Geisler, Holmstrom et al. 
2010, Poole, Thomas et al. 2010, Chan, Salazar et al. 2011). Mitochondria are under 
continuous states of fission and fusion, and mitochondrial fission is important for mitophagy 
induction in liver hepatocytes among other cell types as discussed in section 1.3.1 (Twig, Elorza 
et al. 2008, Kim and Lemasters 2011, Ding and Yin 2012). MFN2 may have a role in mediating 
Parkin recruitment to damaged mitochondria in addition to PINK1 (Chen and Dorn 2013). 
Parkin-induced ubiquitination of Miro initiates mitochondrial arrest, which can segregate 
damaged mitochondria from healthy mitochondria prior to mitophagy (Wang, Winter et al. 2011). 
Parkin-induced ubiquitination of VDAC leads to recruitment of the autophagy adaptor protein 
p62 to the mitochondria (Geisler, Holmstrom et al. 2010). p62 contains both a ubiquitin-
associated domain (UBA) and also an LC3-interacting region (LIR), which allows it to bind to 
ubiquitinated proteins and organelles and transport them to autophagosomes for degradation by 
binding to LC3 on the autophagosome membrane (Manley, Williams et al. 2013). The role of 
p62 in mitophagy is currently controversial because some have shown it is required for 
mitophagy (Ding, Ni et al. 2010, Geisler, Holmstrom et al. 2010), while others have shown that it 
is not (Narendra, Kane et al. 2010, Okatsu, Saisho et al. 2010). However, BNIP3L/Nix is also a 
Parkin substrate, and Parkin-mediated ubiquitination of Nix recruits the autophagy adaptor 
protein Neighbor of BRCA Gene 1 (NBR1) to damaged mitochondria to help shuttle them to the 
autophagosome for degradation (Gao, Chen et al. 2015). Therefore, NBR1 and/or p62 may act 
in the mitophagy pathway to degrade damaged mitochondria. In addition, K48 ubiquitination of 
specific outer mitochondrial membrane proteins by Parkin induces their degradation via the 
proteasome, which causes mitochondrial fragmentation and may improve mitophagy efficiency 
by segregating mitochondria into smaller pieces so they can be more easily engulfed by 
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autophagosomes (Chan, Salazar et al. 2011, Yoshii, Kishi et al. 2011). However, the exact 
mechanism for how autophagosomes are recruited to damaged mitochondria after Parkin-
induced ubiquitination of outer mitochondrial membrane proteins is unknown.  Parkin-mediated 
induction of mitophagy is shown in Figure 1.3.2B. 
Other proteins involved in activation of the Parkin-mediated mitophagy pathway are Nix 
and Smurf1.  In addition to its role in recruiting NBR1, Nix also promotes the recruitment of 
Parkin to depolarized mitochondria after CCCP treatment in MEF cells. CCCP treatment caused 
mitochondrial depolarization, ROS accumulation, and translocation of Parkin to mitochondria in 
Parkin-expressing MEF cells while NIX-deficient MEF cells failed to induce mitochondrial 
depolarization and Parkin recruitment, suggesting that NIX may also be required for Parkin-
dependent mitophagy induction (Ding, Ni et al. 2010). SMURF1 is an E3 ubiquitin ligase similar 
to Parkin that was found to have a role in CCCP-induced mitophagy mediated by Parkin. Unlike 
Parkin, the ubiquitin ligase function of SMURF1 does not play an important role in mitophagy 
induction. Instead, the C2 domain of SMURF1 is required for engulfment of damaged 
mitochondria by autophagosomes. In addition, SMURF1-deficient mice have accumulated 
mitochondria that are damaged in their heart, brain, and liver (Orvedahl, Sumpter et al. 2011).  
Parkin-induced mitophagy is negatively regulated by ubiquitin-specific peptidases 30 
(USP30) and USP15, which are deubiquitinases localized to mitochondria that inhibit Parkin-
mediated mitophagy by removing ubiquitin from damaged mitochondria previously attached by 
Parkin.  Knockdown of USP30 rescued defective mitophagy caused by pathogenic mutations in 
Parkin and improved mitochondrial integrity in Parkin- or PINK1-deficient flies, protecting them 
against paraquat toxicity (Bingol, Tea et al. 2014). Knockdown of USP15 in Park2 mutated 
human fibroblasts rescued mitophagy and also protected from mitochondrial defects in 
Drosophila (Cornelissen, Haddad et al. 2014). Parkin has also been shown to ubiquitinate itself 
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1.3.3 Methods for Mitophagy Detection  
 EM and Western blot analysis were used for mitophagy analysis in this dissertation. EM 
is an easy method for detection of mitophagy induction via visualization of mitochondria in 
autophagosomes and autolysosomes. Mitochondria present in autophagosomes are identified 
by their density and cristae, while mitochondria in autolysosomes are identified by their density 
along with the occasional presence of their membrane structure.  However, this method is not 
very quantitative because it only allows visualization of a few cells.  
Mitophagy can also be assessed by Western blot analysis for mitochondrial protein 
degradation along with changes in the autophagy markers LC3-II and p62 (previously discussed 
in section 1.2.5).  For mitochondrial protein degradation, it is important to look at several 
mitochondrial proteins from the outer membrane, inner membrane, and matrix because they 
have been shown to be degraded by different systems at different rates. Mitochondrial 
membrane proteins are degraded via the proteasomal system while the mitochondrial matrix 
proteins are removed by autophagy (Chan, Salazar et al. 2011, Yoshii, Kishi et al. 2011). 
However, not all matrix proteins are removed by autophagy. It is still unclear how autophagy 
selectively removes some matrix proteins but not others, but Abeliovich et al. showed that 
different mitochondrial matrix proteins are degraded at distinct different rates during yeast 
mitophagy. They found that mitochondria underwent an active matrix protein segregation 
process, which is regulated by the yeast fission molecule Dynamin-1. In addition, the rates of 
mitophagic degradation of matrix proteins correlate with the degree of physical segregation of 
specific matrix proteins (Abeliovich, Zarei et al. 2013) These findings suggest that mitochondrial 
dynamics are important for mitochondrial matrix remodeling/segregation, which may help to 
explain why mitochondrial proteins are degraded at different rates by mitophagy.  In addition to 
mitochondrial protein degradation, mitochondrial and cytosolic protein extracts can be used to 
look for increases in p62 and LC3-II protein expression in the mitochondrial fraction, which hints 
33 
 
at induction of mitophagy. When using p62 and LC3-II as mitophagy markers, it is best to use 
an autophagic flux assay (previously discussed in section 1.2.5).  When monitoring occurrence 
of mitophagy, it is important to use a combination of techniques to overcome pitfalls of currently 
available assays. More reliable assays are needed for quantification and detection of mitophagy 




1.4 Mitophagy Protects against Liver Injury 
Mitochondria are considered the “power house” of the cell due to being the major site of 
ATP production. Mitochondria also have other functions including heme synthesis, β-oxidation 
of fatty acids, and maintenance of calcium homeostasis (Duchen 2004). It is well known that 
mitochondria act as central executioners of cell death including apoptotic and necrotic cell 
death. As a result, mitochondrial dysfunction is a key event in progression of liver injury and 
disease due to accumulation and release of damaging reactive oxygen species (ROS), 
decreased oxidative phosphorylation and impaired ATP synthesis, and release of pro-apoptotic 
proteins or opening of their mitochondrial permeability transition pore for initiation of cell death 
by apoptosis or necrosis. Mitochondrial damage is reflected by decreased respiratory 
parameters, decreased enzyme activity, accumulation of mitochondrial DNA mutations, and 
increased oxidative stress (Hill, Benavides et al. 2012). Mitochondrial dysfunction plays a role in 
progression of many different types of liver disease such as alcoholic liver disease, non-
alcoholic liver disease, Hepatitis C, cholestasis (Grattagliano, Russmann et al. 2011) and drug-
induced liver injury (Han, Dara et al. 2013).  
Mitochondria can maintain homeostasis through many different mechanisms. They have 
their own proteolytic system, allowing them to degrade misfolded proteins that could potentially 
disrupt mitochondrial function (Baker and Haynes 2011, Matsushima and Kaguni 2012). In 
addition, outer mitochondrial membrane proteins that are damaged can be degraded by the 
proteasome (Karbowski and Youle 2011). Mitochondria can also repair damaged components 
via constant fission and fusion (further discussed in section 1.3.1), which allows for segregation 
of damaged mitochondria and exchange of material between healthy mitochondria (Twig, Elorza 
et al. 2008, van der Bliek, Shen et al. 2013). Furthermore, mitochondria-derived vesicles can 
bud off of mitochondria and fuse with lysosomes to degrade their cargo (further discussed in 
section 1.5.1) (Soubannier, Rippstein et al. 2012) or damaged mitochondria can form 
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mitochondrial spheroids and acquire lysosomal markers to possibly serve as an alternative 
pathway for removal of damaged mitochondria (further discussed in section 1.5.2) (Ding, Guo et 
al. 2012, Ding, Li et al. 2012, Yin and Ding 2013). Finally, mitophagy (discussed in section 1.3) 
initiates engulfment of damaged mitochondria by autophagosomes to trigger their degradation in 
the lysosome (Youle and Narendra 2011, Ding and Yin 2012, Lemasters 2014), which is an 
important mechanism for protection against liver injury. Mitophagy is activated by many different 
cellular stress conditions including loss of mitochondrial membrane potential, changes in 
mitochondrial bioenergetics, accumulation of cellular ROS, mitochondrial DNA damage, or 
accumulation of protein aggregates in the mitochondria (Liu, Sakakibara et al. 2014). Removing 
damaged mitochondria by mitophagy prevents the spread of oxidative stress, respiratory chain 
damage and mitochondrial DNA mutation, which helps to prevent cell death, maintain 
mitochondrial bioenergetics, and uphold fatty acid oxidation by preserving a healthy population 
of mitochondria.  
 
1.4.1 Mitophagy Prevents Apoptosis and Necrosis 
 Hepatocyte cell death via either apoptosis or necrosis worsens liver disease and injury 
progression. Cell death by apoptosis in the liver plays major roles in progression of cholestasis, 
alcoholic liver disease, Hepatitis C, and fibrosis (Luedde, Kaplowitz et al. 2014). Apoptosis is a 
method of programmed-cell death that is characterized by chromatin condensation, DNA 
fragmentation, cell shrinkage, and cellular fragmentation into membrane-enclosed and 
organelle-containing apoptotic bodies. Apoptosis occurs by either the extrinsic or intrinsic 
pathway. The extrinsic pathway is mediated by death receptors Fas, Tumor necrosis factor-
alpha (TNF-α) receptor 1 (TNF-R1), and death receptors 4 and 5 (DR4/5) and their 
corresponding ligands FasL (Fas ligand), TNF-α, and TRAIL (TNF-related apoptosis-inducing 
ligand), which are all expressed in the liver. After a ligand binds its death receptor, a proteolytic 
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cascade results in activation of effector caspases and leads to cell death. The intrinsic pathway 
is triggered by DNA damage, oxidative stress, and toxins among other intracellular stress 
inducers, which causes mitochondrial damage and release of mitochondrial apoptotic factors 
such as cytochrome c and SMAC/DIABLO to trigger apoptosis. This pathway is regulated by 
proteins of the B-cell lymphoma-2 (Bcl-2) family. However, in some cell types such as 
hepatocytes, activation of the extrinsic apoptotic pathway is not sufficient to induce apoptosis. In 
hepatocytes, upon activation of the extrinsic pathway, caspase 8 cleaves the pro-apoptotic 
protein Bid into tBid (truncated bid), which translocates to the mitochondria and activates Bax or 
Bak. Bax or Bak is then inserted into the mitochondrial membrane, which results in 
permeabilization of the mitochondrial outer membrane and release of pro-apoptotic proteins 
from the mitochondrial intramembrane space into the cytosol and thus activates the intrinsic 
apoptotic pathway. Proteins released include proteins that promote further caspase activation 
(cytochrome c and SMAC/DIABLO) and proteins that translocate to the nucleus to degrade DNA 
(apoptosis inducing factor and endonuclease G) (Guicciardi, Malhi et al. 2013). 
Necrosis in the liver is caused by drug-induced liver injury, such as acetaminophen 
overdose (further discussed in section 1.6) (Luedde, Kaplowitz et al. 2014) and 
ischemia/reperfusion-induced liver injury (Guicciardi, Malhi et al. 2013). Necrosis results from  
permeabilization of the cell membrane, loss of membrane potential and cell membrane rupture, 
which leads to release of cellular contents followed by an inflammatory response (Guicciardi, 
Malhi et al. 2013). Interestingly, mitochondrial damage also plays a critical role in either 
acetaminophen overdose or ischemia/reperfusion-induced necrosis. The lack of apoptosis in 
these conditions is likely due to the severe mitochondrial damage resulting in the rapid depletion 
of cellular ATP levels because ATP is required for caspase activation. 
 Mitochondria that are damaged produce ROS and release pro-apoptotic proteins or 
result in inflammation when necrotic, which amplifies cell death and injury. Therefore, it is 
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important to remove these damaged mitochondria to avoid hepatocellular death and injury in the 
liver (Mizushima, Levine et al. 2008). Mitophagy is protective against both apoptotic and 
necrotic cell death in the liver by removing damaged mitochondria.   For example, mitophagy 
has been shown to be protective against apoptosis and injury induced by alcoholic-liver disease 
(further discussed in section 4) (Ding, Li et al. 2010, Lin, Zhang et al. 2013) and also against 
necrosis in acetaminophen-induced liver injury (further discussed in section 3) (Ni, Bockus et al. 
2012, Ni, Williams et al. 2013, Lin, Wu et al. 2014, Saberi, Ybanez et al. 2014).  
 
1.4.2. Mitophagy Maintains Mitochondrial Bioenergetics  
 Mitochondrial bioenergetics refers to a mitochondrion’s capacity and efficiency for ATP 
production (Liesa and Shirihai 2013) and are regulated by substrate availability, cell energy 
requirements, and the overall quality and abundance of the mitochondria population (Hill, 
Benavides et al. 2012). Interestingly, mitochondrial bioenergetics and mitochondrial dynamics 
are linked. Cells in an environment rich with nutrients have fragmented mitochondria, while cells 
in a starvation environment have more elongated and fused mitochondria. Furthermore, these 
elongated mitochondria avoid degradation by mitophagy, once again emphasizing the 
importance of mitochondrial fragmentation for mitophagy induction as previously discussed in 
section 1.3.1 (Molina, Wikstrom et al. 2009, Gomes, Di Benedetto et al. 2011).   
 Removal of damaged mitochondria via mitophagy is crucial for preventing cell death and 
injury caused by mitochondrial uncoupling, which is described as a dysfunctional proton 
gradient in mitochondria that leads to uncoupling of oxidative phosphorylation and ATP 
production. Uncoupling causes damaged mitochondria and cell death by apoptosis (Hill, 
Benavides et al. 2012). Removing uncoupled mitochondria via mitophagy prevents spread of 
oxidative stress, cell death, and liver injury by maintaining a healthy population of mitochondria 
that can produce necessary energy efficiently for cell survival.  
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1.4.3 Mitophagy Maintains Fatty Acid Oxidation 
 Mitochondrial fatty acid oxidation (FAO) plays many important functions in the liver 
including providing substrates for gluconeogenesis, contribution of electrons to the respiratory 
chain for oxidative phosphorylation and ATP production, generation of acetyl-CoA for 
gluconeogenesis and ketogenesis (Kompare and Rizzo 2008), and degradation of lipids to 
prevent hepatocellular steatosis (Gao and Bataller 2011). 
Fatty acids are a common source of energy and are often stored as non-toxic 
triaglycerols. They originate from several sources including de novo lipogenesis, triacylglycerol 
stores, and plasma non-esterified fatty acids released from adipose tissue (Nguyen, Leray et al. 
2008). Long-chain fatty acids used for FAO are stored mainly in the adipose tissue as 
components of triglycerides or phospholipids. Lipases cause these triglycerides to release their 
fatty acids, which are then transported to the liver and muscle via the bloodstream. For use in 
FAO, these long-chain fatty acids must first be converted into acylcarnitine esters so they can 
be transported across the inner mitochondrial membrane into the mitochondrial matrix. The rate-
limiting enzyme for shuttling these carnitines across the mitochondrial membrane is carnitine 
palmitoyltransferase I (CPT I), which is inhibited by malonyl-CoA in fed conditions. However, in 
fasting conditions, malonyl-CoA concentrations drop and CPTI is activated to begin FAO. Once 
in the mitochondria, fatty acids are processed by β-oxidation resulting in the release of acetyl-
CoA, which can enter the TCA cycle, and production of FADH2 and NADH, which donate their 
electrons to the electron transport chain for ATP production (Kompare and Rizzo 2008, Nguyen, 
Leray et al. 2008).  
Several liver diseases are exacerbated due to dysfunctional mitochondria and FAO such 
as fatty liver caused by alcoholic-liver disease (Beyoglu and Idle 2013) and drug-induced liver 
injury (Begriche, Massart et al. 2011).  For example, β-oxidation is inhibited while fatty acid 
synthesis is upregulated in alcoholic liver disease, which results in an accumulation of lipids in 
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the liver and development of liver steatosis (Begriche, Massart et al. 2011, Gao and Bataller 
2011). In addition, liver steatosis is induced by several different pharmaceuticals such as 
amiodarone, ibuprofen, acetaminophen, and tamoxifien, which inhibit enzymes needed for 
effective β-oxidation (Begriche, Massart et al. 2011). Consequences of reduced or inhibited β-
oxidation include accumulation of fatty acids that are esterified and stored as triglycerides or an 
accumulation of fatty acids that remain in an un-esterified form. If accumulated in their un-
esterified form, fatty acids can cause further mitochondrial damage and injury. In addition, faulty 
β-oxidation can impair energy output due to reduced production of ketone bodies and ATP 
(Begriche, Massart et al. 2011).  Because mitophagy acts as an important regulator of 
mitochondrial homeostasis and helps to maintain a healthy population of mitochondria, it is likely 
that mitophagy helps defend against lipid accumulation in the liver by removing damaged 
mitochondria incapable of performing efficient β-oxidation.  
 
1.4.4 Mitophagy and Mitochondrial Biogenesis Must be Balanced 
 Mitochondria have evolved several methods to adapt to cellular stress induced by drugs 
or disease including mitophagy activation to degrade damaged mitochondria and stimulation of 
mitochondrial biogenesis to replace damaged mitochondria removed by mitophagy. The number 
of mitochondria in cells is balanced by mitochondrial biogenesis and degradation by mitophagy. 
Changes in demand for mitochondrial function can shift the balance between these, but failing 
to restore the balance leads to mitochondrial dysfunction, cell death, and disease. For example, 
a decrease in mitochondria is associated with cell death, aging, Parkinson’s disease, and liver 
disease. However, failure to remove mitochondria that are damaged leads to apoptosis and 
disease due to an accumulation of damaged mitochondria and overall mitochondrial dysfunction 
(Hill, Benavides et al. 2012, Zhu, Wang et al. 2013). 
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Mitochondrial biogenesis consists of de novo synthesis of mitochondrial components 
from other cellular precursors, formation of mitochondrial membranes, and division of currently 
existing mitochondria (Michel, Wanet et al. 2012). Mitochondrial biogenesis requires 
mitochondrial DNA transcription and translation, transcription and translation of nuclear DNA, 
and the assembly of complexes needed for oxidative phosphorylation. In addition, mitochondrial 
biogenesis requires protein import because most mitochondrial proteins are encoded by nuclear 
DNA, synthesized in the cytosol, and later transported into the mitochondria (Zhu, Wang et al. 
2013, Palikaras and Tavernarakis 2014). Regulators of mitochondrial biogenesis include 
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1α), nuclear 
respiratory factors 1 and 2 (Nrf1/2), and mitochondrial transcription factor A (TFAM) and are 
activated by nutrient availability, hormones, and growth factors (Palikaras and Tavernarakis 
2014).  
There must be cross-talk between mitochondrial biogenesis and mitophagy pathways in 
order to provide a balanced population of healthy, functioning mitochondria. There are several 
pathways that simultaneously regulate both mitochondrial biogenesis and autophagy in order to 
maintain their balance including Parkin and AMPK.  Parkin and AMPK promote both mitophagy 
and mitochondrial biogenesis simultaneously. The role of Parkin in mitochondrial biogenesis is 
further discussed in section 1.5.3. AMPK, a protein kinase, is activated in response to 
environmental stress or nutrient deprivation and activates mitochondrial biogenesis by either 
enhancing SIRT1 deacetylation of PGC-1α resulting in its nuclear translocation (Canto, Gerhart-
Hines et al. 2009), or by enhancing PGC-1α activity through phosphorylation (Jager, Handschin 
et al. 2007, Scarpulla, Vega et al. 2012). While activating mitochondrial biogenesis, AMPK 
simultaneously upregulates mitophagy by either suppressing mTOR, which is a negative 
regulator of autophagy (Mihaylova and Shaw 2011), or by phosphorylating and activating 
ULK1/2 (Kim, Kundu et al. 2011) (discussed in section 1.2.3).   
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1.5 Roles of Parkin Independent of Mitophagy.  
Parkin has several roles in maintenance of cellular homeostasis in addition to its role in 
promoting induction of mitophagy including removal of mitochondrial vesicles, prevention of 
mitochondrial spheroid formation, activation of mitochondrial biogenesis, lipid transport, and cell 
cycle regulation. The various roles of Parkin are summarized in Figure 1.5.  
 
1.5.1 Removal of Mitochondrial Vesicles 
Parkin and PINK1 stimulate the biosynthesis of mitochondria-derived vesicles (MDVs) 
under conditions of mitochondrial oxidative stress. Even though this pathway requires Parkin 
and PINK1, it is different from canonical mitophagy because it is stimulated by ROS production 
instead of mitochondrial depolarization. In addition, vesicles bud off of damaged mitochondria 
and are degraded in the lysosome along with their contents without involvement of the 
autophagy pathway (McLelland, Soubannier et al. 2014). These vesicles contain oxidized 
proteins (Soubannier, Rippstein et al. 2012), and they may regulate mitochondrial quality control 
using a mechanism faster than mitophagy to prevent complete mitochondrial depolarization 
while preserving mitochondrial function by selectively degrading damaged mitochondrial 
contents (Soubannier, Rippstein et al. 2012, McLelland, Soubannier et al. 2014).  
 
1.5.2 Prevention of Mitochondrial Spheroid Formation 
Mitochondrial spheroids are structurally unique mitochondria with a ring or cup-like 
morphology. They look similar to autophagosomes with the interior lumen being surrounded by 
mitochondrial membranes, but they have a small opening that connects the spheroid lumen to 
the cytosol, unlike autophagosomes (Figure 1.6.5).  The significance of this opening is currently 
unclear. These spheroids can enwrap contents of the cytosol such as endoplasmic reticulum, 
lipid droplets, or other mitochondria. They are also positive for lysosome proteins and may have 
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some amount of degradation capacity, but it remains to be proven if they actually degrade 
contents within their lumen. Formation of mitochondrial spheroids requires the presence of ROS 
in addition to either MFN1 or MFN2, which allow for mitochondrial fusion. Deletion of either 
MFN1 or MFN2 inhibits spheroid formation, indicating that both fusion proteins are important for 
the formation of mitochondrial spheroids (Ding, Guo et al. 2012). Parkin can therefore inhibit 
formation of mitochondrial spheroids by inducing proteasomal degradation of MFN1/2 by 
ubiquitination, which was previously discussed in section 1.3.2. MEF cells, which have an 
undetectable Parkin expression level, formed mitochondrial spheroids after CCCP treatment. 
When Parkin was overexpressed in these cells, MFN1 and MFN2 were degraded and 
mitochondria underwent typical mitophagy instead of forming mitochondrial spheroids (Ding, Li 
et al. 2012). These data suggest that Parkin prevents mitochondrial spheroid formation in order 
for mitophagy to occur. Whether or not these spheroids represent a protective mechanism in the 
liver in addition to mitophagy requires further investigation (Ding, Guo et al. 2012, Ding, Li et al. 
2012, Ni, Williams et al. 2013, Yin and Ding 2013).  
 
1.5.3. Activation of Mitochondrial Biogenesis 
Parkin is implicated in activation of mitochondrial biogenesis via regulation of Tfam 
(Kuroda, Mitsui et al. 2006, Rothfuss, Fischer et al. 2009) and Pgc-1α (The roles of Tfam and 
Pgc-1α in mitochondrial biogenesis were discussed in section 1.4.4). Parkin directly regulates 
Tfam in proliferating and in differentiated SH-SY5Y cells (human neuroblastoma cell line) along 
with mouse and human brain. Parkin regulates Tfam by binding it and enhancing its 
transcriptional activity, resulting in increased transcription and replication of mitochondria DNA 
(mtDNA) and suppression of mtDNA damage during oxidative stress. Parkin co-associates with 
Tfam and mtDNA (Kuroda, Mitsui et al. 2006, Rothfuss, Fischer et al. 2009). Parkin regulates 
Pgc-1α indirectly by ubiquitinating and inducing proteasomal degradation of PARIS (Parkin 
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Interacting Substrate), which is a transcriptional repressor of Pgc-1α.  Degradation of PARIS by 
Parkin caused up-regulation of mitochondrial biogenesis in SH-SY5Y cells and in mouse and 
human brain, which protected against neurodegeneration (Shin, Ko et al. 2011). The role of 
Parkin in mediating mitochondrial biogenesis, in combination with mitophagy, in the brain is 
thought to be an important protective mechanism against Parkinson’s disease by maintaining a 
healthy population of functional mitochondria. However, the role of Parkin in mediating 
mitochondrial biogenesis in the liver has not been studied.  
 
1.5.4. Fat Transport 
 Parkin KO mice are smaller and gain weight slowly compared to WT mice (Palacino, 
Sagi et al. 2004), suggesting that Parkin may have some role in lipid metabolism. Parkin 
regulates fat uptake by stabilizing CD36 expression through monoubiquitination. CD36 is a 
transporter for long chain polyunsaturated fatty acids. When challenged with a high-fat diet, 
Parkin KO mice were protected against weight gain, insulin resistance, and steatosis of the liver. 
However, WT mice gained weight and developed liver steatosis and insulin resistance after 
high-fat diet feeding, which was concluded to be due to Parkin’s role in stabilizing expression of 
CD36. In addition, fat uptake was shown to be affected by Parkin in the brain because fat 
uptake was increased in SH-SY5Y cells overexpressing Parkin and decreased in cells from 
patients with Parkin-mutant associated Parkinson’s disease (Kim, Stevens et al. 2011).  Parkin 
expression was also found to be increased in white adipose tissue after high-fat diet feeding 
(Kim, Stevens et al. 2011, Cummins, Holden et al. 2014), and Parkin stabilization of CD36 
expression in adipocytes is important for fat accumulation during adipogenesis (Kim, Stevens et 
al. 2011). Interestingly, Parkin expression decreases in the brain substantia nigra in response to 
high-fat diet feeding, differing from in vitro results from Kim et al. This decrease in Parkin 
expression was associated with increased expression of PARIS and decreased Pgc-1α 
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(previously discussed in section 1.5.3), suggesting that consumption of a high fat diet may 
increase vulnerability to Parkinson’s disease by inhibiting mitochondrial biogenesis (Khang, 
Park et al. 2015). Nevertheless, all of these findings suggest that Parkin has a role in regulating 
lipid metabolism.  
 
1.5.5. Cell Cycle Regulation and Tumor Suppression 
 Parkin is a tumor suppressor, and it is one of the most frequently deleted genes in 
human cancers. The Park2 gene was found to be mutated in many different types of cancer 
including cervical, colorectal, gastric, glioblastoma, and lung adenocarcinoma among others. 
Cancer-causing mutations are likely due to inactivation of Parkin activity. Interestingly, cancer-
associated mutations for Park2 occur within the same regions as mutations causing Parkinson’s 
disease, but human patients with Park2 mutations do not have greater incidences of cancer with 
the exception of one family containing eight people with lung cancer that were recently found to 
have germline Park2 mutations  (Veeriah, Morris et al. 2010, Alcalay, Clark et al. 2012, Xu, Lin 
et al. 2014).  
Copy number loss of Park2 is associated with breast, brain, lung, ovarian, and 
pancreatic cancers, and the Park2 gene is also suggested to be inactivated in leukemia and 
colorectal cancer by promoter hypermethylation  (Xu, Lin et al. 2014). In addition, decreased 
expression of Parkin is associated with liver (Wang, Denison et al. 2004), bladder, lung, breast, 
brain, and thyroid cancers among others (Xu, Lin et al. 2014), and restoration of Parkin 
expression in breast cancer cell lines (Tay, Yeo et al. 2010) and glioma cells (Veeriah, Taylor et 
al. 2010) slowed cellular proliferation. Furthermore, Parkin expression is reduced in human 
hepatocellular carcinoma primary tumors and cell lines (Wang, Denison et al. 2004), and Parkin 
KO mice develop liver tumors at 18 months of age (Fujiwara, Marusawa et al. 2008).  
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 The involvement of Parkin in tumorigenesis is likely due to its role in cell cycle regulation, 
its transcriptional regulation by p53, and its maintenance of mitochondrial homeostasis. Parkin 
ubiquitinates and mediates proteasomal degradation of Cyclin E and Cyclin D1 in vitro, and 
Parkin loss upregulates expression of these proteins leading to progression through the cell 
cycle and increased proliferation (Veeriah, Morris et al. 2010, Gong, Zack et al. 2014). Cyclin D1 
is complexed with Cyclin-dependent kinases (CDK) CDK4 and CDK6 and is required for 
transition from G1 phase to the DNA replication phase (S phase) of the cell cycle, which occurs 
through Cyclin D1/CDK4/CDK6-mediated phosphorylation and inactivation of the cell cycle 
inhibitor Retinoblastoma protein. This leads to the release of transcription factors, such as E2F-
1, which induce expression of genes needed for advancement through the cell cycle, such as 
Cyclin E and Cyclin A. Cyclin E forms a complex with CDK2 and is also important for 
progression from G1 into S phase by phosphorylating Retinoblastoma protein, similar to Cyclin 
D1, in addition to phosphorylating the cell-cycle inhibitor p27. Cyclin A participates in regulation 
of multiple steps of the cell cycle via interaction with CDK1 and CDK2, which are associated 
with the G2/ M phase (mitosis/cell division) transition or S phase, respectively (Vermeulen, Van 
Bockstaele et al. 2003). In addition, Parkin regulates Beta-catenin protein levels in the brain 
through ubiquitination and degradation (Rawal, Corti et al. 2009). Beta-catenin is well known to 
induce expression of genes necessary for cell-cycle progression and proliferation including 
Cyclin D1, and it is commonly mutated in cancer (Nejak-Bowen and Monga 2011). However, the 
role of Parkin in regulation of beta-catenin in the liver is unknown.  
Parkin expression is also transcriptionally regulated by p53, which is a well-known anti-
cancer gene that arrests cell cycle progression and initiates DNA repair and / or apoptosis upon 
DNA damage (Zhu, Lu et al. 2014).  Mutations and down-regulation of p53 are associated with 
many types of cancer, and loss of p53 can also further cancer progression by decreasing Parkin 
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expression in addition to loss of its other anti-tumorigenic functions (Zhang, Lin et al. 2011, 
Viotti, Duplan et al. 2014).  
Finally, Parkin’s mediation of mitophagy (section 1.3.2) and mitochondrial biogenesis 
(section 1.5.3) likely play anti-tumorigenic roles by maintaining a healthy population of 
mitochondria because damaged mitochondria are well known to be involved in cancer 
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1.6.1. Overview of Acetaminophen (APAP) 
 Acetaminophen (APAP) is a widely used drug with analgesic and antipyretic properties, 
but its therapeutic mechanism of action is currently unknown. APAP can be taken orally, 
intravenously, or rectally, and it can be taken individually or in combination with other drugs, 
such as over the counter cold and flu medications or prescribed pain medications like 
Percocet®. APAP is the most commonly used drug in the United States (Kaufman, Kelly et al. 
2002) with approximately 50 million adults taking some formulation of APAP each week 
(Hinson, Roberts et al. 2010). APAP overdose is the most common cause of acute liver failure 
in the United States (Larson, Polson et al. 2005), and it is responsible for approximately 26,000 
hospitalizations per year with nearly 500 cases resulting in death (Nourjah, Ahmad et al. 2006). 
APAP is responsible for approximately 40% of all cases of acute liver failure in the United States 
(Larson, Polson et al. 2005, Blieden, Paramore et al. 2014), and care for these cases costs an 
estimated 87 million dollars per year (Bond and Novak 1995). APAP is considered safe when 
taken at the therapeutic doses (350-600 mg per mouth every 4 to 6 hours for a daily maximum 
of 4 grams for an adult) (Schilling, Corey et al. 2010), but it can cause severe liver damage and 
even death when taken in greater amounts.  APAP overdose often happens during suicide 
attempt or by accident when several medications containing APAP are taken in combination.   
 
1.6.2 APAP Metabolism and Mechanism of Toxicity 
 APAP is absorbed from the duodenum and metabolized in the liver after ingestion. The 
majority of APAP taken at a therapeutic dose is eliminated during phase II metabolism by 
glucoronidation or sulfation, which makes APAP more water soluble and allows for its excretion 
in the urine by the kidney. Glucoronidation, which is catalyzed by UDP-glucuronosyl 
transferases (UGT), is responsible for approximately 60% of APAP conjugation and excretion. 
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Sulfation, which is catalyzed by sulfotransferases (SULT), accounts for approximately 30% of 
APAP conjugation and excretion. The remaining approximate 10% of APAP is converted to the 
reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) during phase I metabolism by 
cytochrome p450s (Hinson, Roberts et al. 2010, McGill and Jaeschke 2013).  NAPQI is an 
electrophile that reacts with proteins by binding to their sulfhydryl groups (Jollow, Mitchell et al. 
1973, Corcoran, Mitchell et al. 1980, Streeter, Dahlin et al. 1984). Even though NAPQI is a 
reactive metabolite, it is detoxified and excreted once it is bound to glutathione (GSH) (Mitchell, 
Jollow et al. 1973). The cytochrome p450s CYP2E1, CYP1A2, CYP2D6, and CYP3A4 have all 
been shown to have a role in metabolizing APAP to NAPQI (Raucy, Lasker et al. 1989, Patten, 
Thomas et al. 1993, Snawder, Roe et al. 1994, Dong, Haining et al. 2000), but CYP2E1 is the 
most prominent cytochrome p450 responsible for this (Cheung, Yu et al. 2005, McGill and 
Jaeschke 2013).  
When taken at therapeutic doses, APAP is considered safe because the reactive 
metabolite NAPQI is detoxified by GSH and excreted. However, an abundance of NAPQI 
causes GSH depletion in APAP overdose situations, leaving NAPQI free to bind to cysteine 
residues of proteins, forming protein adducts (Streeter, Dahlin et al. 1984, Hinson, Reid et al. 
2004). APAP protein adducts in hepatocytes lead to their necrosis and subsequent liver injury 
(Jollow, Mitchell et al. 1973, Bartolone, Cohen et al. 1989, Roberts, Bucci et al. 1991). Most 
adducted proteins are cytosolic, but several mitochondrial proteins also contain adducts (Qiu, 
Benet et al. 1998). Known adducted proteins include glutamine synthase, glutamate 
dehydrogenase, aldehyde dehydrogenase, glutathione peroxidase, proteasome subunit 5, and 
ATP synthase α subunit. However, the exact role of APAP-adduction of these proteins in the 
development of APAP-induced hepatotoxicity is not yet known (Hinson, Roberts et al. 2010).  
Formation of mitochondrial protein adducts is crucial for initiation of APAP toxicity 
because mitochondrial protein adducts can lead to mitochondrial damage, production of reactive 
50 
 
oxygen species (ROS), and subsequent cell death (Pumford, Roberts et al. 1990, Jaeschke, 
McGill et al. 2012). APAP overdose promotes mitochondrial translocation of Bax, which together 
with Bak, forms pores in the outer mitochondrial membrane. Pore formation leads to release of 
cytochrome c in addition to endonuclease G and apoptosis inducing factor, which cause DNA 
fragmentation and eventual necrosis (Bajt, Farhood et al. 2008). APAP overdose also causes 
oxidative stress leading to mitochondrial transition pore (MPT) opening, which causes 
mitochondrial depolarization, mitochondrial swelling, and decreased respiration and ATP 
synthesis.  MPT opening further exacerbates oxidative stress and mitochondrial damage, 
causing hepatocytes to undergo necrosis leading to liver injury (Kon, Kim et al. 2004, 
Masubuchi, Suda et al. 2005). 
APAP-induced oxidative stress causes activation of c-Jun N-terminal kinase (JNK), 
which results in its mitochondrial translocation, increased oxidative stress, and exacerbation of 
APAP-induced liver injury (Gunawan, Liu et al. 2006, Henderson, Pollock et al. 2007, Hanawa, 
Shinohara et al. 2008, Saito, Lemasters et al. 2010). JNK is activated by phosphorylation during 
the early phase of APAP-induced liver injury (2 to 4 hours after APAP administration in mice) 
(Gunawan, Liu et al. 2006, Henderson, Pollock et al. 2007), and inhibition of JNK activation in 
mice and mouse hepatocytes by a one hour pretreatment with the JNK inhibitor SP600125 was 
protective against APAP-induced liver injury (Gunawan, Liu et al. 2006, Henderson, Pollock et 
al. 2007). Post-treatment with the JNK inhibitor also protected against APAP-induced liver injury 
at 5 hours, but lost its protective effect by 8 hours post-treatment  (Henderson, Pollock et al. 
2007). Even though use of a JNK inhibitor, which blocks both JNK1 and JNK2, was protective 
against APAP-induced liver injury and necrosis, JNK1 knockout mice were not protected against 
APAP-induced hepatotoxicity (Gunawan, Liu et al. 2006, Henderson, Pollock et al. 2007). The 
role of JNK2 is controversial because JNK2 KO mice have been found to be both partially 
protected (Gunawan, Liu et al. 2006) and not protected (Henderson, Pollock et al. 2007) against 
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APAP-induced liver injury.  These data suggest that simultaneous loss of both JNK1 and JNK2 
activation may be required for protection against APAP-induced liver injury, but this is still under 
debate.  In addition, it was suggested that APAP-induced activation of JNK occurs through 
oxidative-stress mediated activation of apoptosis-signal-relating kinase 1 (ASK1), which is an 
upstream mediator of JNK phosphorylation. A 30 minute pretreatment with an inhibitor of ASK1 
(GS-459679) protected against APAP-induced liver injury by inhibiting JNK activation, 
translocation of JNK to mitochondria, and reducing oxidative stress. A 1.5 hour post-treatment 
with the ASK1 inhibitor also protected against APAP-induced liver injury, but this protection was 
lost by 3 hours post-treatment (Xie, Williams et al. 2013). 
In summary, APAP-induced hepatotoxicity occurs by conversion of APAP to the reactive 
metabolite NAPQI, which is bound by GSH and causes GSH depletion upon APAP overdose. 
NAPQI then binds to mitochondrial proteins, which initiates mitochondrial damage and oxidative 
stress leading to MPT pore opening. MPT pore opening causes more oxidative stress and 
mitochondrial damage and leads to reduced respiration and decreased production of ATP. 
Oxidative stress also leads to JNK activation and JNK mitochondrial translocation, which 
exacerbates mitochondrial damage and oxidative stress, leading to hepatocellular necrosis and 
subsequent liver injury. There are also several factors that affect APAP metabolism, causing 
greater risk of APAP overdose and liver injury. For example, malnutrition and pre-existing liver 
disease cause a reduction in GSH levels, resulting in impaired detoxification of NAPQI. 
CYP2E1-inducing drugs or induction of CYP2E1 via chronic alcohol abuse can also cause 
increased risk of APAP overdose by resulting in greater NAPQI production after APAP use 






1.6.3 Mechanisms of Repair in APAP-induced Liver Injury 
 The most important mechanism of repair in APAP-induced liver injury is hepatocellular 
proliferation, which allows for replacement of damaged hepatocytes. Liver regeneration begins 
approximately 24 hours after APAP treatment in mice. TNFα, IL-6, vascular endothelial growth 
factor (VEGF), and β-Catenin each contribute to initiation of hepatocyte proliferation after APAP-
induced liver injury (Chiu, Gardner et al. 2003, James, Lamps et al. 2003, Donahower, 
McCullough et al. 2006, Kato, Ito et al. 2011, Bhushan, Walesky et al. 2014). TNFα is a well-
known activator of the NF-κB pathway, which results in transcription of many proliferative genes, 
such as Cyclin D1 (Guttridge, Albanese et al. 1999). TNFα and NF-κB along with the cell cycle 
proteins Cyclin D1 and Cyclin A (Cyclin D1 and Cyclin A were previously discussed in section 
1.5.5) are induced after APAP treatment in mice and mediate liver regeneration after APAP 
treatment (Chiu, Gardner et al. 2003, Bhushan, Walesky et al. 2014). Mice lacking the TNFα 
receptor 1 (TNFR1 KO) exhibit increased liver injury along with decreased Cyclin D1, Cyclin A, 
and hepatocyte proliferation, suggesting that TNFα is an important mediator of liver 
regeneration after APAP-induced liver injury (Chiu, Gardner et al. 2003).  
IL-6 is also involved in liver regeneration by activating the transcription factor signal-
transducer and activator of transcription 3 (STAT-3), which induces expression of genes 
involved in cellular proliferation such as Cyclin D1 among many others (Wang, Lafdil et al. 2011, 
Carpenter and Lo 2014).  Loss of IL-6 in mice did not result in increased APAP-induced liver 
injury compared to WT mice, but IL-6 KO mice had decreased proliferating hepatocytes after 
APAP treatment. In addition, pretreatment of IL-6 KO mice with IL-6 reduced liver injury and 
increased proliferation levels after APAP treatment, suggesting IL-6 is a mediator of liver 
regeneration after APAP overdose (James, Lamps et al. 2003).  However, this is controversial 
because IL-6 was also shown to be down-regulated after APAP treatment. In addition, IL-6 
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expression and STAT-3 activation were upregulated in mouse livers that were unable to 
regenerate (Kato, Ito et al. 2011, Bhushan, Walesky et al. 2014). 
VEGF, which is an important regulator of angiogenesis, is also upregulated after APAP 
treatment along with its receptors VEGFR1, VEGFR2, and VEGFR3 (Donahower, McCullough 
et al. 2006, Kato, Ito et al. 2011). Treatment with a VEGF receptor inhibitor (Semaxanib/ 
SU5416) resulted in slightly increased liver injury 48 hours after APAP treatment, but not in the 
pre-regenerative phase at 6 and 24 hours. The VEGFR inhibitor also caused reduced 
hepatocyte proliferation (Donahower, McCullough et al. 2006). Use of VEGFR1 Tyrosine-Kinase 
(TK) KO mice showed that VEGF is an important mediator of liver regeneration after APAP 
treatment. VEGFR1-TK KO mice had increased liver injury 48 hours after APAP treatment 
compared to WT mice, but not in the early phases after APAP treatment. In addition, these mice 
had decreased proliferation along with increased hemorrhage and mortality after APAP-
treatment compared to WT mice (Kato, Ito et al. 2011).  These data suggest that VEGF and 
angiogenesis have a role in liver regeneration after APAP overdose. 
The Wnt/β-catenin pathway also contributes to liver regeneration after APAP overdose 
by inducing expression of Cyclin D1. The Wnt/β-catenin pathway was activated after APAP 
treatment, and mice overexpressing β-catenin had increased liver regeneration, but similar liver 
injury, compared to WT mice (Bhushan, Walesky et al. 2014). Bhushan et al. also demonstrated 
that liver regeneration following APAP-induced liver injury is dependent on a dose-response. A 
lower 300 mg/kg dose of APAP resulted in liver regeneration while a higher 600 mg/kg dose 
inhibited regeneration, leading to sustained liver injury and mortality in mice. Therefore, in 
addition to induction of pathways mentioned in this section, the ability of the liver to regenerate 
after APAP overdose depends on if the APAP amount consumed is less than the threshold dose 




1.6.4. Clinical signs of APAP Toxicity and Treatment Options 
During APAP overdose, patients experience nausea, vomiting, and abdominal pain 
within 2-3 hours after ingestion, which can progress to jaundice and encephalopathy within 
several days (Blieden, Paramore et al. 2014). Liver damage and dysfunction occur within 24 
hours and peak between 3 and 4 days after overdose (Boyer and Rouff 1971). Clinical signs of 
APAP overdose include increased serum levels of the enzymes alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) and signs of liver dysfunction such as hyperbilirubinemia 
and increased prothrombin time (Hinson, Roberts et al. 2010). Levels of 3-cysteine-APAP 
adducts in serum also correlate with patient liver toxicity (Muldrew, James et al. 2002). 
However, adduct levels were also increased in plasma in the absence of liver injury, suggesting 
that this parameter may not directly correlate with liver injury (McGill, Lebofsky et al. 2013).  The 
half-life of APAP, usually 1.5 to 3 hours in the blood (Nelson and Morioka 1963), also increases 
after overdose and correlates with the extent of liver damage (Schiodt, Ott et al. 2002).  
N-acetyl-cysteine (NAC) is the only treatment option for APAP overdose other than liver 
transplantation (Lancaster, Hiatt et al. 2015). In 1973, Mitchell et al. administered cysteine to 
mice, which reduced their APAP-induced liver injury (Mitchell, Jollow et al. 1973). These 
experiments eventually led to the development of NAC (Mucomyst®) for treatment of APAP 
hepatotoxicity in 1976 (Piperno and Berssenbruegge 1976, Peterson and Rumack 1977).  When 
administered during APAP metabolism, NAC is a very effective therapeutic option in cases of 
APAP overdose. NAC functions by maintaining a supply of GSH because it increases GSH 
synthesis and it also directly conjugates to NAPQI, leading to its detoxification and prevention of 
liver injury.  However, if administered too late after APAP metabolism, NAC is ineffective 
because it can no longer reduce the amount of reactive metabolite available to initiate liver 
injury (Corcoran, Racz et al. 1985, Corcoran, Todd et al. 1985, Corcoran and Wong 1986). For 
example, patients treated with NAC within 10 hours after overdose had 4-fold decreased liver 
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injury compared to patients treated between 10 and 16 hours and 9-fold decreased liver injury 
compared to patients treated between 16 and 24 hours (Rumack, Peterson et al. 1981). Even 
though JNK inhibitors and ASK1 inhibitors (discussed in section 1.6.2) are protective against 
APAP-induced liver injury in mice, they also must be given very early after APAP overdose to be 
effective. Therefore, therapeutic use of these inhibitors would likely not produce better outcomes 
than NAC.  
 
1.6.5. Autophagy Protects against APAP-induced Liver Injury by Removing Damaged 
Mitochondria 
Autophagy was extensively discussed in section 1.2. Our lab demonstrated that 
autophagy is induced after APAP treatment in both mouse livers and primary mouse 
hepatocytes, and this autophagy induction is likely due to APAP-induced suppression of mTOR. 
Pharmacological induction of autophagy via rapamycin protected against APAP-induced 
hepatocellular necrosis in primary hepatocytes, while autophagy inhibition by 3-MA and CQ 
exacerbated necrotic cell death. In addition, a 3 hour post-treatment with rapamycin also 
protected against APAP-induced necrosis in primary hepatocytes. Furthermore, rapamycin 
treatment protected against APAP-induced liver injury, and inhibition of autophagy by 
chloroquine exacerbated APAP-induced liver injury, in vivo. We showed that protection against 
APAP-induced liver injury by autophagy is likely through selective removal of mitochondria by 
mitophagy (mitophagy was discussed in section 1.3) because many autophagosomes contained 
mitochondria after APAP treatment, and mitochondrial proteins were degraded in primary 
hepatocytes after APAP treatment (Ni, Bockus et al. 2012). However, the mechanism for 
induction of mitophagy in the liver after APAP overdose is unknown.   
We also demonstrated that APAP induces zonated induction of mitophagy in the liver. 
The liver is divided into periportal, intermediate, and centrilobular zones. These zones have 
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differences in CYP450 enzyme expression and GSH levels with centrilobular hepatocytes 
having the highest expression of CYP450 enzymes and the lowest GSH levels (Lindros 1997, 
Jungermann and Kietzmann 2000).  APAP is mainly metabolized in the centrilobular zone 
where expression of CYP450s is highest and GSH is the lowest, which causes the majority of 
hepatocellular necrosis to occur near the central vein (Jaeschke, Gores et al. 2002). Treatment 
of GFP-LC3 transgenic mice with APAP increased the formation of GFP-LC3 positive 
autophagosomes, which were also localized mainly to the centrilobular zone in the liver (Ni, 
Bockus et al. 2012). Autophagosomes likely localize to this particular area of the liver in order to 
degrade mitochondria damaged by APAP adduct formation via mitophagy. 
We characterized APAP-induced liver injury into four zones. The four zones include 
hepatocellular necrosis, mitochondrial spheroid formation, mitophagy, and mitochondrial 
proliferation. Zone 1 contains necrotic hepatocytes. Zone 2 contains mitochondrial spheroids 
(discussed in section 1.5.2), which may protect against the spread of hepatocellular necrosis 
induced by APAP. However, the role of mitochondrial spheroid formation in protection against 
APAP-induced liver injury is not clear.  Zone 3, which is adjacent to Zone 2, has normally 
structured autophagosomes containing mitochondria and is termed the “autophagy active area”. 
This zone has minimally damaged mitochondria after APAP treatment due to containing less 
CYP450s and more GSH, so the hepatocytes can adapt and use mitophagy to selectively 
degrade damaged mitochondria to prevent the spread of cellular necrosis.  Zone 4, the 
outermost area surrounding Zone 3, contains proliferating hepatocytes. This area has very little 
damage from APAP overdose. Therefore, it does not have a need for mitophagy induction. In 
contrast, mitochondria in this area must proliferate in order to provide energy needed for 
hepatocellular proliferation and liver regeneration to repair/replace damaged hepatocytes 



































































































































































1.7. Alcoholic Liver Disease 
Alcohol consumption and abuse are major causes of chronic liver disease, which is a 
significant health problem in the United States and around the world.  Alcoholic liver disease 
(ALD) is a substantial problem that is caused by heavy alcohol consumption in addition to other 
environmental and genetic factors. Significant research progress has been made for 
understanding ALD pathogenesis, but a universal treatment to cure ALD is still lacking.  
  
1.7.1. Metabolism, Pathogenesis, and Risk Factors for ALD 
 Alcohol metabolism occurs mainly in the liver, and the predominant pathway is mediated 
by alcohol dehydrogenase (ADH) in the cytosol, which metabolizes alcohol into acetaldehyde. 
Alcohol can also be oxidized by CYP2E1 in microsomes to acetaldehyde.  In addition, catalase 
can oxidize alcohol to acetaldehyde in peroxisomes, but this is not a common pathway. 
Acetaldehyde is a reactive metabolite of alcohol that reacts with thiol and amino groups on 
proteins forming acetaldehyde-adducts, causing inhibition of protein function and tissue injury. 
Acetaldehyde is further metabolized into acetate by aldehyde dehydrogenase (ALDH1 or 
ALDH2), which is a harmless metabolite that can further be metabolized to acetate and acetyl-
CoA for participation in metabolic pathways (Cederbaum 2012). Alcohol metabolism by ADH 
and ALDH require reduction of NAD+ to NADH. Therefore, oxidative alcohol metabolism results 
in a decreased NAD+ / NADH ratio and oxidative stress, leading to mitochondrial damage, down-
regulation of metabolic pathways that require NAD+ as a co-enzyme, and liver injury 
(Cederbaum, Lu et al. 2009).  
The pathogenesis of ALD in humans is characterized by steatosis (mild stage), which is 
an accumulation of fat in hepatocytes. In most heavy alcohol consumers, steatosis is caused by 
inhibiting fatty acid oxidation while increasing uptake of fat into the liver along with fatty acid and 
triglyceride synthesis. Steatosis is reversible with a few weeks of abstinence from alcohol, but  
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approximately 8-20% of heavy drinkers with steatosis can further develop steatohepatitis 
(moderate stage) and fibrosis and cirrhosis (advanced stage), and some (3-10%) eventually 
develop hepatocellular carcinoma (HCC) with prolonged alcohol abuse. Alcoholic steatohepatitis 
is characterized by hepatic inflammation and injury in addition to steatosis and also includes 
fibrotic and cirrhotic disease states. Steatohepatitis can also be reversible depending on if liver 
cirrhosis has developed. However, once cirrhosis has developed, less than 10% of patients can 
reverse their liver disease with abstinence. Most patients that stop using alcohol once cirrhosis 
has developed have a survival time of approximately 5 years after diagnosis (Teli, Day et al. 
1995, Diehl 2002, Altamirano and Bataller 2011). Approximately 20% of all cases of liver 
cirrhosis in the United States are related to alcohol abuse (Singal, Kamath et al. 2013), and 
approximately 5 million people in the United States are thought to have alcohol-induced 
steatohepatitis (Basra and Anand 2011). Cirrhosis is the end stage of ALD, and it is 
characterized by massive fibrosis and the presence of regenerative nodules in the liver in 
addition to loss of liver function. Fibrosis is an exacerbated wound-healing response induced by 
liver injury that is characterized by an accumulation of extracellular matrix proteins, such as 
collagen, which are produced predominantly by hepatic stellate cells. Continuous activation of 
this wound healing response leads to cirrhosis of the liver, which can eventually progress to 
HCC (Teli, Day et al. 1995, Diehl 2002, Altamirano and Bataller 2011, Streba, Vere et al. 2014).  
Most heavy alcohol consumers do not progress beyond steatosis of the liver, which 
suggests that other factors contribute to progression of ALD in addition to heavy alcohol 
consumption. There have been several factors shown to contribute to progression and severity 
of ALD in humans including race, sex, and comorbidities like obesity or hepatitis C virus. 
Genetic polymorphisms and epigenetic modifications also contribute to ALD progression. In 
addition, drinking patterns have been shown to have a role in ALD progression.   
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Two of the most important factors in susceptibility to ALD progression are race and sex. 
African-Americans and Hispanics are more likely to progress to alcohol-induced cirrhosis than 
Caucasians (Stinson, Grant et al. 2001, Stewart 2002). In addition, women are more likely to 
progress to ALD compared to men after alcohol consumption (Sato, Lindros et al. 2001).  
Comorbidity with other diseases, such as obesity or hepatitis C virus (HCV), in addition 
to lifestyle factors also contribute to ALD progression. Obesity and metabolic syndrome have a 
synergistic effect on alcohol-induced liver injury (Naveau, Giraud et al. 1997, Chiang and 
McCullough 2014), and obesity is associated with an increased mortality rate in ALD patients 
(Stepanova, Rafiq et al. 2010). HCV is also associated with severity of ALD (Degos 1999, 
Monto, Patel et al. 2004), and the risk of developing cirrhosis increases in HCV patients that are 
heavy alcohol consumers (Harris, Gonin et al. 2001). Smoking also contributes to ALD severity 
and progression to liver cirrhosis (Corrao, Lepore et al. 1994, Pessione, Ramond et al. 2003, 
Altamirano and Bataller 2010). In contrast, drinking coffee protects against ALD severity and 
development of alcohol-induced liver cirrhosis (Corrao, Lepore et al. 1994, Stroffolini, Cotticelli 
et al. 2010).  
Genetic polymorphisms and epigenetics also contribute to ALD progression and 
severity. For example, several polymorphisms of genes necessary for alcohol metabolism have 
been identified including polymorphisms in ADH2 and ADH3, ALDH2, and in the CYP2E1 
promoter (Monzoni, Masutti et al. 2001, Zintzaras, Stefanidis et al. 2006). In addition to genetic 
polymorphisms, epigenetics also contributes to ALD progression. Alcohol influences epigenetics 
and histone modification in the GI tract and liver, which may increase progression and severity 
of ALD. For example, alcohol alters expression of ADH due to histone modification. More 
critically, epigenetic changes induced by alcohol consumption may be transmitted to offspring, 
which could affect their development (Shukla and Lim 2013).  
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Finally, the amount and duration of alcohol use in addition to the type of alcohol 
consumed and the pattern of alcohol consumption all have a role in progression of ALD. Women 
that drink more than 40 grams of alcohol per day and men that drink more than 80 grams per 
day were shown to be more likely to develop ALD, but some developed ALD by consuming less 
amounts of alcohol. In addition, wine drinkers were shown to be less likely than beer or liquor 
drinkers to develop alcoholic cirrhosis, but this is controversial. Heavy daily drinking was also 
shown to increase the risk for developing ALD in comparison to weekly binge drinking (Streba, 
Vere et al. 2014).  
 
1.7.2 Clinical Signs and Treatment Options for ALD 
 Early stages of ALD, such as steatosis, are usually asymptomatic. Once patients 
progress to alcoholic steatohepatitis, most will have hepatomegaly and pain. Patients may also 
have jaundice, fever, encephalopathy, or splenomegaly.  However, some steatohepatitis 
patients are asymptomatic. Patients that have progressed to liver cirrhosis can also present 
without symptoms, but most will have portal hypertension and hepatocellular dysfunction, which 
will cause them to be jaundiced and have ascites, hepatic encephalopathy, and bleeding in the 
gastrointestinal tract (Diehl 2002).  
 There are no specific clinical tests for diagnosis of ALD.  ALD can cause elevation of 
ALT and AST, and AST levels are normally two to three times higher than ALT levels in ALD. 
Increased serum alkaline phosphatase levels along with decreased potassium, magnesium, and 
phosphate levels may indicate ALD. Patients may also have low levels of serum albumin, 
prolonged thrombin time, and elevated bilirubin levels (Diehl 2002, Streba, Vere et al. 2014).  
There may also be increases in serum inflammatory cytokines in steatohepatitis including TNFα, 
IL-6, and IL-8 (McClain, Hill et al. 1993). However, these serum markers are present in many 
different types of liver disease and do not specifically indicate ALD, so other liver diseases or 
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causes of liver injury must be ruled out before ALD can be diagnosed. Knowledge of a history of 
alcohol abuse is also helpful in combination with these disease markers for diagnosis. Imaging 
studies, such as sonography, may be used to visualize liver steatosis and ascites. Liver biopsy 
is the most reliable test for diagnosing ALD, but it is also the most invasive (Diehl 2002, Streba, 
Vere et al. 2014).  
 The only therapeutic options for ALD patients are abstinence from alcohol or liver 
transplant. Abstaining from alcohol has been shown to reverse ALD in early disease states and 
can decrease mortality rates even in late-stage cirrhosis (De, Gangopadhyay et al. 2009). 
Corticosteroids, such as prednisolone, reduced mortality by 37% in alcoholic steatohepatitis 
patients, but they are only effective in patients with hepatic encephalopathy (Imperiale and 
McCullough 1990). The TNFα inhibitor pentoxifylline improved survival rates in patients with 
alcoholic steatohepatitis.  Pentoxifylline has a lower risk of gastrointestinal bleeding than 
corticosteroids, which makes it a better treatment option. Pentoxifylline also had a lower 
mortality rate compared to prednisolone treatment in one clinical trial. However, there were no 
differences in 6-month survival rates in patients that were given pentoxifylline in combination 
with prednisolone versus patients given prednisolone only (De, Gangopadhyay et al. 2009, 
Mathurin, Louvet et al. 2013). Liver transplant is the best option for decreasing mortality in ALD. 
However, the option for liver transplantation is only given to those with severe disease and / or 
to patients who have been sober for at least 6 months (Diehl 2002).  
 
1.7.3 Role of Autophagy in ALD                                   
Our lab and others recently demonstrated that alcohol consumption activates autophagy 
to selectively remove excess lipid droplets and damaged mitochondria, which attenuates 
alcohol-induced steatosis and liver injury in mice (Ding, Li et al. 2010, Ding, Manley et al. 2011, 
Dolganiuc, Thomes et al. 2012, Lin, Zhang et al. 2013).  However, there is also evidence to 
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suggest that alcohol consumption may suppress autophagy, particularly in chronic alcohol 
consumption conditions (Donohue 2009, Thomes, Ehlers et al. 2013). Several possibilities could 
explain these discrepancies including animal models used to assess ALD, assays used to 
determine autophagy, and the limitation of steady-state assessment of autophagy using only 
one time point in vivo. For example, it is now well known that use of LC3-II levels to monitor 
autophagy is troublesome because LC3-II itself is degraded in autolysosomes during 
autophagy.  For this reason, autophagic flux assays (discussed in section 1.2.5) are now 
mandatory for assessing autophagy (Klionsky, Abdalla et al. 2012), and autophagy flux was not 
always evaluated when determining the effect of ethanol on autophagy. Autophagy is also a 
dynamic process, and autophagic activity can fluctuate during experimental conditions over time 
(Ni, Bockus et al. 2011). Moreover, autophagy activity can be influenced by circadian rhythm 
(Ma, Panda et al. 2011). Therefore, special attention should be paid to experimental conditions 
when evaluating the effect of alcohol on autophagy.  
Using an acute-binge ethanol gavage model (33% v/v, 4.5g/kg), we demonstrated that 
ethanol treatment increased autophagosome numbers by electron microscopy, assessment of 
GFP-LC3 positive autophagosomes by confocal microscopy, and detection of LC3-II protein 
levels by Western blot analysis in vivo and in vitro (Ding, Li et al. 2010). Intriguingly, we further 
demonstrated that acute ethanol-induced autophagy selectively removed damaged 
mitochondria and excess lipid droplets, but not long-lived proteins (Ding, Li et al. 2011). 
Induction of autophagy by ethanol is mediated by ethanol-induced production of ROS and 
inhibition of mTOR, and induction of autophagy requires ethanol metabolism.  
Other recent studies also found that chronic ethanol treatment increased 
autophagosome content and autophagic flux in mouse livers and cultured hepatocytes (Lin, 
Zhang et al. 2013, Thomes, Ehlers et al. 2013). Otsuki’s group demonstrated that autophagy 
was protective in rats fed the Lieber-DeCarli ethanol diet for 10 weeks. This group noticed an 
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induction of autophagosomes engulfing damaged mitochondria or lipids in addition to several 
lysosomes containing degraded organelles in ethanol-fed rats compared to control rats by 
electron microscopy. Interestingly, they found several autophagosomes that contained both 
mitochondria and lipid droplets, which suggest that these degradative pathways may be linked. 
They also saw an induction of LC3-II puncta and an increase in autophagosome-lysosome 
fusion after ethanol treatment compared to controls (Eid, Ito et al. 2013). However, this study 
lacked an autophagy flux assay, so whether the accumulation of autophagosomes was due to 
the induction of autophagy by ethanol treatment is not known.  Lin et al. also showed that 
chronic ethanol consumption activates autophagy using mice fed the Lieber-DeCarli diet for 4 
weeks. They showed that autophagy was activated in the chronic feeding model using an 
autophagy flux assay, where co-treatment with CQ and ethanol feeding increased GFP-LC3 
puncta and protein levels more than ethanol feeding alone. However, they only treated mice 
with the ethanol diet for 4 weeks, so the role of ethanol feeding for a longer period of time on 
autophagy should be more critically evaluated (Lin, Zhang et al. 2013).  
In contrast to the evidence supporting acute and chronic ethanol induction of autophagy, 
other studies suggest that ethanol may suppress hepatic autophagy (Donohue 2009, Fortunato, 
Burgers et al. 2009, Wu, Wang et al. 2012).  It is well known that chronic alcohol consumption 
can cause hepatomegaly and protein accumulation (Baraona, Leo et al. 1975, Donohue 2009), 
which would suggest impaired autophagy.  However, it should be noted that alcohol 
consumption inhibits hepatic proteasome activity, another important cellular catabolic pathway 
in addition to autophagy (Donohue, Zetterman et al. 1998, Dolganiuc, Thomes et al. 2012, 
Thomes, Trambly et al. 2012). Moreover, there is crosstalk between proteasome-mediated 
degradation and autophagy, and proteasome inhibition can increase autophagy as a 
compensatory mechanism (Ding, Ni et al. 2007, Ding and Yin 2008, Wu, Cho et al. 2010). 
Therefore, chronic alcohol consumption-induced accumulation of hepatic proteins and 
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hepatomegaly could be due to multiple factors and might not be due simply to impaired 
autophagy. While Cederbaum’s group recently reported that acute ethanol inhibited autophagy, 
his findings were only based on the observations that ethanol treatment decreased LC3-II 
protein and LC3 positive puncta levels, and an autophagy flux assay was not implemented (Wu, 
Wang et al. 2012, Yang, Wu et al. 2012). Despite the controversy on the autophagy status of 
acute versus chronic alcohol exposure conditions, all studies unanimously demonstrated a 
beneficial role for autophagy in protecting against alcohol-induced steatosis and hepatotoxicity. 
Therefore, pharmacological induction of autophagy may be a promising approach for treating 
ALD.  
In addition to hepatocytes, there are many other cell types such as hepatic stellate cells 
(HSCs) and macrophages in the liver that also play a role in the pathogenesis of ALD. Emerging 
evidence indicates that autophagy in these and other cell types in the liver may also be critical in 
liver physiology and pathogenesis. HSCs are one of the key cells responsible for regulating 
hepatic fibrosis, and recent evidence suggests that autophagy in HSCs promotes liver fibrosis 
by providing free fatty acids as an energy source for HSC activation through lipophagy 
(Hernandez-Gea, Ghiassi-Nejad et al. 2012). Cre-induced specific deletion of Atg7 in HSCs 
attenuated CCl4-induced fibrosis in vivo (Hernandez-Gea, Ghiassi-Nejad et al. 2012).  The 
decreased fibrogenic capacity of HSCs by inhibiting autophagy was also confirmed in vitro using 
primary cultured HSCs and immortalized HSC cell lines (Thoen, Guimaraes et al. 2011, 
Hernandez-Gea, Ghiassi-Nejad et al. 2012). Interestingly, a study from Friedman’s group 
recently showed that autophagy was activated in HSCs in an 8-week chronic ethanol feeding 
model in rats. They showed that ER stress is induced in HSCs isolated from ethanol-fed rats, 
and that this ER stress further induced autophagy activation and subsequent HSC activation 
(Hernandez-Gea, Hilscher et al. 2013). These results imply that chronic ethanol-induced 
autophagy in HSCs may promote fibrosis during the pathogenesis of ALD. In contrast to HSCs, 
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specific deletion of autophagy in macrophages was also reported to exacerbate CCl4-induced 
fibrosis in mouse livers by promoting HSC activation through enhanced secretion of 
inflammatory cytokines from macrophages (Mallat, Lodder et al. 2014).  Moreover, we also 
found that hepatocyte-specific Atg5 knockout mice had severe liver injury, and these mice 
develop fibrosis (Ni, Woolbright et al. 2014). However, due to a lack of proper animal models to 




















2.1. Specific Aim 1: Determine the Role of Parkin in Acetaminophen-induced Liver Injury 
We have previously shown that autophagy protects against acetaminophen-induced liver 
injury (discussed in section 1.6.5) by removing damaged mitochondria via mitophagy. However, 
the mechanism for removal of these mitochondria is unknown.  My preliminary data suggested 
that Parkin-induced mitophagy is important for protection against acetaminophen-induced liver 
injury because Parkin was recruited from the cytosol to the mitochondria after acetaminophen 
treatment. In addition, mitochondrial protein ubiquitination increased after acetaminophen 
treatment, indicating that Parkin was performing its E3 ligase function. Therefore, my goal for 
Aim 1 was to determine the role of Parkin-induced mitophagy in protection against 
acetaminophen-induced liver injury. The objective of this aim was to determine if Parkin is 
important for the mitophagy that occurs in acetaminophen-induced liver injury and if an 
alternative mechanism for mitophagy induction occurs in the absence of Parkin during 
acetaminophen-induced liver injury using WT and Parkin KO mice. I hypothesized that Parkin-
induced mitophagy is a protective mechanism in acetaminophen-induced liver injury.  
2.2. Specific Aim 1: Sub-Aim 1.  
Surprisingly, my preliminary data showed that Parkin KO mice were protected against 
APAP-induced liver injury, and this protection was not due to differences in APAP metabolism 
between WT and Parkin KO mice.  My goal was to determine the mechanisms by which Parkin 
KO mice are protected against acetaminophen-induced liver injury. As discussed in section 
1.5.5, Parkin negatively regulates Cyclin D1 and Cyclin E (Veeriah, Morris et al. 2010, Yeo, Ng 
et al. 2012). In addition, Parkin expression is down-regulated in various cancers, including 
hepatocellular carcinoma (Wang, Denison et al. 2004, Fujiwara, Marusawa et al. 2008), and 
aged Parkin-deficient mice develop spontaneous liver tumors (Fujiwara, Marusawa et al. 2008). 
Therefore, the objective of this aim was to determine if Parkin regulates cellular proliferation in 
the acetaminophen-induced liver injury model. Differences in regulation of other pathways 
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involved in acetaminophen-induced liver injury, such as JNK activation, were also evaluated for 
WT and Parkin KO mice.  I hypothesized that Parkin KO mice are protected against 
acetaminophen-induced liver injury due to an upregulation of proliferative proteins in the 




















2.3. Specific Aim 2: Determine the Role of Parkin in Alcohol-induced Liver Injury 
We and others have previously shown that autophagy protects against alcohol-induced 
liver injury by removing damaged mitochondria via mitophagy (discussed in section 1.7.3). 
However, the mechanism of mitophagy induction in the liver after alcohol treatment is unknown. 
My preliminary data showed that Parkin protected against ethanol-induced liver injury and 
steatosis in the acute-binge model, and Parkin’s protection against ethanol-induced steatosis 
was not due to decreased lipid synthesis. We also found that Parkin translocated to 
mitochondria after ethanol treatment. Therefore, I hypothesized that Parkin attenuates ethanol-
induced liver injury and steatosis by promoting selective removal of damaged mitochondria 
(mitophagy), which allows for prevention of cell death and maintenance of mitochondrial 































Chapter 3. Chronic Deletion and Acute Knockdown of Parkin have Differential Responses 








This chapter was reproduced with permission: 
 
This research was originally published in Journal of Biological Chemistry. Williams, J. A., H. M. 
Ni, A. Haynes, S. Manley, Y. Li, H. Jaeschke and W. X. Ding. "Chronic Deletion and Acute 
Knockdown of Parkin have Differential Responses to Acetaminophen-Induced Mitophagy and 
Liver Injury in Mice”. Journal of Biological Chemistry. 2015. © The American Society for 






We previously demonstrated that pharmacological induction of autophagy protected 
against acetaminophen (APAP)-induced liver injury in mice by clearing damaged mitochondria. 
However, the mechanism for this mitochondria removal by autophagy is unknown. Parkin, an E3 
ubiquitin ligase, has been shown to be required for mitophagy induction in cultured mammalian 
cells following mitochondrial depolarization, but its role in vivo is not clear. The purpose of this 
study was to investigate the role of Parkin-mediated mitophagy in protection against APAP-
induced liver injury. We found that Parkin translocated to mitochondria in mouse livers after 
APAP treatment followed by mitochondrial protein ubiquitination and mitophagy induction. To 
our surprise, we found that mitophagy still occurred in Parkin knockout (KO) mice after APAP 
treatment based on electron microscopy analysis and Western blot analysis for mitochondrial 
proteins, and Parkin KO mice were protected against APAP-induced liver injury compared to 
wild type mice. Mechanistically, we found that Parkin KO mice had decreased activated c-Jun 
N-terminal kinase (JNK), increased induction of myeloid leukemia cell differentiation protein 
(Mcl-1) expression, and increased hepatocyte proliferation after APAP treatment in their livers 
compared to WT mice. In contrast to chronic deletion of Parkin, acute knockdown of Parkin in 
mouse livers using adenovirus-shRNA reduced mitophagy and Mcl-1 expression but increased 
JNK activation after APAP administration, which exacerbated APAP-induced liver injury. 
Therefore, chronic deletion (KO) and acute knockdown of Parkin differentially regulate APAP-







APAP overdose is the main cause of acute liver failure in the United States and can 
even lead to death (Larson 2007). APAP is metabolized by cytochrome P450s (Cyp), mainly by 
CYP2E1, to the reactive metabolite NAPQI (N-acetyl-p-benzoquinone imine), which is bound 
and detoxified by glutathione (GSH) after therapeutic doses of APAP.  APAP overdose causes 
GSH depletion and allows for NAPQI to bind to proteins, which leads to mitochondrial 
dysfunction and hepatocyte necrosis (McGill, Sharpe et al. 2012).  APAP was extensively 
discussed in section 1.6. We previously found that pharmacological induction of autophagy via 
rapamycin was protective against APAP-induced liver injury, likely by removing damaged 
mitochondria (Ni, Boggess et al. 2012). However, the mechanism for removal of these damaged 
mitochondria in the liver is unknown.  
As previously discussed in section 1.2, autophagy is an evolutionarily conserved process 
that results in degradation of cellular proteins and organelles due to a cell’s “self-eating”.  In 
addition to providing the cell with nutrients and energy in response to starvation, this process 
rids the cell of misfolded proteins and damaged organelles through the formation of double-
membrane autophagosomes. Autophagosomes can engulf individual organelles, protein 
aggregates, or portions of cytoplasm before fusing with lysosomes to degrade their contents 
(Parzych and Klionsky 2014). Autophagy is a protective process that can be either selective or 
non-selective. Non-selective autophagy occurs during starvation to break down the cell’s 
components in order to provide a source of energy and nutrients. Selective autophagy occurs in 
nutrient-rich or poor conditions as a protective mechanism by ridding the cell of protein 
aggregates and damaged organelles (Reggiori, Komatsu et al. 2012). Mitophagy is a selective 
form of autophagy that is specific for removal of damaged mitochondria, and mitophagy has 
been shown in vitro to be mediated by the E3 ubiquitin ligase Parkin. Parkin is recruited to 
damaged mitochondria by PTEN-induced putative kinase 1 (PINK1) to initiate their removal by 
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mitophagy by performing K48 and K63 ubiquitination of mitochondrial outer membrane proteins 
(Narendra, Tanaka et al. 2008, Geisler, Holmstrom et al. 2010, Matsuda, Sato et al. 2010, 
Narendra, Jin et al. 2010, Vives-Bauza, Zhou et al. 2010, Chan, Salazar et al. 2011) (discussed 
in section 1.3.2).  
Parkin-induced mitophagy is mainly known for its protective role in the brain because loss of 
Parkin has been linked to Autosomal Recessive Parkinsonism (Kitada, Asakawa et al. 1998). 
We recently found that parkin is also ubiquitously expressed in several tissues in mouse, 
including the liver (Ding and Yin 2012). Therefore, we investigated the role of Parkin in 
mitophagy induction as a mechanism of protection in APAP-induced liver injury. We found that 
Parkin-induced mitophagy is likely a mechanism of protection in APAP-induced liver injury 
because Parkin translocated to mitochondria and increased the level of mitochondrial protein 
ubiquitination after APAP treatment. However, we surprisingly found that Parkin knockout (KO) 
mice also had mitophagy in their livers after APAP treatment likely due to other compensatory 
mechanisms. In addition, Parkin KO mice were protected against APAP-induced liver injury 
compared to wild type (WT) mice. Mechanistically, we found that Parkin KO mice had 
decreased activation of JNK, increased induction of Mcl-1 expression, and increased 
proliferation, which are all known important factors in mediating APAP-induced necrosis and 
liver injury. In contrast to chronic deletion of Parkin, acute knockdown of Parkin in mouse livers 
resulted in reduced mitophagy and Mcl-1 expression but increased JNK activation after APAP 
administration, which exacerbated APAP-induced liver injury. Our results thus revealed that 
chronic deletion (KO) and acute knockdown of Parkin differentially regulate APAP-induced 





3.3 Experimental Procedures 
Materials. APAP was purchased from Sigma (A7085), and the kit for alanine aminotransferase 
(ALT) measurement was purchased from Pointe Scientific (A7526-450). The following 
antibodies were used for western blot analysis: anti-Parkin (Santa-Cruz, SC-32282), anti-
Ubiquitin (Santa Cruz, SC-8017), anti-β-Actin (Sigma, A5441), anti-Cyp2e1 (Abcam, ab19140), 
anti-CyclinD1 (Lab Vision, RB-9041), anti-phosphorylated JNK (Cell Signaling, 4668S), anti-
phosphorylated GSK-3β (Ser9) (Cell Signaling, 5558), anti-GSK-3α/β (Cell Signaling, 5696), 
anti-phosphorylated glycogen synthase (Cell Signaling, 4858), anti-JNK (BD, 554285), anti-
CoxIV (Mitosciences, MS407), anti-Mcl-1 (Rockland, 600-401-394), anti-Tom20 (Santa-Cruz, 
SC11415), anti-Cyclophilin D (Mitosciences, E0667), and anti-GAPDH (Cell Signaling, 2118). 
The APAP-adduct antibody was a gift from Dr. Lance Pohl (NIH) (Matthews, Roberts et al. 
1996, Ryan, Bourdi et al. 2012). Anti-PCNA antibody (Santa-Cruz, SC-56) was used for 
immunostaining.  Horseradish peroxidase or biotin-conjugated antibodies were from Jackson 
ImmunoResearch Lab. Adenovirus (Ad) negative shRNA and Ad shRNA for mouse Parkin were 
purchased from Vector Biolabs (Malvern, PA). 
 
Animal Experiments. WT C57BL/6J (#000664) and whole body Parkin KO mice (C57BL/6J 
background, #006582) were purchased from the Jackson Laboratory. All animals received 
humane treatment, and all protocols were approved by the Institutional Animal Care and Use 
Committee at the University of Kansas Medical Center. Eight to 12 week old male mice were 
treated with either 500 mg/kg of APAP or saline by IP injection and were sacrificed 0.5, 1, 2, 6, 
or 24 hours after treatment. To achieve knockdown of Parkin in mouse livers, two month old 
male C57BL/6J mice were injected intravenously via tail vein with Ad-negative (Neg) shRNA or 
Ad-Parkin shRNA (1×109 PFU per mouse) for 4 days. Then the mice were further treated with 
either APAP (500 mg/kg) or saline by IP injection for 6 hours. Liver injury was determined by 
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measuring serum ALT. Formalin-fixed liver sections were embedded in paraffin and cut into 5 
µm sections before staining with hematoxylin and eosin (H&E) to determine liver cellular 
necrosis.  
 
Western Blot Analysis.  Total liver lysates were prepared using RIPA buffer. Heavy membrane 
(HM) mainly enriched with mitochondria and cytosolic fractions were prepared as described 
previously (Ding, Ni et al. 2004). Briefly, liver tissues were homogenized in HIM buffer (200 mM 
mannitol, 70 mM sucrose, 5 mM Hepes, 0.5 mM EGTA (pH 7.5) containing protease inhibitors) 
using a dounce homogenizer.  Homogenates were centrifuged at 1,000 x g to remove debris, 
and the supernatant was centrifuged at 10,000 x g for 10 minutes to separate HM and cytosolic 
fractions. The supernatant was kept as the cytosolic fraction, and the pellet containing the HM 
fraction was further washed by centrifugation and re-suspended in HIM buffer. Protein (20-30 
µg) was separated by a 12% SDS-PAGE gel before transfer to a PVDF membrane.  
Membranes were probed using indicated primary and secondary antibodies and developed with 
SuperSignal West Pico chemiluminescent substrate (Pierce).  
  
Proliferating Cell Nuclear Antigen (PCNA) Staining. Formalin-fixed liver sections were 
embedded in paraffin and cut into 5 µM sections before staining with anti-PCNA antibody. 
Sections were deparaffinized in xylene and dehydrated in ethanol followed by incubation in 
hydrogen peroxide to quench peroxidases. Tissues were then blocked using Ultra V-Block 
(Thermo Scientific, TA-125-UB) for 5 minutes and incubated with PCNA antibody (1:100) 
overnight at 4°C. Sections were further incubated with biotinylated secondary antibody for 30 
minutes, and PCNA-positive cells were detected using ABC reagent (Vector, PK-6100) and 
DAB peroxidase substrate (Vector, SK-4105). Sections were counterstained with hematoxylin 
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(Sigma, GHS132) for 30 seconds. Six fields at 200 x magnification were quantified for PCNA 
positive cells per tissue, and results were expressed as percent PCNA positive hepatocytes.  
 
Culture of Primary Hepatocytes. As described previously (Ni, Bockus et al. 2012), murine 
hepatocytes were isolated from WT and Parkin KO mice by a retrograde, non-recirculating 
perfusion of livers with 0.05% Collagenase Type IV (Sigma). Cells were cultured in William’s 
medium E with 10% fetal bovine serum but no other supplements for 2 hrs for attachment. Cells 
were then cultured in the same medium without serum overnight before treatment. All cells were 
maintained in a 37°C incubator with 5% CO2. For assessing mitochondrial membrane potential, 
hepatocytes were first loaded with Tetramethylrhodamine, methyl ester (TMRM) (50 nM) for 15 
minutes and then treated with APAP (0, 5, 10 mM) for 8 hours. Cells were further stained with 
Hoechst 33342 (1 µg/mL) for 5 minutes followed by fluorescence microscopy. For assessing 
necrosis after APAP treatment, hepatocytes were stained with propidium iodide (PI, 1 µg/mL) for 
5 minutes followed by fluorescence microscopy. 
 
Caspase-3 Activity. Caspase-3 activity was determined using Ac-DEVD-AFC fluorescent 
substrate (Enzo) and 20 µg of protein from mouse liver lysates after treatment with saline or 
APAP as we previously described (Ding, Ni et al. 2004). Liver lysate from an Atg5 KO mouse 
was used as a positive control (Ni, Boggess et al. 2012).  
 
GSH Measurement. Glutathione (GSH) and glutathione disulfide (GSSG) levels in liver tissue 
were measured using a modified Tietze assay (Jaeschke and Mitchell 1990). For GSH 
measurement, liver tissues were homogenized in sulfosalicylic acid (3%) followed by 
centrifugation and dilution in potassium phosphate buffer. Samples were then subjected to a 
cycling reaction using glutathione reductase and dithionitrobenzoic acid, and GSH levels were 
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determined by spectrophotometry. For GSSG, reduced GSH was removed using N-
ethylmaleimide, and the GSSG measurement was performed using a similar spectrophotometer 
method as for GSH.  
 
Analysis of Proteasome Activity. Proteasome activity was determined using a Suc-LLVY-
AMC substrate (Enzo) for the 20s proteasome subunit and 20 µg of protein from mouse liver 
lysates after treatment with APAP or saline as previously described (Williams, Hou et al. 2013). 
 
Electron microscopy. Tissues were fixed with 2% glutaraldehyde in 0.1M phosphate buffer 
(pH 7.4) followed by 1% OsO4.  After dehydration, thin sections were stained with uranyl acetate 
and lead citrate for observation under a JEM 1016CX electron microscope.  
 
Statistical Analysis. Statistical analysis was conducted with Student’s t test or one-way 





3.4.1 Parkin Translocated to Mitochondria after APAP Treatment, but Parkin KO Mice 
were Resistant to APAP-induced Liver Injury.  
During Parkin-mediated mitophagy in cultured cells, Parkin translocates from the cytosol 
to depolarized mitochondria resulting in mitochondrial degradation (Narendra, Tanaka et al. 
2009, Ding, Ni et al. 2010, Vives-Bauza, Zhou et al. 2010). We previously showed that APAP 
administration induces mitophagy in mouse livers (Ni, Bockus et al. 2012). Therefore, we 
investigated the role of Parkin in mitophagy induction in the liver after APAP treatment.  We first 
treated WT mice with APAP (500 mg/kg) for 6 hours and determined Parkin translocation to 
mitochondria by western blot analysis using cytosolic and mitochondrial fractions.  Parkin 
translocated to mitochondria after APAP treatment, which was accompanied by increased 
ubiquitination of mitochondrial proteins, suggesting that Parkin may play a role in APAP-induced 
mitophagy (Figure 3.4.1 A).  
To determine if Parkin-induced mitophagy was a protective mechanism against APAP-
induced liver injury, we treated WT and Parkin KO mice with APAP (500 mg/kg) for 6 and 24 
hours. We expected Parkin KO mice to have increased liver injury after APAP treatment due to 
an inability to induce mitophagy. However, we surprisingly found that Parkin KO mice were 
protected from APAP-induced liver injury compared to WT mice (Figure 3.4.1 B-C). Parkin KO 
mice had significantly less liver injury compared to WT mice after APAP treatment for 6 and 24 
hours as determined by serum ALT levels.  WT mice had a mean serum ALT of 5309 U/L at 6 
hours and 8290 U/L at 24 hours, and KO mice had a mean serum ALT of 2813 U/L at 6 hours 
and 2649 U/L at 24 hours (Figure 3.4.1 B). WT mice also had a significantly greater area of 
hepatocellular necrosis than KO mice after APAP treatment for 6 and 24 hours as determined 
by H&E staining. Saline treated WT and Parkin KO mice did not develop any cellular necrosis 
(Figure 3.4.1 C).  
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APAP is well known to induce cell death via necrosis and not apoptosis (McGill and 
Jaeschke 2013), so we ensured that protection in Parkin KO mice was not due to APAP 
induction of cell death via apoptosis instead of necrosis by assessing caspase-3 activity in liver 
tissue lysates. Neither WT nor Parkin KO mice had any induction of caspase-3 activity after 
APAP treatment, indicating that APAP did not induce apoptosis in WT or Parkin KO mice, as 
expected. Lysate from an Atg5 KO mouse was used as a positive control for caspase-3 
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3.4.2 Protection in Parkin KO Mice was not due to Differences in APAP Metabolism or 
Oxidative Stress.  
 APAP is metabolized primarily by CYP2E1 to its reactive metabolite NAPQI, which is 
detoxified by GSH at therapeutic doses. GSH is depleted during APAP overdose, which allows 
for NAPQI to form protein adducts and induce mitochondrial damage and subsequent 
hepatocellular necrosis (McGill and Jaeschke 2013). To ensure that protection in KO mice was 
not due to differences in APAP metabolism, we treated WT and Parkin KO mice with APAP (500 
mg/kg) or saline control and measured GSH levels 0.5, 1, 2, 6, and 24 hours after treatment. 
WT and Parkin KO mice had similar basal levels of GSH and similar GSH depletion at 0.5, 1, 
and 2 hours after APAP treatment. WT and Parkin KO mice also had similar recovery of GSH 
after APAP treatment for 6 and 24 hours (Figure 3.4.2 A). Furthermore, WT and Parkin KO 
mice had similar levels of protein adducts and Cyp2e1 protein expression after APAP or saline 
treatment for 6 hours (Figure 3.4.2 B). These results suggest that protection in Parkin KO mice 
was not due to differences in metabolism of APAP between WT and Parkin KO mice.  
 Glutathione disulfide (GSSG) levels and the ratio of GSSG to GSH are markers of 
oxidative stress. WT and Parkin KO mice had similar basal GSSG levels and GSSG to GSH 
ratio. WT and Parkin KO mice also had similar GSSG levels and GSSG to GSH ratios after 
APAP treatment for 0.5, 1, 2, and 6 hours. Parkin KO mice had slightly less GSSG than WT 
mice after APAP treatment for 24 hours, but the decrease in KO mice was not significant 
compared to WT mice (Figure 3.4.2 C-D). These results suggest that differences in injury 
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3.4.3 Mitophagy Occurred in Both WT and Parkin KO Mice after APAP Treatment 
We compared and quantified the number of autophagosomes and lysosomes containing 
mitochondria (hereafter referred to as mitophagosomes) by electron microscopy (EM) between 
WT and Parkin KO mice after APAP treatment. We also performed an autophagy flux assay 
with a combination of APAP and chloroquine (CQ) treatment. CQ blocks lysosome degradation, 
which allows for accurate quantification of autophagosome and lysosome components 
(Klionsky, Abdalla et al. 2012). Treatment with APAP significantly increased the number of 
mitophagosomes, which was further enhanced in the presence of CQ in WT mice, indicating 
that APAP induces mitophagy flux in mouse livers. Surprisingly, Parkin KO mice also had an 
increased number of mitophagosomes, which was also further enhanced by the presence of CQ 
treatment, although the number of mitophagosomes was lower compared to WT mice (Figure 
3.4.3 A-B). 
WT and Parkin KO mice also both showed slight degradation of the mitochondrial outer 
membrane protein Tom20 as well as the mitochondrial matrix protein Cyclophilin D after APAP 
treatment (Figure 3.4.3 C-E). We recently reported that APAP treatment in mice causes distinct 
mitochondrial changes in different zones of the mouse liver. In addition to mitophagy, APAP 
also induces mitochondrial biogenesis adjacent to portal areas likely to promote liver repair (Ni, 
Williams et al. 2013). This could offset the levels of mitochondrial degradation mediated by 
mitophagy using total liver lysates. A better quantitative approach, such as the use of a micro-
dissection approach to isolate tissues from different zones of the liver, may need to be 
established in the future. Taken together, these results indicate that APAP may induce 
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3.4.4 Parkin KO Mice had Decreased JNK Activation Compared to WT Mice after APAP 
Treatment 
 Activation of JNK by phosphorylation and its translocation to the mitochondria are well 
known to exacerbate APAP-induced liver injury (Gunawan, Liu et al. 2006, Henderson, Pollock 
et al. 2007, Hanawa, Shinohara et al. 2008, Saito, Lemasters et al. 2010).  To determine if WT 
and Parkin KO mice had differences in JNK activation, we measured protein levels of 
phosphorylated JNK (pJNK) in WT and Parkin KO mouse livers after APAP treatment for 2 and 
6 hours. Parkin KO mice had slightly less JNK activation 2 hours after APAP treatment 
compared to WT mice, and JNK activation was significantly less in Parkin KO mice compared to 
WT mice 6 hours after APAP treatment (Figure 3.4.4 A-B). WT and Parkin KO mice had similar 
levels of total JNK protein expression (Figure 3.4.4 A). In addition, we investigated 
mitochondrial JNK activation using cytosolic and mitochondrial fractions from WT and Parkin KO 
mouse liver lysates after APAP treatment for 6 hours. We found that JNK translocated to 
mitochondria after APAP treatment, and the level of total JNK levels on mitochondria was 
surprisingly higher in Parkin KO mice compared to WT mice (Figure 3.4.4 C-D).  However, the 
active form of JNK (pJNK) on mitochondria was much lower in Parkin KO mice compared to WT 
mice after APAP treatment (Figure 3.4.4 C-D). These results suggest that Parkin may promote 
JNK activation once it translocates to mitochondria, and the regulation of JNK mitochondrial 
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3.4.5 Parkin KO Mice had Increased Mcl-1 Expression Compared to WT Mice after APAP 
Treatment 
Mcl-1 is an anti-apoptotic protein that has been shown to be protective against APAP-
induced liver injury (Shinohara, Ybanez et al. 2010, Sharma, Gadang et al. 2012). We 
measured protein levels of Mcl-1 using total lysate from WT and Parkin KO mouse livers 6 
hours after APAP treatment. Mcl-1 protein expression was increased after APAP treatment in 
both WT and Parkin KO mice, and Parkin KO mice had higher basal levels of Mcl-1, which were 
sustained after APAP treatment compared to WT mice (Figure 3.4.5 A-B). It has been reported 
that GSK-3β phosphorylates Mcl-1 and promotes its proteasomal degradation (Maurer, Charvet 
et al. 2006). We found that APAP treatment increased the phosphorylation levels of Akt and 
GSK-3β at serine 9 (Ser 9) in both WT and Parkin KO mouse livers. Since Akt-mediated Ser 9 
phosphorylation of GSK-3β negatively regulates its activity, we also determined the 
phosphorylated levels of glycogen synthase (GS), which is one of the substrates of GSK-3β. We 
found that there was a dramatic reduction in phosphorylated levels of GS in Parkin KO but not 
WT mouse livers after APAP treatment (Figure 3.4.5 A), suggesting decreased GSK-3β activity 
in APAP-treated Parkin KO mouse livers.   
It is known that Mcl-1 is degraded by the ubiquitin proteasome system (Nijhawan, Fang 
et al. 2003, Maurer, Charvet et al. 2006), and APAP treatment tended to slightly decrease 
proteasome activity in WT mice, but these changes did not reach statistical differences (Figure 
3.4.5 C). In addition, Parkin KO mice overall tended to have slightly decreased proteasome 
activity although APAP treatment did not further alter the proteasome activity, and these 
changes were also not statistically different (Figure 3.4.5 C). Collectively, these data suggest 
that protection in Parkin KO mice against APAP-induced liver injury was likely due to decreased 
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3.4.6 Parkin KO Mice had Increased Proliferation Compared to WT Mice 
 Following APAP-induced cellular necrosis, it is well known that the liver has the capacity 
for repair and complete recovery if the level of injury is not too severe. Parkin KO mice have 
previously been shown to have increased proliferation leading to eventual development of 
hepatocellular carcinoma (HCC) at 18 months (Wang, Denison et al. 2004, Fujiwara, Marusawa 
et al. 2008). Therefore, we evaluated proliferation levels in WT and Parkin KO mice after APAP 
treatment to determine if greater levels of hepatocyte proliferation could be an additional 
mechanism of protection against APAP-induced liver injury in KO mice. Parkin KO mice had 
significantly increased basal expression levels of the proliferation proteins CyclinD1 and 
proliferating cell nuclear antigen (PCNA) compared to WT mice. In addition, Parkin KO mice had 
increased expression of these proliferative proteins compared to WT mice after APAP treatment 
for 6 hours as shown by CyclinD1 and PCNA western blot analysis (Figure 3.4.6 A-B and E-F). 
Immunohistochemistry for PCNA staining also revealed an increase in the number of PCNA 
positive cells in APAP-treated Parkin KO mice compared with APAP-treated WT mice, but these 
changes did not reach statistical significance (Figure 3.4.6 C-D). This was likely due to large 
variations in the immunohistochemistry analysis from the limited liver areas that we could 
assess in each sample, although we counted 6 random images from each sample. 
Nevertheless, these data suggest that increased proliferation levels in Parkin KO mice may 
provide protection against APAP-induced liver injury by allowing for faster replacement of 
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3.4.7 APAP Treatment Induced Proteasomal Degradation of Mcl-1 and Necrosis in 
Cultured Mouse Hepatocytes Independent of Parkin 
 To further determine whether the proteasome plays a role in APAP-induced changes of 
Mcl-1, we treated primary cultured mouse hepatocytes with APAP in the presence or absence of 
Bortezomib (Bort), a proteasome inhibitor. Unlike the in vivo mouse liver, there was no 
difference in basal levels of Mcl-1 between the hepatocytes isolated from WT and Parkin KO 
mice. APAP treatment decreased Mcl-1 levels, which were recovered by Bort in both WT and 
Parkin KO hepatocytes. Bort treatment alone also increased Mcl-1 levels compared to control 
hepatocytes independent of Parkin (Figure 3.4.7 A-B). These results indicate that APAP-
induced changes in Mcl-1 are mediated by the proteasome. Intriguingly, WT hepatocytes lost 
the expression of Parkin after 24 hours culture (Figure 3.4.7 C), which is a time point that we 
started treating hepatocytes with drugs including APAP in previous studies (Ni, Bockus et al. 
2012). We found that APAP treatment for 8 hrs increased the number of cells with decreased 
mitochondrial membrane potential (Figure 3.4.7 D-E). Consistent with our previous findings, 
APAP treatment also increased necrotic cells in WT hepatocytes. Interestingly, we found that 
there was no difference in APAP-induced necrosis between WT and Parkin KO hepatocytes 
(Figure 3.4.7 F-G). Taken together, Parkin is dispensable for APAP-induced Mcl-1 degradation 
and necrosis in primary cultured mouse hepatocytes. 
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3.4.8 Acute Knockdown of Parkin in Mouse Livers Impaired Mitophagy and Exacerbated 
APAP-induced Liver Injury 
 Since Parkin KO mice have no obvious phenotypes, it is possible that the mice may 
develop compensatory and adaptive mechanisms for the chronic loss of Parkin, which may 
contribute to their resistance to APAP-induced liver injury. To overcome the potential 
compensation and adaptation by the chronic loss of Parkin, we determined APAP-induced 
mitophagy and liver injury after acute knockdown of Parkin in mouse livers using an Ad-shRNA 
approach. We found that Ad-Parkin shRNA by tail vein injection dramatically reduced the 
expression of Parkin in mouse livers but had no effect on the expression of Parkin in mouse 
pancreas or skeletal muscle (Figure 3.4.8 A). In contrast to Parkin KO mice, mice given Ad-
Parkin shRNA had increased serum ALT levels and hepatic necrosis compared with mice given 
Ad-Neg shRNA (Figure 3.4.8 B-C). Notably, mice that received adenovirus treatment had 
decreased sensitivity to APAP administration since ALT levels were less compared to the non-
viral infected mice that were treated with the same dose of APAP (Figure 3.4.8 B). Our results 
are consistent with a previous study that showed reduced susceptibility to APAP after viral 
infection in mice (Getachew, James et al. 2010). There were no significant differences in 
Cyp2e1 or APAP-adduct levels between Ad-Parkin and Ad-Neg shRNA treated groups, but Ad-
Parkin shRNA markedly decreased hepatic Parkin expression (Figure 3.4.8 D). 
 The Ad-Parkin shRNA-treated mice had increased phosphorylated levels of JNK but 
decreased levels of Mcl-1 and PCNA compared to Ad-Neg shRNA-treated mice after 
administration of APAP (Figure 3.4.8 E). The levels of LC3-II, a marker for autophagy, were 
increased after APAP treatment in both Ad-Neg and Ad-Parkin-treated mice (Figure 3.4.8 E), 
suggesting that APAP increased the numbers of autophagosomes/autolysosomes independent 
of Parkin. Moreover, the number of mitophagosomes was significantly decreased in mouse 
livers treated with Ad-Parkin shRNA compared with Ad-Neg shRNA after administration of 
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APAP (Figure 3.4.8 F-G). These results suggest that acute knockdown of Parkin in mouse 
livers had impaired mitophagy and hepatocyte proliferation, decreased hepatic Mcl-1 expression 
and increased JNK activation, which exacerbated liver injury in response to APAP 
administration.  Consistent with the LC3-II results from Western blot analysis, the number of 
total autophagosomes was very comparable between groups of Ad-Parkin shRNA and Ad-Neg 
shRNA after administration of APAP (Figure 3.4.8 H), suggesting that acute knockdown of 
Parkin does not affect general autophagy.  These results suggest that acute knockdown of 
Parkin in mouse livers impaired mitophagy and hepatocyte proliferation, decreased hepatic Mcl-
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 In this study, we found that APAP treatment induced Parkin translocation to 
mitochondria and increased levels of mitochondrial protein ubiquitination in WT mouse livers. 
However, we found that Parkin differentially regulated mitophagy and APAP-induced liver injury 
depending on whether Parkin was chronically deleted in mice or acutely knocked down in 
mouse livers. We found that mitophagy still occurred in Parkin KO mouse livers after APAP 
treatment, suggesting that Parkin may be dispensable for mitophagy under chronic Parkin loss 
conditions. Moreover, we surprisingly found that Parkin KO mice were protected against APAP-
induced liver injury compared to WT mice. In contrast, mice with acute knockdown of Parkin had 
decreased hepatic mitophagy and increased APAP-induced liver injury. 
 
3.5.1 Parkin was Dispensable for APAP-induced Mitophagy in Parkin KO Mice but not in 
Mice with Acute Knockdown of Hepatic Parkin 
Parkin translocated to mitochondria after APAP treatment in WT mice, which correlated 
with an increase in mitochondrial protein ubiquitination, suggesting that Parkin-induced 
mitophagy occurs in mouse liver after APAP treatment. However, we found Parkin KO mice had 
similar mitochondrial protein degradation after APAP treatment, although there was a slight 
reduction in the number of mitophagosomes in Parkin KO mice compared to WT mice. 
Mitophagy is likely a protective mechanism against APAP-induced liver injury by promoting 
removal of damaged mitochondria in both WT and Parkin KO mice. However, it appears that 
Parkin is not required for mitophagy induction in the liver because mitophagy still occurred in 
Parkin KO mouse livers after APAP treatment. In contrast, mice with acute knockdown of Parkin 
had significantly reduced mitophagy after APAP administration. These results suggest that 
alternative compensatory mechanisms for mitophagy independent of Parkin may occur when 
Parkin is chronically deleted in mice after APAP administration. To support this notion, it was 
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previously reported that compensatory mitophagy also occurred in Parkin KO mouse hearts 
(Piquereau, Godin et al. 2013). It is likely that compensatory and adaptive alternative 
mechanisms for mitophagy independent of Parkin cannot be established within the relative short 
time period after acute Parkin knockdown. Alternatively, although it seems to be less likely, the 
loss of Parkin in other tissues in Parkin KO mice may also affect the mitophagy signaling 
pathway in the liver. The tissue cross-talk regulating mitophagy in the liver is currently unknown. 
It was recently reported that at least three distinct types of mitophagy could occur in 
hepatocytes: 3-methyladenine (3-MA) sensitive, 3-MA insensitive and mitochondrial derived 
vesicles (Czaja, Ding et al. 2013, Lemasters 2014). We previously showed that 3-MA inhibited 
APAP-induced autophagy and enhanced APAP-induced necrosis in cultured mouse 
hepatocytes (Ni, Bockus et al. 2012). These results suggest that APAP may induce 3-MA 
sensitive mitophagy. In addition to canonical mitophagy, we also showed that APAP could 
induce the formation of mitochondrial spheroids, a process of mitochondria remodeling that 
forms unique vesicle-like structures derived directly from mitochondria in mouse livers (Ding, 
Guo et al. 2012, Ni, Williams et al. 2013).  
The identification of mitophagy in Parkin KO mice after APAP administration suggests 
that Parkin may not be essential for mitophagy induction in vivo. The mechanism for alternative 
Parkin-independent mitophagy induction in the liver is currently unknown but could be due to 
upregulation of other important proteins or pathways in the absence of Parkin that have been 
shown to have a role in the mitophagy pathway (discussed in section 5.1.1). For example, 
Parkin-independent mitophagy in Parkin KO mice may be mediated by another E3 ubiquitin 
ligase, such as March5, Smurf1, or Mulan. In addition, Parkin-independent mitophagy may 
occur via Bcl2/adenovirus E1B 19kDa interacting protein 3 (Bnip3), Fun14 domain containing 1 
(Fundc1), or Nix. Bnip3 and Fundc1 have both been shown to play a role in mitophagy induction 
for removal of damaged mitochondria to prevent accumulation of reactive oxygen species 
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during hypoxia (Zhang, Bosch-Marce et al. 2008, Liu, Feng et al. 2012). Nix also plays a role in 
selective removal of mitochondria during red blood cell maturation (Schweers, Zhang et al. 
2007, Sandoval, Thiagarajan et al. 2008, Zhang and Ney 2008). In addition, Nix has been 
shown to play a role in Parkin-dependent mitophagy induction by promoting mitochondrial 
depolarization and translocation of Parkin to mitochondria (Ding, Ni et al. 2010). Cardiolipin, a 
phospholipid located on the inner mitochondrial membrane, has also been recently shown to 
have a role in mitophagy induction in neurons by translocating to the outer mitochondrial 
membrane and interacting with LC3 (Chu, Ji et al. 2013, Chu, Bayir et al. 2014).  Therefore, 
cardiolipin may also have a role in Parkin-independent mitophagy induction in the liver. Even 
though the mechanism of Parkin-independent mitophagy induction in the liver is not currently 
understood, induction of mitophagy in both WT and Parkin KO mouse livers was likely a 
mechanism of protection against APAP-induced liver injury by removing damaged mitochondria. 
However, in addition to mitophagy, Parkin KO mice had other protective mechanisms against 
APAP-induced liver injury and necrosis compared to WT mice, which are further discussed 
below. 
 
3.5.2 JNK Activation was Differentially Regulated in Parkin KO and Acute Parkin 
Knockdown Mice after APAP Treatment  
Another mechanism of protection in Parkin KO mice was decreased JNK activation 
compared to WT mice after APAP treatment. JNK activation, particularly in the mitochondria, 
has been shown to exacerbate APAP-induced liver injury (Gunawan, Liu et al. 2006, 
Latchoumycandane, Goh et al. 2007, Hanawa, Shinohara et al. 2008, Saito, Lemasters et al. 
2010). Parkin has been previously shown to negatively regulate JNK activity in Drosophila (Cha, 
Kim et al. 2005, Hwang, Kim et al. 2010). Parkin-mutant flies contained high levels of 
phosphorylated JNK in their dorsomedial neurons, resulting in shrinkage of the neuronal cell 
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body, which was not present in control flies. Neuron cell body morphology was normal when 
Parkin-mutant flies were treated with a dominant negative form of JNK, confirming that the 
morphology changes were caused by increased JNK activation in the absence of Parkin (Cha, 
Kim et al. 2005). Parkin was also found to suppress JNK activation in the Drosophila eye during 
development by transcriptionally repressing basket (bsk), which is a gene encoding for JNK 
(Hwang, Kim et al. 2010). In addition, Parkin was shown to suppress JNK activation in vitro in 
EPP85 human pancreatic carcinoma cells via mono-ubiquitination of heat-shock protein 70 
(HSP70), but the exact mechanism for how mono-ubiquitinated HSP70 inhibits activation of JNK 
is unknown (Liu, Aneja et al. 2008).  Furthermore, Parkin was shown to inhibit JNK activity in 
COS1 monkey kidney fibroblasts (Cha, Kim et al. 2005). Parkin and JNK were co-transfected 
into COS1 cells, and co-expression of Parkin reduced JNK activation (Cha, Kim et al. 2005). 
Consistent with these findings, we found that APAP increased JNK activation in acute Parkin 
knockdown mouse livers. In contrast, JNK activation was decreased in Parkin KO mouse livers 
compared to WT mice after APAP treatment. These results suggest that acute knockdown and 
chronic loss of Parkin differentially impact JNK activation, which is likely due to induction of 
some adaptive mechanisms in the mouse livers when Parkin is chronically absent. 
The adaptive mechanisms for JNK inhibition after APAP treatment in Parkin KO mice is 
currently unknown but may involve mono or polyubiquitination of upstream or downstream 
mediators of JNK activation. For example, chronic loss of Parkin may affect the degradation of 
MAP kinase phosphatase-1 (MkP-1), an endogenous inhibitor of JNK activation (Doddareddy, 
Rawling et al. 2012). Parkin has also been shown to stabilize proteins via monoubiquitination, 
so chronic loss of Parkin may also stabilize upstream activators of JNK such as Apoptosis 
signal-regulating kinase 1 (Ask1) via monoubiquitination (Dunn, Wiltshire et al. 2002). Taken 
together, it appears that chronic and acute Parkin loss have contrasting impacts on JNK 
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activation in mouse livers after APAP treatment, which may subsequently protect against or 
exacerbate APAP-induced liver injury.  
  
3.5.3 Mcl-1 Expression was Differentially Regulated in Parkin KO and Acute Parkin 
Knockdown Mice after APAP Treatment 
 Mcl-1 is an anti-apoptotic Bcl-2 protein that is mostly localized to the mitochondrial 
membrane (Warr and Shore 2008), and its stabilization has been shown to play a protective role 
against APAP-induced hepatocellular necrosis (Sharma, Gadang et al. 2012). Parkin KO mice 
had increased liver Mcl-1 expression compared to WT mice before and after APAP treatment, 
which may be another mechanism for their protection against APAP-induced liver injury. APAP 
has been shown to induce degradation of Mcl-1 in the early phase of liver injury in starved mice 
(1 to 4 hours after treatment) (Shinohara, Ybanez et al. 2010), but we did not observe 
degradation of Mcl-1 in WT or Parkin KO mice after APAP treatment in fed mice. We actually 
observed an increase in Mcl-1 expression after APAP treatment. This discrepancy could be due 
to several possibilities. First, we used fed mice to avoid the possible interference of starvation-
induced autophagy whereas Shinohara et al. used starved animals. Starvation may inactivate 
AKT and interfere with AKT-GSK3β-mediated Mcl-1 phosphorylation and proteasomal 
degradation. Consistent with this notion, we also found that APAP decreased Mcl-1 in primary 
cultured hepatocytes in serum free medium. Second, we assessed APAP-induced liver injury 6 
hours after treatment, which may allow for recovery of Mcl-1 protein levels. Third, Mcl-1 
expression is regulated by Gsk-3β phosphorylation, which primes it for ubiquitination and 
degradation by the proteasome (Maurer, Charvet et al. 2006). Gsk-3β is known to translocate to 
mitochondria after APAP-induced liver injury where it phosphorylates Mcl-1 to initiate its 
proteasomal degradation (Shinohara, Ybanez et al. 2010). Since phosphorylation of GSK-3β at 
serine 9 normally inhibits its activity (Doble and Woodgett 2003), increased serine 9 
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phosphorylation of GSK-3β may thus contribute to the increased Mcl-1 levels following APAP 
treatment. Fourth, Parkin KO mice tend to have decreased proteasome activity compared to WT 
mice, which may also partially contribute to increased Mcl-1 protein expression compared to WT 
mice. In primary cultured mouse hepatocytes, Parkin seems to be less important in regulating 
Mcl-1 levels after APAP treatment since WT hepatocytes lost the expression of Parkin during 
culture and APAP decreased Mcl-1 protein levels in both cultured WT and Parkin KO 
hepatocytes. The decreased Mcl-1 protein levels were reversed by a proteasome inhibitor, 
supporting the important role of the proteasome in regulating Mcl-1 levels in APAP-treated 
hepatocytes. Finally, Mcl-1 degradation has also been shown to be induced by JNK 
phosphorylation in HeLa cells (Wang, Wang et al. 2014). Parkin KO mice had reduced JNK 
activation, which may be linked to their increased Mcl-1 expression. We found that acute 
knockdown of Parkin in mouse livers had decreased Mcl-1 protein levels after APAP treatment. 
Interestingly, Parkin knockdown mice also had increased JNK activation in their livers after 
APAP treatment, which is opposite from APAP-treated Parkin KO mouse livers. These findings 
are also in line with the known role of JNK in regulating Mcl-1. In addition, the mTOR pathway 
has been shown to have a role in Mcl-1 transcriptional regulation in Parkin KO mouse neurons 
because neurons in Parkin KO mice had increased Mcl-1 expression due to compensatory 
activation of mTOR (Ekholm-Reed, Goldberg et al. 2013). Future work is needed to determine 









3.5.4 Increased Hepatocyte Proliferation in Parkin KO Mice, but not in Mice with Acute 
Knockdown of Parkin, after APAP Treatment 
Parkin KO mice had increased basal hepatocyte proliferation levels and increased 
hepatocyte proliferation after APAP treatment for 6 and 24 hours, which may provide protection 
against APAP-induced hepatocellular necrosis and liver injury by allowing for faster replacement 
of necrotic hepatocytes. Parkin has been previously shown to be a tumor suppressor in liver, 
and Parkin KO mice develop spontaneous liver tumors around 18 months of age (Fujiwara, 
Marusawa et al. 2008). In addition, Parkin expression is significantly decreased or absent in 
most cancer cell lines and human liver tumors (Wang, Denison et al. 2004). This tumor 
suppressive function of Parkin was likely important in protection against APAP-induced liver 
injury, which causes significant hepatocellular necrosis. Hepatocytes undergoing division were 
shown to be protected against carbon tetrachloride due to increased basal hepatocellular 
proliferation (Mehendale, Thakore et al. 1994). Therefore, with increased basal proliferation and 
increased proliferation after APAP treatment compared to WT mice, Parkin KO mice were likely 
able to replace their necrotic hepatocytes faster than WT mice, making them resistant to APAP-
induced hepatocellular necrosis and liver injury. In contrast, acute knockdown of Parkin had 
decreased hepatocyte proliferation with or without APAP treatment. Our results suggest that 
acute and chronic loss of Parkin have different impacts on hepatocyte proliferation, and in turn 








 In conclusion, Parkin-induced mitophagy is likely a mechanism of protection against 
APAP-induced liver injury in WT mice because Parkin translocated to mitochondria after APAP 
treatment. However, Parkin is dispensable for APAP-induced mitophagy in Parkin KO mouse 
livers. Parkin KO mice may inhibit APAP-induced liver injury by attenuating APAP-induced JNK 
activation and Mcl-1 degradation while also increasing hepatocyte proliferation. In addition, 
currently unidentified Parkin-independent mitophagy pathways activated as a compensatory and 
adaptive response during the chronic loss of Parkin likely also play a protective role against 
APAP-induced liver injury by removing damaged mitochondria. These protective effects in 
Parkin KO mice were reversed in mice with acute knockdown of Parkin. Therefore, chronic 
deletion (KO) and acute knockdown of Parkin differentially regulate APAP-induced mitophagy 
and liver injury in mice. Our results also suggest that caution needs to be exercised for data 






















Chapter 4: Parkin Regulates Mitophagy and Mitochondrial Function to Protect Against 












Alcoholic liver disease claims two million lives per year. We previously reported that 
autophagy protected against alcohol-induced liver injury and steatosis by removing damaged 
mitochondria. However, the mechanisms for removal of these mitochondria are unknown. 
Parkin is an evolutionarily conserved E3 ligase that is recruited to damaged mitochondria to 
initiate ubiquitination of mitochondrial outer membrane proteins and subsequent mitochondrial 
degradation by mitophagy. In addition to its role in mitophagy, Parkin has been shown to have 
other roles in maintaining mitochondrial function. We investigated if Parkin protected against 
alcohol-induced liver injury and steatosis using Wild-type (WT) and Parkin knockout (KO) mice 
treated with alcohol by the acute-binge and Gao-binge (chronic plus acute-binge) models. We 
found that Parkin protected against liver injury in both alcohol models, likely due to Parkin’s role 
in maintaining a population of healthy mitochondria. Alcohol caused greater mitochondrial 
damage and oxidative stress in Parkin KO livers compared to WT livers. Parkin KO mice had 
severely swollen and damaged mitochondria that lacked cristae after alcohol treatment, which 
were not seen in WT mice. Furthermore, Parkin KO mice had decreased mitophagy, β-
oxidation, mitochondrial respiration, and cytochrome c oxidase activity after acute alcohol 
treatment compared to WT mice. Interestingly, liver mitochondria seemed able to adapt to 
alcohol treatment, but Parkin KO mouse liver mitochondria had less capacity to adapt to Gao-
binge treatment compared to WT mouse liver mitochondria. Overall, our findings indicate that 
Parkin is an important mediator of protection against alcohol-induced mitochondrial damage, 





Alcoholic liver disease (ALD) (discussed in section 1.7) is a health problem worldwide 
that claims two million lives per year (Rehm, Samokhvalov et al. 2013), and 50% of people in 
the United States over the age of 18 consume alcohol regularly (Nassir and Ibdah 2014). ALD 
pathogenesis begins with liver steatosis, which is reversible with abstinence from alcohol. 
However, with continuous alcohol abuse, ALD can progress in some patients from steatosis to 
steatohepatitis, fibrosis, cirrhosis, and even hepatocellular carcinoma with prolonged alcohol 
abuse. Mechanisms for progression of ALD pathogenesis are still not completely understood. In 
addition, there is currently no cure for ALD other than liver transplantation in severe disease 
states (Gao and Bataller 2011, Williams, Manley et al. 2014). Therefore, a better understanding 
of mechanisms involved in ALD pathogenesis is greatly needed for future generation of 
therapeutics to combat liver disease caused by alcohol.  
Macroautophagy (hereafter referred to as autophagy) (discussed in section 1.2) is a 
protective process that initiates lysosomal degradation of cellular components. Autophagy is 
activated to provide the cell with nutrients during starvation or to remove damaged organelles 
and protein aggregates to prevent cell death and tissue injury. Autophagy occurs through 
formation of double-membrane autophagosomes, which engulf organelles and protein 
aggregates and shuttle them to the lysosome for degradation (Parzych and Klionsky 2014). We 
and others have previously shown that autophagy is protective against alcohol-induced liver 
injury (Ding, Li et al. 2010, Ding, Li et al. 2011, Lin, Zhang et al. 2013). Specifically, we found 
that autophagy protected against alcohol-induced liver injury and steatosis by selectively 
removing damaged mitochondria and lipid droplets by mitophagy and lipophagy, respectively 
(Ding, Li et al. 2010, Ding, Li et al. 2011). Mitophagy (discussed in section 1.3) has been shown 
to be activated as a protective mechanism by many different cellular stress conditions including 
loss of mitochondrial membrane potential, cellular reactive oxygen species (ROS), mitochondrial 
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DNA damage, and mitochondrial accumulation of aggregated proteins (Liu, Sakakibara et al. 
2014), Some of these stresses, such as cellular ROS, nitric oxide and mitochondria DNA 
damage, have been associated with ALD pathogenesis (Zelickson, Benavides et al. 2011, 
Garcia-Ruiz, Kaplowitz et al. 2013, Andringa, Udoh et al. 2014) and likely lead to alcohol-
induced mitophagy activation in the liver (King, Swain et al. 2014). However, mechanisms for 
alcohol-induced activation of mitophagy in the liver are currently unknown.  
Mitophagy has been shown to require Parkin in in vitro models (discussed in section 1.3) 
(Narendra, Tanaka et al. 2008, Chan, Salazar et al. 2011, Ding, Guo et al. 2012). Parkin is an 
evolutionarily conserved E3 ligase that is recruited to damaged mitochondria by phosphatase 
and tensin homolog-induced putative kinase 1 (Pink1) to initiate ubiquitination of mitochondrial 
outer membrane proteins and subsequent mitochondrial degradation by mitophagy (Kawajiri, 
Saiki et al. 2010, Matsuda, Sato et al. 2010, Narendra, Jin et al. 2010). Parkin is mainly known 
for its protective role in the brain because loss of Parkin has been linked to autosomal recessive 
Parkinsonism (Kitada, Asakawa et al. 1998), but we found that Parkin is also expressed in liver 
(Ding and Yin 2012). The role of Parkin-induced mitophagy in vivo is not completely understood. 
We recently demonstrated that Parkin translocated to liver mitochondria after acetaminophen 
treatment in mice. In addition, mitophagy levels were decreased in Parkin knockout (KO) mice 
compared to WT mice after acetaminophen treatment, suggesting that removal of damaged 
mitochondria by Parkin-induced mitophagy is likely a protective mechanism in the liver 
(Williams, Ni et al. 2015). In addition to its role in mitophagy, Parkin has also been shown to 
help maintain mitochondrial function in the brain. Parkin KO mouse brain mitochondria had 
decreased mitochondrial respiration and dysregulation of proteins involved in energy 
metabolism and respiration with aging (Palacino, Sagi et al. 2004, Periquet, Corti et al. 2005, 
Stichel, Zhu et al. 2007). Therefore, we investigated the role of Parkin in mitophagy induction 
and in maintenance of mitochondrial function as protective mechanisms against alcohol-induced 
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liver injury using WT and Parkin KO mice. Two mouse alcohol models were used in this study: 
acute-binge and Gao-binge (chronic plus acute-binge). The acute-binge model represents 
human binge drinking, which is defined as consumption of greater than 4 or 5 drinks in a two-
hour period for women and men, respectively (Shukla, Pruett et al. 2013). The acute-binge 
model is best for studying initial phases of ALD because it causes slight liver injury, steatosis, 
oxidative stress, and mitochondrial damage and dysfunction (Shukla, Pruett et al. 2013, 
Mathews, Xu et al. 2014). The Gao-binge model is thought to better reflect human disease 
because most chronic alcohol abusers also binge drink, and binge drinking in chronic alcohol 
abusers is thought to further progression from alcohol-induced steatosis to more severe liver 
pathologies, such as steatohepatitis. In addition, the Gao-binge alcohol model produces greater 
amounts of liver injury and steatosis than the acute-binge model while also producing 
mitochondrial damage and oxidative stress (Bertola, Mathews et al. 2013, Bertola, Park et al. 
2013, Mathews, Xu et al. 2014, Williams, Manley et al. 2014).  
We found that Parkin KO mice had increased liver injury, oxidative stress, and steatosis 
after alcohol treatment compared to WT mice. Parkin KO mouse livers had decreased 
mitophagy, β-oxidation, mitochondrial respiration, and cytochrome c oxidase (COX) activity 
compared to WT mouse livers after acute-binge alcohol treatment. Decreased hepatic 
mitochondrial function in Parkin KO mice was likely due to increased alcohol-induced 
mitochondrial damage and reduced mitophagy compared to WT mice. Interestingly, liver 
mitochondria seemed able to adapt to Gao-binge treatment, but mitochondria from Parkin KO 
mouse livers seemed less able to adapt to alcohol compared to WT mouse mitochondria 
resulting in severely damaged and swollen mitochondria in Parkin KO mouse livers. Our 
findings indicate that Parkin is an important protector against alcohol-induced liver injury and 




4.3 Materials and Methods 
Materials. Two hundred Proof ethanol (DSP-MD.43), maltose dextran (3653), and the Lieber-
DeCarli ’82 Shake and Pour Liquid Control (F1259SP) and Ethanol (F1258SP) diets were all 
purchased from Bio-Serv. The kit used for alanine aminotransferase (ALT) measurement was 
purchased from Pointe Scientific (A7526-450). The following antibodies were used for western 
blot analysis: anti-Cyp2e1 (Abcam, ab19140), anti-β-Actin (Sigma, A5441), anti-Fasn (cell 
Signaling, 3180S), anti-Acc (Cell Signaling, 3676S), anti-Parkin (Santa-Cruz, SC-32282), anti-
GAPDH (Cell Signaling, 2118), anti-Tom20 (Santa-Cruz, SC11415), anti-p62 (Abnova, 
H00008878-M01), Anti-HSP60 (Santa Cruz, sc-13115), anti-VDAC (Calbiochem, 529534), and 
anti-Cox II (Mitoscience, D1203).  The Anti-LC3 antibody was generated as previously 
described (Ding, Li et al. 2010).   
 
Animal Experiments. Male WT C57BL/6J and whole body Parkin KO mice (C57BL/6J 
background, #006582) were purchased from the Jackson Laboratory. All animals received 
humane treatment, and all protocols were approved by the Institutional Animal Care and Use 
Committee at the University of Kansas Medical Center. Eight to twelve week old male mice 
were treated with ethanol using one of two models: acute-binge (Ding, Li et al. 2010) or Gao-
binge (Bertola, Mathews et al. 2013, Williams, Manley et al. 2014). For acute-binge, mice were 
fasted for 6 hours in the morning and then given ethanol (4.5 g/kg body weight) or an equivalent 
volume of water by oral gavage, which was spaced over 4 gavages spread 15 minutes apart. 
Mice were sacrificed 16 hours after binge.  For Gao-Binge, mice were acclimated to the Lieber-
DeCarli liquid control diet for 5 days followed by further feeding with the liquid control or ethanol 
diet (5%) for 10 days. The mice were then given an 8 hour ethanol (5 g/kg body weight) or 
maltose dextran (9 g/kg body weight) binge by oral gavage on the morning of day 16 (day 11 
after the start of alcohol diet feeding). Gavages for Gao-binge were spaced over 2 gavages 
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spread 15 minutes apart. The volume of control diet given to mice was matched to the volume 
of ethanol diet consumed. Liver injury was determined by measuring serum ALT.  
 
Western Blot Analysis. Total liver lysates were prepared using radioimmunoprecipitation 
assay (RIPA) buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl (lauryl) 
sulfate). Heavy membrane (HM) enriched with mitochondria and cytosolic fractions were 
prepared as described previously (Ding, Ni et al. 2004). Briefly, liver tissues were homogenized 
in HIM buffer (200 mM mannitol, 70 mM sucrose, 5 mM Hepes, 0.5 mM EGTA (pH 7.5)) 
containing protease inhibitors using a dounce homogenizer. Homogenates were centrifuged at 
1,000 x g to remove debris and nuclei, and the supernatant was centrifuged at 10,000 x g for 10 
minutes to separate HM and cytosolic fractions. The supernatant was kept as the cytosolic 
fraction, and the pellet containing the HM fraction was further washed by centrifugation and re-
suspended in HIM buffer. Protein (20-30 μg) was separated by a 12% SDS-PAGE gel before 
transfer to a PVDF membrane. Membranes were probed using appropriate primary and 
secondary antibodies and developed with SuperSignal West Pico chemiluminescent substrate 
(Life Technologies, 34080).  
 
RNA isolation and Real-Time qPCR. RNA was isolated from mouse livers using TRIzol 
reagent (Ambion, 15596-026) and was reverse-transcribed into cDNA using RevertAid Reverse 
Transcriptase (Fermentas, EP0442). qPCR was performed using SYBR Green chemistry 
(Biorad, 1725124). Primer sequences (5’ - 3’) for primers used in qPCR are: Accα F: 
CTCCAGGACAGCACAGATCA, R: TGACTGCCGAAACATCTCTG; Fasn F: 
TGGGTTCTAGCCAGCAGAGT, R: ACCACCAGAGACCGTTATGC; Srebp1 F: 
GATCAAAGAGGAGCCAGTGC, R: TAGATGGTGGCTGCTGAGTG; Acox1 F: 
CAGGAAGAGCAAGGAAGTGG, R: CCTTTCTGGCTGATCCCATA; Cpt1α F: 
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CCAGGCTACAGTGGGACATT, R: GAACTTGCCCATGTCCTTGT; Pparα F: 
ATGCCAGTACTGCCGTTTTC, R: GGCCTTGACCTTGTTCATGT; β-actin F: 
TGTTACCAACTGGGACGACA, R: GGGGTGTTGAAGGTCTCAAA. Real-time qPCR results 
were normalized to β-actin and expressed as fold over WT control (water binge or control diet, 
where appropriate). 
 
Histology. For hematoxylin and eosin (H&E) staining, formalin-fixed liver sections were 
embedded in paraffin and cut into 5 μm sections before staining with H&E. For 4HNE staining, 5 
μm paraffin sections were incubated with 4HNE antibody (Alpha Diagnostics, HNE11-S, 1:250) 
using a standard immunohistochemistry procedure. Briefly, tissue sections were incubated with 
primary antibody for 30 minutes after deparaffinization and antigen retrieval in citrate buffer. 
Sections were then washed and incubated with signal stain boost (Cell Signaling, 8114S) for 30 
minutes and developed using DAB substrate (Vector, SK4105). Tissues were counterstained 
with hematoxylin. Positive areas were determined by Image J and calculated as a percentage of 
liver area. For Oil Red O staining, tissues were fixed in 4% paraformaldehyde overnight at 4°C 
and then transferred to 20% sucrose and stored at 4°C for approximately 24 hours before 
mounting in O.C.T. compound and freezing at -20°C. 6 μm sections were used for staining. 
Briefly, tissues were washed twice with PBS and then incubated with 60% isopropanol for 1 
minute. Tissues were dried in a 37°C incubator for approximately 10 minutes before incubating 
with Oil Red O solution. Oil Red O solution was prepared by adding 0.35g Oil Red O (Sigma, 
0625) to 100 mL of 100% isopropanol, which was further diluted 1.7 times in water and filtered 
immediately before use. Slides were incubated with Oil Red O solution for 15 minutes. The Oil 
Red O solution was aspirated from the slides, and 60% isopropanol was added to the slides for 
several minutes to remove any residual Oil Red O. Slides were then washed in PBS and stained 
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for 30 seconds with hematoxylin (Sigma, GHS132) followed by more washes in dH2O. Slides 
were mounted with glycerol (5:1 in PBS).  
 
Measurement of Liver Triglycerides.  Approximately 20-50 mg of liver tissue was ground into 
powder in liquid nitrogen using a mortar and pestle. Triglycerides were extracted by incubating 
the powdered tissue in a chloroform-methanol mix (2:1) for 1 hour with vigorous shaking. 200 µL 
of water was added to the samples, and the samples were vortexed and centrifuged at 3000 x g 
for 5 minutes to separate out the lipid phase. The lipid phase was removed and dried, and the 
remaining pellet containing lipids was dissolved in a tert-butanol and Triton X-114-Methanol 
(2:1) mixture. Triglyceride levels were measured by colorimetric assay using a kit from Pointe 
Scientific (T7532-500). 
Electron microscopy. Tissues were fixed with 2% glutaraldehyde in 0.1M phosphate buffer 
(pH 7.4) followed by 1% OsO4. After dehydration, thin sections were stained with uranyl acetate 
and lead citrate for observation under a JEM 1016CX electron microscope.  
 
Mitochondrial Respiration.  Complex I (glutamate/malate) mitochondrial respiration was 
measured by Oroboros. Mouse liver mitochondria were freshly isolated after acute-binge 
ethanol treatment and stored on ice until use. To isolate mitochondria, mouse liver tissue was 
minced in 10 mL of mitochondria isolation buffer (70 mM sucrose, 210 mM Mannitol, 5 mM 
HEPES, 1 mM EDTA) with 0.5% BSA using 4 strokes of a dounce homogenizer. The samples 
were then centrifuged at 800 x g for 10 minutes to remove debris and nuclei, and the 
supernatant was decanted through cheesecloth before centrifuging it at 8000 x g for 10 minutes. 
The pellet containing mitochondria was resuspended in 100 µL of mitochondria isolation buffer 
and washed by centrifugation at 8000 x g before final resuspension in 50 µL of mitochondria 
isolation buffer.  Mitochondrial respiration was assessed using 500 µg of protein. We measured 
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State 3, or ADP-dependent, respiration by adding the substrates glutamate (5 μM) and malate 
(5 μM) along with a limiting amount of ADP (0.45 μM) to isolated liver mitochondria after acute-
binge treatment. State 3 respiration represents respiration that is coupled to ATP synthesis 
because substrate is present along with ADP. We measured State 4, or ADP-independent, 
respiration by adding oligomycin (1 μM) to totally deplete ADP levels after measurement of 
State 3 respiration. State 4 respiration represents respiration that is not coupled to ATP 
synthesis because substrate is present, but ADP is not. Carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone (FCCP, 0.1 µM) was then added to uncouple mitochondria in order to 
measure maximal respiratory capacity.  Finally, the electron transport chain complex III and I 
inhibitors antimycin (2 µM) and rotenone (5 µM) were added to measure non-mitochondrial 
oxygen consumption of the sample. State 3 respiration was calculated using the peak plateau 
after ADP addition. State 4 respiration was calculated using the steady state value after 
oligomycin addition. Maximal respiratory capacity was calculated using the peak after FCCP 
addition. The steady state value after antimycin and rotenone addition was subtracted from all 
values, and results were normalized to protein concentration, which was confirmed after 
completion of the respiration assay. Final results were normalized to individual controls for WT 
and Parkin KO mice.  
 
Cytochrome C Oxidase (COX) activity. COX activity was measured using mouse liver total 
protein lysates by a colorimetric assay from Sigma-Aldrich (CYTOCOX1) according to the 
manufacturer’s instructions.  
 
Statistical Analysis. Statistical analysis was conducted with a one-way ANOVA analysis 





4.4.1 Parkin KO Mice had Increased Liver Injury after Alcohol Administration.  
WT and Parkin KO mice were treated with alcohol using two alcohol models: acute-
binge and Gao-binge. Liver injury was determined by measuring serum ALT after alcohol 
treatment, and both WT and Parkin KO mice had increased liver injury after alcohol treatment 
compared to control treatments in both alcohol models. Parkin KO mice also had increased liver 
injury compared to WT mice after both acute-binge and Gao-binge alcohol treatments, but the 
difference in injury between WT and Parkin KO mice was only statistically significant in the Gao-
binge model. Basal ALT levels were similar between WT and Parkin KO mice in both alcohol 
models (Figure 4.4.1 A-B). Liver injury was also overall higher in both WT and Parkin KO mice 
treated with alcohol using the Gao-binge model compared to mice treated with alcohol using the 
acute-binge model, as expected (Bertola, Park et al. 2013) (Figure 4.4.1 A-B). Alcohol 
consumption is well known to induce Cytochrome P450 2e1 (Cyp2e1) expression, which can 
further cause oxidative stress in the liver (Robin, Sauvage et al. 2005, Bansal, Liu et al. 2010, 
Leung and Nieto 2013). WT and Parkin KO mice both had marked inductions of Cyp2e1 after 
alcohol treatment with the Gao-binge model, but the changes of Cyp2e1 were mild with the 
acute-binge model. There were no differences in Cyp2e1 levels between WT and Parkin KO 
mouse livers, suggesting that increased liver injury in Parkin KO mice compared to WT mice 
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4.4.2 Parkin KO Mice had Increased Steatosis Compared to WT Mice after Acute-binge 
but not Gao-binge Treatment.  
Treatment with alcohol using both the acute-binge and Gao-binge models caused liver 
steatosis in WT and Parkin KO mice, which was demonstrated by elevated liver triglycerides 
(Figure 4.4.2 A-B) and increased visualization of lipid droplets by H&E staining (Figure 4.4.2 C-
D), Oil Red O staining (Figure 4.4.2 E-F), and EM (Figure 4.4.2 G-J). The Gao-binge model 
produced more macrosteatosis compared to the acute-binge model in both WT and Parkin KO 
alcohol-treated mouse livers (Figure 4.4.2 C-F).  In addition, Parkin KO mice developed greater 
liver steatosis compared to WT mice after acute-binge alcohol treatment. Livers from acute-
binge treated Parkin KO mice had significantly increased triglyceride levels compared to acute-
binge treated WT mouse livers (Figure 4.4.2 A), which was confirmed by H&E and Oil Red O 
staining (Figure 4.4.2 C, 4.4.2 E). Acute-binge treated Parkin KO mouse livers also had a 
significant increase in the number of lipid droplets per cell compared to acute-binge treated WT 
mouse livers (Figure 4.4.2 G-H). However, the Gao-binge model caused greater triglyceride 
accumulation in WT mouse livers compared to the acute-binge model, but triglyceride levels 
were similar between Parkin KO Gao-binge and acute-binge treated mouse livers (Figure 4.4.2 
A-B). Overall, these data suggest that acute-binge caused greater liver fat accumulation in 
Parkin KO mice compared to WT mice. In addition, the Gao-binge model caused greater 
steatosis in WT mouse livers compared to WT mouse livers treated with the acute-binge model, 
but the Gao-binge and acute-binge models both caused similar levels of steatosis in Parkin KO 

































Figure 4.2.2: Parkin KO mice had increased liver steatosis compared to WT mice after 
acute-binge, but not Gao-binge, treatment.  A-B: Liver triglycerides (TG) were measured 
for WT and Parkin KO mice after acute-binge (A) and Gao-binge (B) alcohol treatment. Data 
shown are means ± S.E. (n= 4 for controls and > 6 for alcohol treated mice. *p<0.05 by one-
way ANOVA, A=acute-binge, GB=Gao-binge). C-D: Representative H&E images from the 
acute-binge model (C) and the Gao-binge model (D) are shown with boxed areas enlarged. 
(LD=lipid droplet, 200x magnification).  E-F: Representative images are shown for Oil Red O 
staining for the acute-binge model (E) and for the Gao-binge model (F) with boxed areas 
enlarged (200x magnification). G: Representative EM images are shown for acute-binge 
treated mice with boxed areas enlarged (Bar=500 nm, N=nucleus, M=mitochondria, LD=lipid 
droplet).  H: Quantification of lipid droplets per cell in acute-binge treated mice. Data shown 
are means ± S.E. (n= > 10 images per mouse from 2 mice per group. *p<0.05 by one-way 
ANOVA). I: Representative EM images are shown for Gao-binge treated mice with boxed 
areas enlarged (Bar=500 nm, N=nucleus, M=mitochondria, LD=lipid droplet).  J: 
Quantification of lipid droplets per cell in Gao-binge treated mice. Data shown are means ± 
S.E. (n= > 10 images per mouse from 2 mice per group. *p<0.05 by one-way ANOVA).  
 
 
Figure 4.4.2 Cont.  
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4.4.3 Steatosis in WT and Parkin KO Mouse Alcohol-treated Livers was not due to Fatty 
Acid Synthesis.  
Alcohol has been shown to cause steatosis in the liver by elevating fatty acid synthesis 
in the intragastric infusion (Ji, Chan et al. 2006)  and chronic alcohol feeding models (You, 
Fischer et al. 2002). To determine if increased liver steatosis after alcohol treatment in WT and 
Parkin KO mouse livers was due to increased fatty acid synthesis, expression levels of several 
fatty acid synthesis genes were measured in mouse livers after alcohol treatment using both the 
acute and Gao-binge models. Gene expression levels of the fatty acid synthesis enzymes 
acetyl-coA carboxylase-alpha (Accα) and fatty acid synthase (Fasn) did not significantly change 
after alcohol treatment by either the acute-binge or Gao-binge alcohol model in WT or Parkin 
KO mice compared to their individual controls. However, basal expression levels of these genes 
were decreased in Parkin KO mouse livers compared to WT mice in the acute model (Figure 
4.4.3 A-B). Liver gene expression levels for sterol regulatory element-binding transcription 
factor 1 (Srebp1) were significantly decreased in WT mouse ethanol-treated livers from both the 
acute and Gao-binge models compared to control livers. Srebp1 gene expression was overall 
decreased in Parkin KO mouse livers compared to WT livers but was not significantly affected in 
Parkin KO mouse livers after alcohol treatment compared to Parkin KO control livers for either 
alcohol model (Figure 4.4.3 A-B). Protein levels for Accα and Fasn were similar to mRNA levels 
(Figure 4.4.3 C-D). These data suggest that alcohol-induced steatosis in WT and Parkin KO 
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4.4.4. Greater Steatosis in Parkin KO Mouse Livers after Acute-binge Alcohol Treatment 
Compared to WT Mouse Livers was due to Decreased β-oxidation.  
Alcohol-induced inhibition of β-oxidation has been shown to cause fatty liver (Sozio and 
Crabb 2008). To determine if increased steatosis in WT and Parkin KO alcohol-treated mouse 
livers was due to decreased fat degradation by β-oxidation, expression levels of several genes 
involved in the β-oxidation pathway were measured including the enzymes peroxisomal acyl-
coenzyme A oxidase 1 (Acox1) and carnitine palmitoyltransferase 1 alpha (Cpt1α) and the 
transcription factor peroxisome proliferator-activated receptor alpha (Pparα). In the acute-binge 
model, gene expression levels for Acox1 and Pparα were significantly increased after alcohol 
treatment in WT mouse livers compared to controls. Expression of Cpt1α was also increased in 
acute-binge treated WT mouse livers compared to controls, but this increase was not 
statistically significant. However, expression levels of these genes in Parkin KO acute-binge 
treated mouse livers did not increase compared to Parkin KO control treated livers. 
Furthermore, the expression levels of Acox1 and Ppara were significantly decreased in Parkin 
KO acute-binge treated mouse livers compared to WT mouse livers. The expression level of 
Cpt1α was also decreased in acute-binge treated Parkin KO mouse livers compared to acute-
binge treated WT mouse livers, but this decrease was not statistically significant. There was no 
difference in basal expression levels for these genes between WT and Parkin KO mice (Figure 
4.4.4. A). These data suggest that liver β-oxidation was likely activated as a protective 
mechanism in WT mouse livers after acute-binge alcohol treatment to help decrease liver 
steatosis. However, β-oxidation genes were not induced after acute-binge treatment in Parkin 
KO mouse livers, suggesting that liver β-oxidation may have been inhibited in Parkin KO mice 
treated with acute-binge. Decreased or inhibited β-oxidation in Parkin KO acute-binge treated 
mouse livers may likely explain the greater levels of steatosis seen in Parkin KO acute-binge 
treated mouse livers compared to WT acute-binge treated livers (Figure 4.4.2 A, C, E, G, H).  
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 Even though expression of β-oxidation genes was increased in WT mouse livers after 
acute ethanol treatment, expression of these genes was not induced by Gao-binge alcohol 
treatment in either WT or Parkin KO mouse livers compared to controls, suggesting that β-
oxidation may have been inhibited in both WT and Parkin KO mouse livers after Gao-binge 
alcohol treatment. In fact, expression of β-oxidation genes was actually decreased in both WT 
and Parkin KO mouse livers after Gao-binge alcohol treatment compared to control-diet fed 
mouse livers, but this decrease was only significant for Cpt1a gene expression in Parkin KO 
Gao-binge treated livers. Surprisingly, Cpt1a expression in Parkin KO mouse control-treated 
livers was significantly increased compared to WT control livers, suggesting that Parkin KO 
mice had higher levels of β-oxidation when fed the control diet compared to WT mice. There 
were no significant differences between Gao-binge treated WT and Parkin KO mouse livers for 
any of the measured β-oxidation genes (Figure 4.4.4 B). Together, these data suggest that β-
oxidation was increased in acute-binge treated WT mouse livers, which likely acted as an 
adaptive mechanism to reduce alcohol-induced liver steatosis. However, this protective adaptive 
mechanism seemed to be down-regulated in Parkin KO acute-binge treated mouse livers, which 
could be a reason for their increased alcohol-induced liver steatosis compared to WT mice. The 
protective response of β-oxidation seemed to be inhibited in both WT and Parkin KO mouse 
livers after Gao-binge alcohol treatment, which may explain why the levels of steatosis in WT 
and Parkin KO mouse livers were increased to similar levels after alcohol treatment using the 
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4.4.5 Reduced Mitophagy in Parkin KO Mice after Alcohol Treatment.  
 Because decreased mitophagy could potentially lead to an increased population of 
damaged and dysfunctional mitochondria and subsequent liver injury, we compared levels of 
mitophagy between WT and Parkin KO mice after alcohol treatment using both the acute-binge 
and Gao-binge models. First, we determined if Parkin translocated to mitochondria in WT 
mouse livers after alcohol treatment. Parkin did not translocate to mitochondria after acute-
binge alcohol treatment for 16 hours (Figure 4.4.5 A). However, Parkin did translocate to 
mitochondria after Gao-binge alcohol treatment in WT mouse livers (Figure 4.4.5 B), 
suggesting that Parkin-induced mitophagy may occur in WT mouse livers after Gao-binge 
alcohol treatment.  
To further determine mitophagy levels between WT and Parkin KO mouse livers, we 
measured protein expression of the autophagy adaptor protein p62 and the autophagosome 
membrane protein microtubule-associated protein light chain 3 (LC3) in total liver lysates from 
WT and Parkin KO mice after acute-binge and Gao-binge treatment. There were no significant 
differences in p62 or LC3-II protein expression after alcohol treatment compared to controls in 
either alcohol model for WT or Parkin KO mice. In addition, there were no differences in 
expression of these proteins between WT and Parkin KO control mice (Figure 4.4.5 C-F).There 
was also no degradation of the mitochondrial outer membrane proteins Translocase of outer 
membrane 20 (Tom20) or Voltage-dependent anion channel (VDAC) or of the mitochondrial 
matrix protein Heat shock protein 60 (Hsp60) after alcohol treatment by either the acute-binge 
or Gao-binge model in WT or Parkin KO mice (Figure 4.4.5 C-F). These data suggest that 
mitophagy levels may be too mild to detect differences between WT and Parkin KO mice by 
Western blot analysis. Alternatively, mice may adapt to alcohol-induced mitochondrial damage 
by compensatory mitochondrial biogenesis, which can further offset mitophagic degradation 
determined by Western blot analysis.  
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We next investigated if there were differences in the number of autophagosomes (Avi) 
and autolysosomes (Avd) containing mitochondria (hereafter referred to as mitophagosomes) 
between WT and Parkin KO mouse livers after alcohol treatment using electron microscopy 
(EM).  In the acute-binge and Gao-binge alcohol models, the levels of mitophagy were 
significantly increased after alcohol treatment in WT mouse livers. However, the number of 
mitophagosomes was significantly decreased in Parkin KO mice compared to WT mice after 
alcohol treatment (Figure 4.4.5 G, I, J, L).  The total number of autophagic vacuoles after 
alcohol treatment was also slightly decreased in Parkin KO mice compared to WT mice, but 
these data were not statistically significant (Figure 4.4.5 G, H, J, K). These data suggest that 
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4.4.6 Mitochondrial Morphological Changes in the Gao-binge Alcohol Model 
 Chronic alcohol feeding has been shown to cause changes to mitochondrial morphology 
(Han, Ybanez et al. 2012). Therefore, we determined if alcohol treatment using the acute-binge 
or Gao-binge alcohol models caused changes to mitochondrial morphology in WT and Parkin 
KO mouse livers by EM.  Alcohol treatment by the acute-binge model did not cause any 
significant changes in mitochondrial morphology in WT mice compared to controls. However, 
some mitochondria in Parkin KO mouse livers appeared to have swelling after acute-binge 
treatment compared to control treated liver mitochondria, but most mitochondria did not appear 
to be significantly damaged by alcohol treatment (Figure 4.4.6 A). Alcohol treatment using the 
Gao-binge model caused significantly damaged and swollen mitochondria in Parkin KO mouse 
livers where approximately 1% of mitochondria were so severely swollen and damaged that 
they lacked cristae. Only approximately 0.14% of mitochondria were this severely damaged in 
Parkin KO mice treated with the acute-binge model (Figure 4.4.6 B-D). These severely swollen 
and damaged mitochondria were not seen in WT mice after alcohol treatment with either model.  
In addition, Parkin KO mice had some liver mitochondria that were elongated after Gao-binge 
alcohol treatment, but WT mice appeared to have more elongated mitochondria after alcohol 
treatment by Gao-binge while Parkin KO mouse livers had more swollen mitochondria (Figure 
4.4.6 F). Elongation of mitochondria is thought to be a cellular adaptive mechanism to chronic 
alcohol treatment (Han, Ybanez et al. 2012). Acute-binge did not have a significant effect on 
mitochondria elongation in either WT or Parkin KO mice (Figure 4.4.6 E).  Overall, these results 
suggest that alcohol produced more damaged mitochondria in Parkin KO mouse livers 
compared to WT mouse livers, which may be due to an inability for Parkin KO mouse liver 
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4.4.7 Mitochondrial Respiration and COX Activity were Decreased in Parkin KO Mice after 
Alcohol Treatment.  
 To further determine if Parkin KO mouse liver mitochondria were more damaged than 
WT mouse liver mitochondria after alcohol treatment, we investigated if there were any 
differences in mitochondrial function between WT and Parkin KO mouse livers by measuring 
respiration rate and COX activity. We found that State 3 and State 4 respiration rates were both 
increased in WT mouse liver mitochondria after acute-binge treatment compared to controls, but 
this increase was not statistically significant (Figure 4.4.7 A-B). However, State 3 and State 4 
respiration rates were decreased in Parkin KO mouse liver mitochondria after acute-binge 
treatment, which was statistically significant for State 3 respiration rates compared to acute-
binge treated WT mice (Figure 4.4.7 A-B). Maximal respiratory capacity was also increased in 
WT mouse liver mitochondria after acute-binge treatment while it was decreased in Parkin KO 
mouse liver mitochondria (Figure 4.4.7 C). Basal respiration rates were similar between WT and 
Parkin KO mouse liver mitochondria (Figure 4.4.7 A-C). COX activity was slightly decreased in 
WT mouse livers after acute-binge treatment, but this decrease was not statistically significant. 
However, COX activity was significantly decreased in Parkin KO mouse livers after acute-binge 
treatment compared to WT control, suggesting that Parkin KO mouse liver mitochondria were 
more damaged after acute-binge treatment than WT mouse liver mitochondria. Parkin KO 
mouse livers also had slightly decreased basal levels of COX activity compared to WT mouse 
livers, but this difference was not significant (Figure 4.4.7 D). Interestingly, there were no 
significant differences in COX activity between control diet and Gao-binge treated WT or Parkin 
KO mice, but Parkin KO mice had slightly less COX activity than WT mice after Gao-binge 
treatment (Figure 4.4.7 E). These data suggest that liver mitochondria in WT mice were likely 
adapting to alcohol treatment, and Parkin KO mouse mitochondria were unable to adapt as well 
as WT mice to alcohol treatment. Overall, these data suggest that Parkin KO mouse livers had 
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more mitochondrial damage initiated by alcohol treatment than WT mouse livers, which likely 
led to their increased liver injury in the acute-binge and Gao-binge models and increased 
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4.4.8 Parkin KO Mice had Increased Lipid Peroxidation after Alcohol Administration.   
Alcohol is well known to cause oxidative stress and increased 4HNE staining as a result 
of increased lipid peroxidation in the liver. WT and Parkin KO mice had increased lipid 
peroxidation after both acute-binge and Gao-binge alcohol treatments, which was demonstrated 
by increased 4-hydroxynonenal (4HNE) staining (Figure 4.4.8 A-D). We also found that 4HNE 
staining occurred mainly in the peri-central vein areas in both WT and Parkin KO mouse livers. 
In addition, Parkin KO mice had increased lipid peroxidation compared to WT mice after alcohol 
treatment in both the acute-binge and Gao-binge models (Figure 4.4.8 A-D). Control levels of 
lipid peroxidation were similar between WT and Parkin KO mice (Figure 4.4.8 A-D).  These 
results suggest that Parkin KO mice had higher levels of alcohol-induced oxidative stress 
compared to WT mice, which was likely due to the greater amount of alcohol-induced 
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In this study, we found that Parkin KO mice had increased liver injury and oxidative 
stress after alcohol treatment compared to WT mice using both the acute-binge and Gao-binge 
alcohol models. In addition, we found that Parkin KO mice had increased steatosis in the acute-
binge model compared to WT mice, but levels of steatosis were similar between WT and Parkin 
KO mice after Gao-binge treatment. Increases in liver injury and steatosis in Parkin KO mice 
were likely due to an increase in alcohol-mediated mitochondrial damage and dysfunction in 
Parkin KO mouse livers compared to WT mouse livers because Parkin KO mouse livers had 
severely swollen and damaged mitochondria that lacked cristae after alcohol treatment, which 
were not observed in WT mouse livers. In addition, Parkin KO mouse livers had decreased 
mitophagy, β-oxidation, mitochondrial respiration, and cytochrome c oxidase activity compared 
to WT mouse livers after acute-binge alcohol treatment. Decreases in Parkin KO mouse 
mitochondrial function were likely due to increased alcohol-induced mitochondrial damage and 
reduced mitophagy in Parkin KO mouse livers compared to WT mouse livers. In addition, 
mitochondria from Parkin KO mouse livers seemed less able to adapt to alcohol compared to 
WT mouse mitochondria resulting in severely damaged and swollen mitochondria in Parkin KO 
mouse livers. Furthermore, Parkin KO mouse livers had greater alcohol-induced oxidative 
stress-mediated lipid peroxidation compared to WT mouse livers. Therefore, our findings 
suggest that Parkin is an important protector against alcohol-induced liver injury and steatosis 
by maintaining mitochondrial integrity and function likely via mitophagy induction after alcohol 
treatment.  
 
4.5.1 Parkin-mediated Mitophagy Likely Protects against Alcohol-induced Liver Injury  
 Mitophagy is a well-known protective mechanism for removing damaged mitochondria to 
prevent cell death and liver injury. For example, mitophagy has been shown to be protective 
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against apoptosis and injury in alcoholic liver disease (Ding, Li et al. 2010, Lin, Zhang et al. 
2013)  and also against necrosis in acetaminophen-induced liver injury (Ni, Bockus et al. 2012, 
Ni, Williams et al. 2013, Lin, Wu et al. 2014). However, the mechanism for how mitophagy is 
induced in the liver by alcohol is currently unknown. Parkin translocated to mitochondria after 
Gao-binge alcohol treatment in WT mice, suggesting that Parkin-induced mitophagy did occur 
after alcohol treatment. EM analysis showed that mitophagosome numbers were significantly 
increased in WT mouse livers, but not in Parkin KO mouse livers, after acute-binge and Gao-
binge alcohol treatment compared to controls. These results suggest a possible defect in 
mitophagy induction after alcohol treatment in Parkin KO mice. Unfortunately, there is currently 
no reliable quantitative assay to quantify mitophagy in vivo, particularly in the liver. We could not 
detect any differences in LC3-II, p62, or mitochondria protein levels between WT and Parkin KO 
mice before or after alcohol treatment by Western blot analysis. This could be due to at least 
two reasons. First, alcohol-induced mitophagy could be mild in the mouse livers compared to 
other mitophagy models such as acetaminophen-induced mitophagy. Second, liver cells may 
adapt to alcohol-induced mitochondrial damage by activating mitochondrial biogenesis, which 
may offset the autophagic degradation of mitochondrial proteins as assessed by Western blot 
analysis.  
 It should be noted that alcohol could still induce mitophagy in Parkin KO mouse livers as 
assessed by EM studies, although the number of mitophagosomes was significantly decreased 
compared to WT mice. These results suggest that other compensatory mechanisms may exist 
for mitophagy induction in the liver in the absence of Parkin.  There are several other proteins 
that have been shown to have important roles in the mitophagy pathway that may help 
compensate for loss of Parkin in the liver. For example, there are other E3 ligases such as 
Smurf1 and Mul1 that have been shown to have a role in mitophagy induction. In addition, Bnip3 
Fundc1, and Nix have been shown to have roles in mitophagy induction during hypoxia, and the 
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inner mitochondrial phospholipid cardiolipin has also recently been shown to be able to induce 
mitophagy in neurons (Ni, Williams et al. 2015). Therefore, it is possible that one or several of 
these proteins are upregulated in the absence of Parkin to induce Parkin-independent 
mitophagy in the liver. However, the exact mediator of Parkin-independent mitophagy induction 
in the liver still needs further investigation.  
Overall, Parkin-induced mitophagy was likely a protective mechanism in the liver after 
alcohol treatment because Parkin KO mice had reduced mitophagy levels and increased liver 
injury after alcohol administration compared to WT mice. However, we have only shown an 
associative relationship between reduced mitophagy and alcohol-induced liver injury in Parkin 
KO mice. Therefore, it is also possible that Parkin plays other roles in maintaining mitochondrial 
function in addition to mitophagy that may protect against alcohol-induced liver injury.  
 
4.5.2 Acute-binge and Gao-binge Alcohol Treatments had Differential Effects on β-
oxidation  
We found that both the acute-binge and Gao-binge models caused hepatic steatosis, 
and increased steatosis was likely not due to increased fatty acid synthesis. Lee and colleagues 
also showed that acute-binge treatment for 24 hours did not result in increased fatty acid 
synthesis (Yin, Kim et al. 2007). The effect of the Gao-binge model on fatty acid synthesis has 
not been previously investigated. Interestingly, we observed that only the acute-binge model, 
but not the Gao-binge model, caused greater steatosis in the livers of Parkin KO mice compared 
to WT mice.  These observations are associated with the different effects of the two alcohol 
models on β-oxidation.  In the acute-binge model, several β-oxidation genes were induced in 
WT mouse livers after alcohol treatment but were left unchanged in Parkin KO mouse livers, 
suggesting that Parkin KO mouse mitochondria lacked the ability to induce β-oxidation as a 
protective mechanism. This inability to induce β-oxidation after acute-binge treatment likely led 
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to their increased levels of liver steatosis compared to WT mice. Gao-binge treatment did not 
cause induction of β-oxidation genes in either WT or Parkin KO mouse livers, suggesting that β-
oxidation was inhibited in both WT and Parkin KO mouse livers after Gao-binge alcohol 
treatment. This may help to explain why the levels of steatosis were similar between WT and 
Parkin KO mice after Gao-binge alcohol treatment. Chronic alcohol feeding is well known to 
cause inhibition of β-oxidation, leading to accumulation of fat in the liver (Mantena, King et al. 
2008). It seems that liver cells were able to adapt to alcohol-induced injury by increasing β-
oxidation in acute-binge treated WT but not in Parkin KO mouse livers. However, this adaptation 
seemed to be lost after Gao-binge treatment. In addition to β-oxidation, the acute-binge and 
Gao-binge alcohol models may also dissimilarly affect fat uptake or secretion (Rasineni and 
Casey 2012), which could lead to differences in levels of liver steatosis after alcohol treatment 
between these models. Differences in alcohol-induced fat uptake and secretion between the 
acute-binge and Gao-binge models remain to be investigated.  
 
4.5.3 Parkin KO Mice had Increased Numbers of Severely Damaged Liver Mitochondria 
and were Less Able to Adapt to Alcohol Treatment, Leading to Decreased Mitochondrial 
Function, Increased Oxidative Stress, and Increased Liver Injury and Steatosis 
Parkin KO mouse livers had severely damaged and swollen mitochondria that lacked 
cristae after acute-binge and Gao-binge alcohol treatments, which were not seen in WT mouse 
livers. In addition, WT mouse livers had more elongated mitochondria after Gao-binge 
treatment, which is thought to be a cellular adaptive mechanism to chronic alcohol treatment 
(Han, Ybanez et al. 2012) , than Parkin KO mouse livers. Furthermore, Parkin KO mouse livers 
had greater levels of lipid peroxidation than WT mouse livers after alcohol treatment, which was 
likely caused by oxidative stress mediated by alcohol-induced mitochondrial damage.  These 
164 
 
results all suggest that mitochondria in Parkin KO mouse livers were more damaged and 
dysfunctional compared to WT liver mitochondria after alcohol treatment.  
Indeed, we found that WT mouse liver mitochondria had increased Complex I respiration 
rates while Parkin KO mouse liver mitochondria had decreased respiration rates after acute-
binge alcohol treatment compared to controls. It has been shown that WT mice have increased 
respiration rates after oral alcohol feeding and intragastric infusion of alcohol, which was 
thought to be due to  increased incorporation of respiratory complexes into the electron 
transport chain as an adaptation method (Han, Ybanez et al. 2012). However, Bailey and 
colleagues showed that State 3 respiration was unaffected by chronic alcohol feeding while 
State 4 respiration was increased (King, Swain et al. 2014). Differences in their results were 
likely due to the alcohol models or alcohol doses used.  We observed increased respiration in 
WT mice treated with acute-binge for both State 3 and State 4 respiration, although it did not 
reach statistical significance.  However, we found significantly decreased respiration in Parkin 
KO mice for State 3 respiration after acute-binge. Moreover, Parkin KO mice had decreased 
COX activity after acute-binge alcohol treatment compared to WT mice. These results suggest 
that Parkin KO mouse liver mitochondria were either more damaged by alcohol treatment or 
lacked the ability to adapt to alcohol treatment compared to WT mice. WT, but not Parkin KO, 
mouse mitochondria were likely attempting to adapt to alcohol treatment by increasing their 
respiration rates. It was previously shown that Parkin KO mice had decreased basal brain 
mitochondria respiration rates at 8 months of age compared to WT mice (Palacino, Sagi et al. 
2004). We did not see any differences in basal liver respiration rates between WT and Parkin 
KO mouse livers at 2 to 3 months of age. It would be interesting to investigate if respiration rates 
are overall decreased in aged Parkin KO mouse livers and if this would have an impact on their 
alcohol-induced liver injury in the future.  
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Mitochondria are dynamic organelles that are well known to alter their fission and fusion 
rates in order to adapt to stress to maintain cellular survival. These fission and fusion events are 
necessary for cell survival because they allow the cell to adapt to changing conditions needed 
for cell growth, division, and distribution of mitochondria (van der Bliek, Shen et al. 2013). 
Mitochondria elongation was seen in chronic alcohol feeding and was suggested to be an 
adaptive response to alcohol treatment (Han, Ybanez et al. 2012). WT mouse livers had many 
elongated mitochondria after Gao-binge treatment, but Parkin KO mouse livers had less 
elongated and more swollen mitochondria than WT mouse livers. Parkin has been shown to 
play a role in regulating mitochondrial fusion and fission by promoting proteasomal degradation 
of mitofusin 1 and mitofusin 2 as well as Drp1 (Wang, Song et al. 2011, Ding, Guo et al. 2012). 
Future work is needed to determine whether these mitochondrial fusion and fission machinery 
proteins play a role in the elongated mitochondria observed in WT mouse livers exposed to 
alcohol. Nevertheless, these observations regarding mitochondrial morphology together with the 
mitochondrial respiration and COX activity data further support the notion that WT liver 
mitochondria seemed more able to adapt to alcohol treatment than Parkin KO mouse liver 
mitochondria. Overall, these data suggest that alcohol caused more damage to mitochondria in 
Parkin KO mouse livers than in WT mouse livers, which likely led to the increased liver injury 
and steatosis seen in Parkin KO mice compared to WT mice.  
4.6 Conclusions 
In conclusion, we found that alcohol caused more liver injury, oxidative stress, and 
steatosis in Parkin KO mice compared to WT mice, which was likely due to increased 
mitochondrial damage and dysfunction in Parkin KO mouse livers compared to WT mouse livers 
after alcohol treatment. This increase in mitochondrial damage and dysfunction in Parkin KO 
mice may have been partly due to decreased mitophagy in these mice. However, it is likely that 
Parkin may have other roles in maintaining mitochondrial function, such as regulation of 
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mitochondrial dynamics in addition to mitophagy, that are also important for protection against 
alcohol-induced steatosis and liver injury. The possible molecular events involved in Parkin-
mediated mitophagy and mitochondrial functions for regulating alcohol-induced steatosis and 



























































































5.1 Discussion of Results 
5.1.1 Parkin-induced Mitophagy Likely Protects against APAP and Alcohol-induced Liver 
Injuries, but Parkin is not Essential for Mitophagy Induction in the Liver. 
We showed that Parkin-induced mitophagy is likely a protective mechanism in APAP 
and alcohol-induced liver injuries because Parkin translocated to mitochondria in WT mice after 
treatment with either APAP or alcohol. In addition, mitophagy was decreased in Parkin KO mice 
compared to WT mice after APAP or alcohol treatment. Furthermore, mice with acute 
knockdown of Parkin had greater liver injury after APAP treatment compared to WT mice, which 
was partly due to a significant decrease in mitophagy. Even though Parkin-induced mitophagy is 
likely a protective mechanism in the liver, we showed that Parkin is not essential for mitophagy 
induction in the liver because mitophagy occurred in Parkin KO mice after treatment with either 
APAP or alcohol. Mitophagy induction in Parkin KO mice was likely due to activation of adaptive 
mechanisms to compensate for the loss of Parkin. However, the Parkin-independent 
mechanisms of mitophagy induction in the liver are unknown and should be further explored.   
 There are several Parkin-independent mediators of mitophagy that may be activated 
during chronic loss of Parkin including NIX/BNIP3L, Bcl2/adenovirus E1B 19 kDa protein-
interacting protein 3 (BNIP3), Fun14 Domain containing 1 (FUNDC1), Cardiolipin, and 
Mitochondrial Ubiquitin Ligase 1 (Mul1). BNIP3 is a pro-apoptotic mitochondrial protein that 
contains a Bcl-2 homology 3 (BH3) domain (Yasuda, Theodorakis et al. 1998), and it induces 
mitophagy in hypoxic conditions and in starvation. BNIP3 is expressed in many tissues including 
the liver, but it is not highly expressed under normal conditions (Galvez, Brunskill et al. 2006). 
BNIP3 gene expression is induced during hypoxia by hypoxia-inducing factor-1 alpha (HIF-1α), 
which undergoes enhanced binding to its HIF-1-responsive element (HRE) on the BNIP3 gene 
promoter during oxygen deprivation (Bruick 2000). Mitophagy induction in MEF cells has been 
shown to be regulated by BNIP3 during hypoxia, which allows for removal of damaged 
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mitochondria and prevention of cell death via protection against ROS accumulation (Zhang, 
Bosch-Marce et al. 2008). Furthermore, phosphorylation of Ser17 and Ser24 in the LIR of 
BNIP3 was shown to initiate cell survival via induction of mitophagy by encouraging co-
localization with LC3, suggesting that the phosphorylation status of BNIP3 decides whether it 
will behave as a pro-apoptotic protein or as a pro-survival protein by initiating mitophagy (Zhu, 
Massen et al. 2013).  
 NIX, also known as BNIP3L, is a homologue of BNIP3 (Chen, Cizeau et al. 1999). In 
addition to its roles in activating Parkin-mediated mitophagy (discussed in section 1.3.2), NIX 
can also activate mitophagy independent of Parkin. NIX activates autophagy by binding to Bcl-2, 
which dissociates the complex of Bcl-2 and Beclin-1, a protein necessary for initiation of 
autophagosome formation (discussed in section 1.2.1) (Bellot, Garcia-Medina et al. 2009). In 
addition, NIX interacts with the autophagosome membrane protein LC3 (Novak, Kirkin et al. 
2010), and may therefore have a role in recruiting autophagosomes to damaged mitochondria. 
Like BNIP3, NIX plays a role in induction of mitophagy during hypoxia due to induction of its 
expression by HIF-1α (Bruick 2000). NIX and BNIP3 seem to have complementary roles in the 
mitophagy response during hypoxia because depletion of either NIX or BNIP3 did not affect 
autophagy, but depletion of both NIX and BNIP3 inhibited the autophagic response to hypoxic 
conditions. In addition, overexpression of both NIX and BNIP3 induced autophagy under normal 
oxygen concentrations (Bellot, Garcia-Medina et al. 2009). In addition to its role in mitophagy 
induction during hypoxia, NIX is also well known to induce mitophagy during red blood cell 
maturation. Red blood cells must eliminate their mitochondria during maturation in order to be 
able to better carry and provide oxygen, and NIX has been shown to be required for these cells 
to eliminate their mitochondria because mitochondrial entry into autophagosomes for 
degradation was blocked in NIX-deficient mice, which led to life-span reduction of red blood 
cells and development of anemia (Schweers, Zhang et al. 2007, Sandoval, Thiagarajan et al. 
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2008). This mechanism of mitophagy induction was also shown to require mitochondrial 
depolarization (Sandoval, Thiagarajan et al. 2008). NIX is also involved in mitophagy induction 
in cells that are undergoing high rates of oxidative phosphorylation, which leads to increased 
ROS production, mitochondrial dysfunction, cell death, and injury. When cells are undergoing 
high rates of oxidative phosphorylation, the GTPase Rheb is recruited to the outer mitochondrial 
membrane where it interacts with NIX and LC3 to induce mitophagy. This Rheb-dependent 
mitophagy pathway was shown to require NIX because depletion of NIX inhibited Rheb-induced 
mitochondrial degradation. Ridding of mitochondria undergoing high rates of oxidative 
phosphorylation via mitophagy helps maintain a healthy population of mitochondria, which 
promotes efficiency of cellular bioenergetics and mitochondrial energy production (Melser, 
Chatelain et al. 2013).  
 FUNDC1 is an outer mitochondrial membrane protein that also contributes to mitophagy 
induction under hypoxic conditions.  Under oxygenated conditions, FUNDC1 is phosphorylated 
by the Src kinase on Tyr18 (Liu, Feng et al. 2012) and by casein kinase II (CK2). During 
hypoxia, the mitochondrial phosphatase phosphoglycerate mutase family member 5 (PGAM5) 
dephosphorylates FUNDC1 on Ser13 (Chen, Han et al. 2014). Hypoxia induces FUNDC1-
dependent mitophagy using a different mechanism than NIX or BNIP3. While mRNA expression 
of NIX and BNIP3 are increased by HIF-1α during hypoxia, mRNA expression of FUNDC1 is 
actually decreased. When oxygen concentrations are low, phosphorylation of FUNDC1 is 
inactivated leading to an abundance of it in its dephosphorylated form. FUNDC1 contains an 
LIR, which allows it to interact with LC3 on autophagosome membranes. The binding affinity of 
FUNDC1 for LC3 increases when FUNDC1 is dephosphorylated (Liu, Feng et al. 2012).  During 
hypoxia, CK2 is inhibited whereas PGAM5 interacts with FUNDC1 resulting in increased 
dephosphorylation of FUNDC1 to promote mitophagy (Chen, Han et al. 2014). Moreover, Bcl2-
like 1 (BCL2L1), but not BCL2, interacts with and inhibits PGAM5, which prevents the 
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dephosphorylation of FUNDC1 and mitophagy (Wu, Xue et al. 2014). Furthermore, knockdown 
of FUNDC1 in HeLa cells prevented hypoxia-induced mitophagy (Liu, Feng et al. 2012), 
suggesting that FUNDC1 is required for mitophagy induction in hypoxic conditions. It is currently 
unknown which has a more important role in mitophagy induction during hypoxia, NIX or 
FUNDC1, but dephosphorylated FUNDC1 has greater binding affinity for LC3 than NIX (Novak, 
Kirkin et al. 2010). 
 Cardiolipin is a phospholipid dimer synthesized in the inner mitochondrial membrane that 
is able to translocate to the outer mitochondrial membrane upon mitochondrial damage and 
depolarization (Ren, Phoon et al. 2014). Cardiolipin initiates the mitophagy pathway upon 
externalization to the outer mitochondrial membrane in SH-SY5Y cells and primary cortical 
neurons after treatment with rotenone, which is an electron transport chain complex I inhibitor. 
Rotenone treatment increased GFP-labeled LC3 puncta, which is a marker of autophagosome 
formation. Rotenone treatment also increased LC3 co-localization with mitochondria, which is 
indicative of mitophagy induction. Prevention of cardiolipin translocation to the outer 
mitochondrial surface inhibited GFP-LC3 co-localization with mitochondria and mitophagy after 
rotenone treatment, (Chu, Ji et al. 2013), and inhibiting the co-localization of LC3 with 
mitochondria after rotenone treatment prevented autophagosome engulfment of mitochondria 
and degradation of the mitochondria in the lysosome (Chu, Bayir et al. 2014). However, 
cardiolipin and Parkin seem to mediate mitophagy under different levels of mitochondrial 
depolarization. For example, CCCP-treated cells caused Pink1 externalization to the outer 
mitochondrial membrane and recruitment of Parkin. However, Rotenone treatment only caused 
approximately 10% of mitochondria to depolarize, which caused cardiolipin translocation to the 
outer mitochondrial membrane but did not recruit Parkin. Cardiolipin translocated to the outer 
mitochondrial membrane after CCCP treatment, but not to the extent as during rotenone 
treatment, suggesting that there may be some overlap in Parkin and cardiolipin-induced 
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mitophagy pathways or that they both may respond to CCCP treatment (Chu, Ji et al. 2013). 
Interestingly, cardiolipin also functions to induce cellular apoptosis.  If cardiolipin is present on 
the outer mitochondrial membrane in its peroxidized form, it initiates cell death through 
apoptosis. However, if it is not peroxidized, it initiates mitophagy to protect the cell from 
apoptotic cell death (Ren, Phoon et al. 2014). Chu et al. proposed that cardiolipin will initiate 
apoptotic cell death if the mitophagy pathway fails to degrade damaged mitochondria (Chu, Ji et 
al. 2013).  
 The E3 ligase Mul1 was recently discovered to act in parallel to Parkin for mitophagy 
induction by ubiquitinating the outer mitochondrial membrane mitofusin proteins in Drosophila 
and mammalian cell lines during mitochondrial depolarization. Overexpression of Mul1 in 
Drosophila reversed Parkin/Pink1 mutant phenotypes including mitochondrial clumping and 
elongated mitochondria. In addition, Pink1 and Mul1 or Parkin and Mul1 double mutant flies had 
worsened phenotypes than either mutant alone including increased mortality and muscle 
degeneration, reduced levels of ATP, and damaged mitochondria. In addition, Parkin KO and 
Mul1 knockdown primary cortical neurons had some increase in mitochondrial depolarization, 
but neurons from Parkin KO mice with Mul1 knocked-down had significantly increased 
mitochondrial depolarization and neuron degeneration.  Mul1 was shown to act in a pathway 
independent of Parkin because knockdown or overexpression of Mul1 in Parkin-expressing 
HeLa cells did not affect Parkin translocation to mitochondria following mitochondrial 
depolarization (Yun, Puri et al. 2014). Therefore, Mul1 may be an important compensatory 
pathway during loss or inactivation of Parkin.  
 Any of these Parkin-independent mediators of mitophagy may be responsible for 
compensatory mitophagy induction in Parkin KO mice. For example, Bnip3 or Nix may mediate 
mitophagy in the absence of Parkin during APAP overdose because APAP overdose activates 
HIF-1α, which has been shown to induce Bnip3 and Nix expression, as previously discussed 
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(James, Donahower et al. 2006). Bnip3, Nix, or Fundc1 may also mediate mitophagy after 
alcohol treatment in the absence of Parkin because alcohol has been shown to cause hypoxia 
in the liver (Ji, Lemasters et al. 1982, Tsukamoto and Xi 1989, Arteel, Raleigh et al. 1996). Mul1 
or cardiolipin may also have a role in mitophagy induction in Parkin KO mice after alcohol or 
APAP treatment because alcohol and APAP both induce mitochondrial depolarization (Kon, Kim 
et al. 2004, Masubuchi, Suda et al. 2005, Zhong, Ramshesh et al. 2014) (Figure 3.4.7D).  
Interestingly, mitophagy was not greatly induced after alcohol treatment in Parkin KO 
mice by the acute-binge or Gao-binge models compared to controls (Figure 4.4.5), but it was 
significantly induced for both of these models in WT mice after alcohol treatment (Figure 4.4.5) 
and in both WT and Parkin KO mice after APAP treatment, although the rate of mitophagy was 
lower in Parkin KO mice (Figure 3.4.3). Our data suggest that Parkin plays a more dominant 
role than Parkin-independent molecules/pathways in triggering APAP-induced mitophagy.  The 
differential roles of Parkin in alcohol and APAP-induced mitophagy could be due to the inability 
of compensatory pathways to induce mitophagy in the alcohol model.  Mitophagy levels after 
alcohol treatment were much lower than after APAP treatment, so it is possible that 
compensatory pathways for mitophagy activation are not needed to compensate for chronic loss 
of Parkin after alcohol treatment. Alternatively, the compensatory mitophagy pathways in Parkin 
KO mice may not have been induced within our alcohol treatment period (acute and Gao-binge). 
It is unclear whether a longer chronic alcohol feeding would trigger compensatory mitophagy in 
Parkin KO mice. Therefore, it would be interesting to determine other mediators of mitophagy in 
the liver after APAP treatment in the future. Parkin KO mice with any of these other mitophagy 
mediators knocked down may provide evidence for one of these pathways acting in the absence 
of Parkin in the liver.  




5.1.2 Parkin KO Mice had Opposite Responses to APAP and Alcohol-induced Liver 
Injuries 
We demonstrated that Parkin KO mice had opposite responses to APAP and alcohol-
mediated liver injuries because Parkin KO mice were protected against APAP-induced liver 
injury while alcohol treatment caused more injury in Parkin KO mice compared to WT mice. 
Parkin KO mice were protected against APAP-induced liver injury because they had decreased 
JNK activation along with increased Mcl-1 expression and hepatocyte proliferation compared to 
WT mice. Compensatory activation of Parkin-independent mitophagy pathways may have also 
had a role in protection against APAP in Parkin KO mice. Parkin KO mice  had more liver injury 
and steatosis after alcohol treatment compared to WT mice because they had severely 
damaged mitochondria and decreased mitochondrial function after treatment with alcohol,  
which was likely due to decreased mitophagy.  These opposing responses in Parkin KO mice to 
APAP and alcohol were likely due to Parkin having multiple roles in maintaining cellular 
homeostasis in addition to mitophagy (discussed in section 1.5).The importance of any of these 
Parkin-regulated pathways in response to liver injury may vary depending on the type and 
amount of damage an agent produces. For example, Parkin’s roles in regulating cell cycle, JNK 
activation, and Mcl-1 expression were likely more important during APAP overdose than its role 
in mediating mitophagy, while Parkin’s role in activating mitophagy was more important than 
other roles of Parkin during alcohol-induced liver injury.   
The role that hepatocellular proliferation plays in repair could lead to differences in 
responses from Parkin KO mice after treatment with APAP or alcohol.  There was massive 
hepatocellular necrosis in APAP-treated mice compared to mild cell death levels in alcohol-
treated mice. APAP overdose is well-known to require a quick induction of hepatocellular 
proliferation and liver regeneration for survival (discussed in section 1.6.3). Even though liver 
regeneration is also required for repair from alcohol-induced cell death (Diehl 2005), current 
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alcohol models do not initiate enough cell death to require as large of a regenerative response 
as APAP overdose. Therefore, Parkin’s role as a tumor suppressor (discussed in section 1.5.5) 
likely played a greater role in protection against APAP compared to alcohol, and increased 
proliferation in Parkin KO mice after APAP treatment may have overshadowed the detrimental 
effects of decreased mitophagy in these mice. To further confirm this, it would be interesting to 
determine if inhibition of proliferation in Parkin KO mice would increase their liver injury after 
APAP treatment.  
In addition to proliferation, JNK activation and Mcl-1 expression have both been shown 
to have roles in APAP-induced liver injury. JNK activation exacerbates APAP-induced liver 
injury (discussed in section 1.6.2), while upregulation of Mcl-1 protects against APAP-induced 
liver injury (discussed in section 3.5.3). Parkin KO mice had decreased JNK activation and 
increased Mcl-1 expression compared to WT mice after APAP treatment, which allowed for their 
protection against APAP-induced liver injury. JNK activation by CYP2E1-induced oxidative 
stress has also been shown to have a role in alcohol-induced liver injury (Yang, Wu et al. 2012). 
However, differences in JNK activation were not evaluated between WT and Parkin KO mice 
after alcohol treatment. Based on APAP results, I would expect Parkin KO mice to have less 
JNK activation in the alcohol model compared to WT mice. However, this protective mechanism 
would likely not overcome the importance of Parkin’s role in mitophagy induction after alcohol 
treatment because Parkin KO mice had increased injury after alcohol treatment compared to 
WT mice. In the future, JNK activation levels should be compared between WT and Parkin KO 
mice after alcohol treatment. If JNK activation is lower in Parkin KO mice than WT mice after 
alcohol treatment, then this would suggest that Parkin’s role in mitophagy is a more important 
protective mechanism and possible therapeutic intervention strategy than manipulation of JNK 
in ALD. However, if JNK activation is higher in Parkin KO mice compared to WT mice after 
alcohol treatment, it would suggest different mechanisms of Parkin-mediated regulation of JNK 
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during APAP and alcohol-induced liver injuries and would reveal JNK activation as another 
mediator of alcohol-induced liver injury in Parkin KO mice in addition to decreased mitophagy 
and mitochondrial dysfunction. The role of Mcl-1 in ALD has not yet been determined. However, 
Mcl-1 is an anti-apoptotic protein that may also provide protection against alcohol-induced cell 
death. Therefore, future evaluation of Mcl-1 in ALD may also provide novel insight into 
mechanisms of alcohol-induced liver injury.   
While other Parkin-mediated pathways showed greater importance after APAP 
treatment, mitophagy was likely the most important Parkin-mediated pathway necessary for 
protection against alcohol-induced liver injury and steatosis. Even though mitophagy was 
decreased in Parkin KO mice after both APAP and alcohol treatment, alcohol treatment caused 
less cell death compared to APAP and did not require an extensive regenerative response for 
repair, so decreased mitophagy was likely more detrimental in Parkin KO mice after alcohol 
treatment, leading to mitochondrial damage and dysfunction and increased liver injury and 
steatosis. Mitochondrial function was not evaluated in WT or Parkin KO mice after APAP 
treatment, but mitochondrial respiration has been shown to be decreased during APAP 
overdose (Meyers, Beierschmitt et al. 1988, Donnelly, Walker et al. 1994, Hanawa, Shinohara et 
al. 2008). Future investigation regarding differences in mitochondrial function after APAP 
treatment between WT mice and Parkin KO mice and between WT mice and mice with acute 
knockdown of Parkin would be interesting. Comparison of WT mice and mice with acute Parkin 
knockdown would be particularly interesting because mice with acute knockdown of Parkin had 
increased liver injury compared to WT mice after APAP treatment. I would expect mice with 
acute knockdown of Parkin to have decreased mitochondrial function because they had 
significantly decreased mitophagy after APAP treatment. If this is true, it may provide further 




5.1.3 Whole-body Knockout and Acute Knockdown of Parkin had Differential Roles in 
APAP-induced Liver Injury 
 Whole-body Parkin KO mice and mice with acute knockdown of Parkin had opposite 
responses to APAP overdose. Parkin KO mice had decreased liver injury while mice with acute 
knockdown of Parkin had increased liver injury compared to WT mice after APAP treatment. In 
addition, Parkin KO mice had increased proliferation and Mcl-1 expression and decreased JNK 
activation while acute Parkin knockdown mice had decreased proliferation and Mcl-1 expression 
and increased JNK activation after APAP treatment.  Opposing responses to APAP overdose in 
Parkin KO and acute knockdown mice were likely due to a lack of time for the acute knockdown 
mice to develop adaptive responses that were present in the Parkin KO mice. These results 
demonstrate that caution should be used when interpreting data from whole-body KO mice due 
to possible upregulation of compensatory pathways and adaptive responses. In addition, our 
results suggest that people with parkin mutations, such as patients with autosomal-recessive 
Parkinson’s disease, may be resistant to APAP overdose compared to people with normal 
Parkin function. However, this has not been investigated.  
 
5.1.4. Potential Therapeutic Options for APAP Overdose and ALD Through Modulation of 
Parkin Recruitment and Activation. 
 APAP-induced liver injury and ALD can both induce severe liver disease, for which there 
is no cure. Therefore, novel therapeutic interventions are needed to help prevent progression of 
these diseases. We have shown that Parkin-mediated mitophagy is still likely a protective 
mechanism in the liver, even though other compensatory mechanisms exist for mitophagy 
induction. Therefore, upregulation of the Parkin-mediated mitophagy pathway during alcohol or 
APAP-induced liver injury may be a beneficial therapeutic target to mediate removal of 
damaged mitochondria to prevent progression of liver injury. This was recently accomplished in 
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vitro by stabilizing Pink1 on the outer mitochondrial membrane via an ATP analog, kinetin 
triphosphate, which recruited Parkin to the mitochondria and prevented cell death in CCCP-
treated Parkin-expressing HeLa cells (Hertz, Berthet et al. 2013). However, this has not been 
evaluated in vivo. In addition to targeting Pink1 stabilization, there are several other potential 
targets related to Parkin activation or its recruitment to mitochondria. For example, Parkin 
activation could also be increased by changing its auto-inhibiting conformation (discussed in 
section 1.3.2), but methods for changing the conformation of Parkin have not been developed. 
Inhibition of Pink1 kinase activity could also be a therapeutic target since Pink1 
autophosphorylation and phosphorylation of Parkin and ubiquitin are needed for Parkin 
recruitment to mitochondria and for activation of its E3 ligase activity (discussed in section 
1.3.2). However, this avenue for regulation of Parkin activity has not yet been explored. There 
are also several deubiquitinating enzymes that have been shown to regulate Parkin activity 
including USP15, USP30, and USP8.  USP15 and USP30 are deubiquitinating enzymes that 
remove ubiquitin added to proteins by Parkin, thereby inhibiting Parkin-mediated mitophagy 
downstream of Parkin recruitment to mitochondria. Knockdown of both USP15 and USP30 were 
shown to enhance Parkin-mediated mitophagy and mitochondrial clearance in neurons and in 
Drosophila (Bingol, Tea et al. 2014, Cornelissen, Haddad et al. 2014, Cunningham, Baughman 
et al. 2015). USP8 removes ubiquitin chains on Parkin itself, which was shown to increase its 
mitochondrial translocation (Durcan, Tang et al. 2014). Therefore, modulation of these 
deubiquitinating enzymes may be another therapeutic target for activating Parkin-mediated 
mitophagy.  However, targeting Parkin as a therapeutic option presents several problems due to 
the many roles Parkin plays in the cell in addition to mitophagy (discussed in section 1.5). In 
addition, therapeutics for inducing Parkin-regulated mitophagy would have to be directly 
targeted to the liver for treatment of ALD or APAP because Parkin is expressed in many tissues 
in addition to the liver including thymus, muscle, heart, brain, kidney, and spleen (Ding and Yin 
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2012). Another possible therapeutic target would be to up-regulate compensatory mitophagy 
mediators responsible for inducing mitophagy in the liver in the absence of Parkin (discussed in 
section 5.1.1). However, these pathways are not yet defined.  
 
5.2 Future Directions 
Parkin-independent mechanisms of mitophagy induction in the liver should be further 
investigated. A better understanding of mitophagy induction in the liver may allow for future 
development of  novel therapeutic options for treatment of APAP overdose and ALD along with 
other forms of liver injury that involve mitochondrial damage and dysfunction. To determine 
Parkin-independent mechanisms for induction of mitophagy in the liver, acute knockdown of 
Parkin-independent mediators of mitophagy such as Mul1 or Bnip3 in Parkin KO mice should be 
performed, and these mice should be treated with APAP to determine if mitophagy is inhibited 
when potential compensatory pathways in addition to Parkin are blocked.  
In addition, more critical evaluation of differences in mechanisms of injury between 
Parkin KO mice treated with APAP and alcohol should be conducted. JNK activation and Mcl-1 
expression should be compared between WT and Parkin KO mice after alcohol treatment to 
determine if either of these pathways contributes to alcohol-induced liver injury. Mitochondrial 
function should also be compared between WT and Parkin KO mice in addition to comparison 
between WT mice and mice with acute knockdown of Parkin after APAP treatment to gain a 
better understanding regarding the role of mitochondrial function and mitophagy in protection 
against APAP-induced liver injury.   
Finally, Parkin’s role in liver regeneration should be better defined. Parkin KO mice had 
increased expression of the proliferative markers Cyclin D1 and PCNA before and after APAP 
treatment compared to WT mice. However, these markers are only suggestive of liver 
regeneration, so the role of Parkin in liver regeneration should be further evaluated using partial 
181 
 
hepatectomy.  It would also be interesting to determine if inhibition of proliferation in Parkin KO 
mice would increase their liver injury after APAP overdose.  
 
5.3 Concluding Remarks 
We showed that Parkin translocated to mitochondria after APAP and alcohol treatments, 
and Parkin KO mice had reduced levels of mitophagy compared to WT mice. In addition, mice 
with acute knockdown of Parkin had greater liver injury after APAP treatment compared to WT 
mice, which was partly due to a significant decrease in mitophagy. Therefore, Parkin-mediated 
mitophagy plays a protective role against APAP and alcohol-induced liver injuries.  
Interestingly we found that mitophagy still occurred, although to a lesser extent 
compared to WT mice, in Parkin KO mice after APAP treatments, suggesting that adaptive 
compensatory mechanisms for mitophagy induction exist in the liver during chronic loss of 
Parkin. We also revealed that Parkin KO mice had opposite responses to APAP and alcohol-
mediated liver injuries, which was likely due to Parkin having multiple roles in maintaining 
cellular homeostasis in addition to mitophagy. In addition, our results suggest that data from 
evaluation of drug-induced liver injury mechanisms using whole-body knockout mice should be 
interpreted with caution due to the possible upregulation of adaptive and compensatory 
pathways in knockout mice. Overall, modulating Parkin-mediated mitophagy may be a 
promising therapeutic approach for targeting drug and alcohol-induced liver injuries. 
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